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ABSTRACT  
 
This thesis reports a clinical study designed to assess myocardial, renal and 
lung outcomes following cardiac surgery. In a single centre, prospective 
randomized, placebo intervention-controlled trial the effects of intermittent 
upper limb ischaemia (remote ischaemic preconditioning (RIPC)) were 
compared in non-diabetic adult patients undergoing on-pump multi-vessel 
coronary artery surgery. Patients, investigators, anaesthetists, surgeons and 
critical care teams were all blind to group allocation. Subjects were 
randomized(1:1) to RIPC(or placebo) stimuli (3x upper limb (or dummy arm) 5 
minute cycles of 200mmHg cuff inflation/deflation) during sternotomy and 
conduit procurement. Anaesthesia, perfusion, cardioplegia and surgical 
techniques were standardized.  
Groups were well matched on demographic and operative variables. In 
contrast to prior smaller studies, RIPC did not reduce troponin T (48 hour area 
under the curve (AUC); 6hour and peak) release, improve post-operative 
haemodynamics (cardiac indices; low cardiac output episodes incidence; 
IABP usage; inotrope and vasoconstrictor use; M mode, 2D contrast-
enhanced echocardiography and tissue Doppler imaging) or offer anti-
arrhythmic benefit (de novo left bundle branch block or Q waves; ventricular 
tachyarrhythmia incidence). RIPC did not afford renal (peak creatinine, AUC 
urinary albumin-creatinine ratios, dialysis requirement) or lung protection 
(intubation times, 6hour and 12 hour pO2/FiO2 ratios). Case urgency did not 
influence RIPC effect.  
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V 
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CHAPTER 1: THE DEVELOPMENT AND CURRENT STATUS OF 
SURGERY FOR ISCHAEMIC HEART DISEASE 
 
Section 1: Development of coronary artery surgery and 
cardiopulmonary bypass 
 
1.0 Introduction 
Currently surgery on the heart and/or great vessels (cardiac surgery) 
represents an established form of medical practice. Its applications have 
extended to include treatment of ischaemic, congenital, valvular heart disease 
and transplantation. 
In the financial year ending 2008, 22846 patients underwent isolated coronary 
artery bypass surgery, on symptomatic and prognostic grounds, with a 
mortality rate of 1.5% [1]. Access to the heart is a recent phenomenon and its 
history is linked with controversy. 
 
2.0 Early History of Cardiac Surgery 
In 1801 Fransciso Romero, a Catalonian physician, performed an open 
pericardiostomy to treat a pericardial effusion and became credited with the 
title of ‘The First Heart Surgeon’ [2]. He went on to present his work at the 
Society of the School of Medicine in Paris in 1815 but considered too 
aggressive in his procedure his work was silenced for many years. 
The future, at this stage for cardiac surgery, continued to look bleak and in 
1881, the founding father of modern abdominal surgery, Theodore Billroth 
announced:  
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‘Anyone who would attempt to operate on the heart should loose the 
respect of his colleagues‘   
By 1896 Stephen Paget, surgeon and son of the distinguished surgeon and 
pathologist Sir James Paget, wrote: 
‘Surgery of the heart has probably reached the limits set by Nature; no 
new methods and no new discovery can overcome the natural difficulties that 
attend a wound of the heart’  
In 1893, Dr. Daniel Hale Williams (Figure 1.1) a surgeon from Chicago, 
successfully operated on a 24-year-old man who had been stabbed during a 
fight by suturing an artery and vein inside the chest wall and a tear in the 
pericardium [3]. 
 
Figure 1.1: Dr Daniel Hale Williams 
 
A wound in the right ventricle was noted but was not bleeding, so Williams did 
not place a stitch through the heart wound. The patient recovered and 
Williams reported this case four years later [3][4]. This operation was the first 
successful surgery involving a documented stab wound to the heart. At the 
time, Williams' surgery was considered bold and daring, and although he did 
not actually place a stitch through the wound in the heart, his treatment seems 
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to have been appropriate. Under the circumstances, he most likely saved the 
patient's life.  
On the 4th of September 1895 the first surgery on the heart itself was 
performed, albeit unsuccessfully, by the Norwegian surgeon Axel Cappelen at 
Rikshospitalet in Kristiania, now Oslo.  
A 24 year old man presented in deep shock following a stab injury to the left 
axilla. Cappelen accessed the chest through a left thoracotomy and ligated 
the bleeding coronary artery. The young man awoke and appeared to respond 
well in the first 24 hours but then became pyrexial and passed away from 
mediastinitis on the third postoperative day [5]. 
A year on, after suturing a stab wound to the right ventricle without any 
complications, Ludwig Rehn (Figure 1.2) had performed the first successful 
surgery of the heart. In his own words: 
... Today the patient is cured. He looks very good. His heart action is 
regular. I have not allowed him to work physically hard. This proves the 
feasibility of cardiac suture repair without a doubt! I hope this will lead to more 
investigation regarding surgery of the heart. This may save many lives.  
Ten years after Rehn's initial repair, he had accumulated a series of 124 
cases with a mortality of 60% [6]. His successful work was inspirational to 
other pioneers and reversed the prevailing belief of inviolability of the heart 
and marked the beginning of cardiac surgery [7]. 
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Figure 1.2: Dr Ludwig Rehn 
  
3.0 A brief history of Coronary Artery Surgery 
The dawn of coronary artery surgery was heralded by Alexis Carrel in a 
canine model who published in 1910 [8]:  
I attempted to perform an indirect anastomosis between descending 
aorta and the left coronary artery. It was for many reasons a difficult 
operation. On account of the continuous motion of the heart, it was not easy 
to dissect and to suture the artery. In one case, I implanted one end of a long 
carotid artery, preserved in a cold storage, on the descending aorta. The other 
end was passed through the pericardium and anastomosed to the pericardial 
end of the coronary near the pulmonary artery. Unfortunately, the operation 
was too slow. Three minutes after the interruption of the circulation fibrillary 
contractions appeared, but the anastomosis took five minutes. By massage of 
the heart, the dog was kept alive, but he died less than two hours afterwards. 
It shows that the anastomosis must be done in less than three minutes.  
Claude Beck, in 1930, tried to revascularise myocardium in experimental 
models by attaching adjacent tissues (pericardium, pericardial fat, pectoralis 
muscle, omentum) in the hope of forming collateral blood flow to the 
ischaemic myocardium [9][10].  Postmortem examination revealed that 
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anastomotic vessels had developed between these tissues and the 
myocardium. Beck subsequently performed this operation with modifications 
on 16 patients.  
In 1946 Arthur Vineberg reported successful implantation of the internal 
mammary artery through a tunnel in the myocardium but not actually 
anastomosing the left internal mammary artery to the coronary artery [11]. 
Mason Sones later validated Vineberg's concept by demonstrating 
communications between the graft in the myocardium and the coronary 
system by angiography in two patients operated on 5 and 6 years earlier. In 
the middle 1960s the Vineberg operation with many variations was performed 
at many institutions in the United States and Canada [12]. 
Coronary arterial endarterectomies were also attempted for the treatment of 
ischemic coronary disease but mortality was high, and the procedure was 
abandoned as an isolated operation [13]. 
From 1960 to 1967, isolated cases of coronary grafting were reported. None 
had an impact on the development of coronary surgery. In 1960 Robert Goetz 
performed the first coronary artery bypass operation in a human, which was 
successful [14]. The right internal mammary artery was connected to the right 
coronary artery using a non suture technique. The patient was asymptomatic 
for a year, then developed recurrent angina and died of a myocardial 
infarction.  
The first clinical case of successful coronary artery bypass surgery using 
autogenous saphenous vein was performed by Garett, Dennis and DeBakey 
on a 42-year-old man in 1964 [15]. The vein was placed from the aorta to the 
left anterior descending. The internal mammary artery had been anastomosed 
6 
 
to the left coronary artery in 1952 by Vladimir Demikhov, in a canine model 
[16] and Longmire performed the first internal mammary to coronary artery 
anastomosis in humans [17]. 
In 1967 Kolessov reported his experience with mammary artery–coronary 
artery anastomoses for treatment of angina pectoris in six patients [18] 
through a left thoracotomy without extracorporeal circulation or preoperative 
coronary angiography. The following year, Green et al [19] and Bailey and 
Hirose [20] separately published reports in which the internal mammary artery 
was used for coronary artery bypass in patients. Bailey and Hirose carried out 
the anastomosis on the beating heart and then Green et al advocated using 
cardiopulmonary bypass, fibrillating the vented heart, cross-clamping the 
aorta, and washing all blood from the coronary system while performing the 
anastomosis.  
Favalaro used saphenous vein for bypassing coronary obstructions [21]. 
However, the start of modern coronary bypass surgery took place in 1969 
when Johnson et al reported a series of 301 patients who had undergone 
various operations for coronary disease since early 1967 [22]. 
Johnson presented guidelines for direct surgery: 
One: Do not limit grafts to proximal portions of large arteries....  
Two: Do not work with diseased arteries. Vein grafts can be made as 
long as necessary and should be inserted into distal normal arteries.  
Three: Always do end-to-side anastomosis....  
Four: Always work on dry, quiet field. Consistently successful fine 
vessel anastomoses cannot be done on a moving, bloody target....  
Five: Do not allow the haematocrit to fall below 35.  
7 
 
The direct anastomosis between the internal mammary artery and the 
coronary artery was not initially as popular as the vein graft technique; 
however, due to the persistence of Drs. Green, Loop, Grondin, and others, 
internal mammary artery grafts eventually became the conduit of choice when 
their superior long-term patency became known [23]. 
 
4.0 The development of cardiopulmonary bypass 
Successful cardiopulmonary bypass development requires understanding of 
cardiovascular physiology, a mechanism to pump blood, and a technique to 
ventilate blood whilst preventing it from clotting [24]. 
Credit for anticoagulation in the heart-lung machine is owed to McLean in 
1916 [25][26] who discovered heparin [27][28]. The work of John Gibbon led 
to the first successful demonstration that life could be maintained by an 
artificial heart and lung and that the native heart and lungs could resume 
function [29]. Dennis et al went on to develop a heart-lung machine to support 
circulation intraoperatively in a young girl during atrial septal defect closure 
[30][31]. Although the machine was successful in purpose the patient did not 
survive. 
With the help of General Motors in 1952 Dodrill and colleagues developed a 
mechanical blood pump [32] that successfully bypassed the left-side of the 
human heart. Dodrill went on to successfully perform right-sided heart bypass 
[33] and in 1955 transferred use of the oxygenator to human models.  
John Gibbon, with the assistance of the International Business Machines 
(IBM) Corporation, built a machine which contained a rotating vertical cylinder 
oxygenator and a modified DeBakey rotary pump. The machine was 
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successful in canine models and Gibbon went on to develop a machine with a 
larger oxygenator planned for human models [34]. 
Whilst Gibbons early experience in experimental and human models with the 
heart lung machine was mixed [35] Lillehei studied ‘controlled cross-
circulation’ [24] in canine models. The circulation of one dog was temporarily 
used to support that of a second dog while the second dog's heart was 
temporarily stopped and opened. After a simulated repair in the second dog, 
the animals were disconnected and allowed to recover. This technique with a 
blood pump and bubble oxygenator was then extended to human models 
[24][36][37] (Figure 1.3). 
Figure 1.3: Crosscirculation by Lillehi 
 
  
In 1955 Kirklin started an open heart program at the Mayo Clinic [38] using his 
own modified Gibbon-IBM heart-lung machine [39]. This propelled many 
international university groups by 1957 to have followed suit and start the era 
of modern cardiac surgery. 
An international drive in the pursuit of excellence continues to reduce 
complication rates and increase recovery time of patients undergoing cardiac 
surgery. Today with the refinement of anaesthetic, surgical and perfusion 
protocols cardiac surgical procedures are routine and commonplace. 
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Section 2: The need for myocardial protection  
 
1.0 Introduction  
Coronary heart disease (CHD) is the leading cause of death world-wide and 
can manifest as acute myocardial ischaemia-reperfusion injury with 
detrimental effects.  
Myocardial injury has been found to occur in 10-40% of cases during coronary 
intervention and can be characterized by a slight increase of markers of 
myocardial necrosis, without symptoms, electrocardiographic changes or 
impairment of cardiac function [40]. Coronary artery bypass graft (CABG) 
surgery, the procedure of choice for coronary artery revascularisation in a 
large number of patients with severe CHD, can also result in myocardial injury 
leading to worse short and long-term clinical outcomes. As a trend in 
progressively increased preoperative patient risk profile has been observed 
worse outcomes are envisaged in the future.  
This projection of poorer outcomes has alerted the medical fraternity to the 
need for treatment strategies designed to protect the heart in terms of 
reducing myocardial injury and preserving left ventricular systolic function.  
Microvascular protection during the acute event has become the focus of a 
variety of emerging technologies. The goal of these mechanical and 
pharmacologic therapies is the restoration of normal metabolic function at the 
myocyte level [41]. 
Myocardial protection aims at preventing myocardial tissue loss and current 
methods include cardioplegia, off-pump coronary artery bypass surgery 
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(OPCAB), ischaemic preconditioning, on-pump beating heart surgery and 
intermittent ischaemic arrest. 
 
2.0 Brief history of myocardial protection 
Early work on circulatory arrest in 1914 by Alexis Carrel found that: 
….it was possible to clamp the pedicle of the heart (aorta and 
pulmonary artery) for two and a half or three minutes without any subsequent 
trouble. As soon as the clamp was removed, the heart resumed its pulsations, 
and after a very short time, the pulsations were again normal. [42] 
Hooker in 1929 suggested that potassium inhibition induced by an excess of 
potassium chloride could be used to stop the heart leading Melrose in 1955 
[43] to present the first experimental study describing induced arrest by 
potassium-based cardioplegia. Blood cardioplegia was used: 
"to preserve myocardial energy stores at the onset of cardiac ischemia."  
Melrose goes on to state that  
"...
 they have succeeded in evolving a reliable method of stopping and 
restarting the heart at both normal and reduced body temperatures."  
Unfortunately, the Melrose solution proved to be toxic to the myocardium, and 
as a result, cardioplegia was not used widely for several years.  
Gay and Ebert [44] and Tyres [45] demonstrated that cardioplegia with lower 
potassium concentrations was safe. Studies by Kirsch, [46] Bretschneider [47] 
and Hearse [48] demonstrated the effectiveness of cardioplegia with other 
constituents and renewed interest in this technique.  
Gay and Ebert in 1973 demonstrated a significant reduction in myocardial 
oxygen consumption during potassium-induced arrest when compared with 
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that of the fibrillating heart [44]. They also showed that the problems in the use 
of the Melrose solution in the early days of cardiac surgery probably were due 
to its hyperosmolar properties and perhaps not to the high potassium 
concentration.  
Follette, in 1978, [49] demonstrated in experimental and clinical studies that 
hypothermic, intermittent blood cardioplegia provided better myocardial 
protection than normothermic, continuous coronary perfusion and/or 
hypothermic, intermittent blood perfusion without cardioplegia solution.  
Since the 1980s the use of cardioplegia as a form of myocardial preservation 
technique has become established and commonplace in surgical practice. 
Debate remains over the ideal composition of cardioplegia solution. 
Formulations, methods of delivery, and recommended temperature continue 
to refine and evolve.  
 
3.0 Reperfusion Injury 
An increasing body of evidence suggests a multifactorial mechanism for 
myocyte injury and microvascular collapse that is associated with a profound 
impact on long-term outcomes. 
During cardiac surgery, the reperfusion of blood following prolonged 
ischaemia (e.g. aortic crossclamping) provides oxygen and substrate for the 
return of oxidative metabolism and rewarming increases the metabolic rate 
toward normal. There is potential, with reperfusion, to add further injury to the 
ischaemic damage sustained by cells through a localised inflammatory 
response whose basic components are: 
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• Free radical injury 
• Calcium overload 
• Complement activation 
• Neutrophil activation 
• Cytokine system 
• Endothelial response to ischaemia/reperfusion injury 
 
4.0 Cardioplegia 
4.1 Introduction to cardioplegia 
Over thirty years ago, the development of hyperkalaemic cardioplegic 
solutions revolutionised cardiac surgery by offering effective chemically-
induced cardiac arrest and myocardial protection during global ischaemia.  
Despite remaining the most widely-used cardioplegic technique, 
hyperkalaemia can have detrimental effects due to the Na and Ca loading of 
the cardiac cell induced by depolarisation of the cell membrane. Efforts over 
the last two decades to establish better cardioplegic agents have mainly 
remained limited to animal experiments. The failure of these approaches to 
progress to clinical trials may be due to a lack of clear criteria that a 
cardioplegic agent should meet at a cellular level and, more importantly, at a 
system level [50]. 
 
4.2 Principles of Cardioplegia     
During the interruption of coronary circulation by the intraoperative cross-
clamping of the aorta cardioplegia is used to arrest the heart and reduce 
myocardial metabolism. In the absence of cardioplegia cross-clamping alone 
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would induce anaerobic metabolism, depletion of myocardial energy stores 
and cause severe myocardial dysfunction. Cardioplegic solutions today are 
able to provide myocardial protection of over 3 hours without adversely 
affecting myocardial function [51]. 
The optimal results from cardioplegia are based on the principles of prompt 
diastolic arrest, buffering, reducing calcium levels, an adequate delivery 
system, temperature and the addition of substrates designed to optimize 
myocardial metabolism or prevent cell damage (Table 1.1). 
Table 1.1: Principles and composition of cardioplegia [51] 
PRINCIPLE COMPOSITION 
Prompt diastolic arrest KCl 20-25 mEq.L-1 
Buffering THAM, bicarbonate 
Reduction of calcium levels Citrate-phosphate-dextrose (CPD) 
Adequate delivery Antegrade+/-retrograde administration 
Temperature Cold vs. tepid vs. warm 
Substrate additives to optimize 
myocardial metabolism or prevent cell 
damage 
Aspartate glutamate 
Na+-H+ exchange inhibitors 
Insulin 
Magnesium 
Procainamide 
L-arginine 
Calcium channel blockers 
THAM = tris(hydroxymethyl)aminomethane; CPD = citrate-phosphate-dextrose 
 
4.2.1 Prompt diastolic arrest 
Prompt diastolic arrest of the heart is achieved by administering a solution 
containing approx 20-25 mEq/L of potassium chloride (KCl). Three methods of 
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delivery currently employed are crystalloid cardioplegia, blood cardioplegia 
and miniplegia. 
 
4.2.1.1  Crystalloid cardioplegia  
In crystalloid cardioplegia potassium is added to a crystalloid solution that is 
administered undiluted. The resulting solution provides little substrate and no 
oxygen to the heart during ischaemic arrest. It functions primarily by arresting 
the heart at cold temperatures and has the potential to be oxygenated by 
bubbling oxygen through the solution although this is uncommon [51]. 
 
4.2.1.2  Blood cardioplegia 
When potassium is concentrated in a smaller bag of crystalloid solution and is 
administered in a mixture with blood in varying ratios (most commonly 4:1 
blood) blood cardioplegia is produced. This form of cardioplegia provides 
oxygen, natural buffering agents, antioxidants and free-radical scavengers. 
Standard additives include buffers such as THAM to achieve an alkaline pH, 
citrate-phosphate-dextrose (CPD) to lower calcium levels and mannitol to 
maintain slight hyperosmolarity. The cardioplegia mixture formed then passes 
through a separate heater/cooler system in the extracorporeal circuit and 
infusion rate and pressure can be controlled [52]. 
 
4.2.1.3 Miniplegia 
When potassium is added directly to blood to minimize haemodilution 
miniplegia is formed. 
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4.2.2 Reduction in cardiac oxygen demand  
By arresting the heart at normothermia cardiac oxygen demand is reduced by 
nearly 90%. Maintenance of arrest during the cross-clamp period is achieved 
by readministering the solution every 15-20minutes so as to deliver potassium 
and washout the metabolic byproducts that have been generated.  A low 
potassium solution (12-15mEq.L-1) is used to maintain the arrest while 
avoiding an excess potassium load. A high potassium solution should be used 
if the heart resumes any activity [51]. 
In the case of cold blood cardioplegia alone, this can be given retrograde into 
the coronary sinus as an alternative to subsequent doses of cardioplegia to 
optimise tissue oxygenation and metabolism while minimising potassium load  
[51]. 
 
4.2.3 Temperature 
The reduction in myocardial metabolism attributable to hypothermia is quite 
insignificant compared with that achieved by diastolic arrest. Nonetheless, 
systemic hypothermia supplemented by use of topical cold saline and topical 
cooling devices that surround the left ventricle and protect the phrenic nerve 
from cold injury is routinely used in patients receiving cold cardioplegia [51]. 
Since enzymatic and cellular reparative processes function better at 
normothermia, some surgeons use ‘warm cardioplegia’ for myocardial 
protection. However because of the tendency for the heart to resume 
electrical activity at normothermia, this must be given continuously or with 
only brief interruptions to protect the heart. When given continuously it can 
obscure the operative field [51]. 
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Warm cardioplegia can be used as an adjunct to cold cardioplegia when given 
at the beginning and the end of the period of aortic cross-clamping. 
Administering 500mL of warm cardioplegia immediately after aortic cross-
clamping may be beneficial in actively ischaemic hearts with energy depletion 
by providing a brief period of time during which oxygen can be used to repair 
cell damage and replace energy stores. 
Terminal warm blood cardioplegia (‘hot shot’) is commonly given just before 
the removal of the aortic cross clamp as it has been shown to improve 
myocardial metabolism. The heart tends to remain asystolic for several 
minutes after removal of the aortic cross clamp, during which time the heart is 
able to ‘repair’ cellular processes or replenish energy stores while the oxygen 
demand is low [53][54]. 
 
4.2.4 Route of delivery 
Cardioplegia is initially administered antegrade (Figure 1.4) into the aortic root 
and then may be given retrograde through a catheter placed in the coronary 
sinus (Figure 1.5). 
  
  Figure 1.4: Antegrade cardioplegia cannula with a side port for venting 
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The efficacy of antegrade cardioplegia (ACP) delivery may be compromised 
by severe coronary artery stenosis and is often dependent on collateral flow. 
Sufficient root distension may not be achieved in patients with more than mild 
aortic insufficiency and it can be cumbersome to readminister ACP during 
aortic and mitral valve operations.  
 
Figure 1.5: Retrograde cardioplegia catheter with self-inflating balloon 
for measuring coronary sinus pressure 
 
 
Retrograde cardioplegia (RCP) is easy to administer, either intermittently or 
continuously, and does not interrupt the flow of an operation. RCP does 
provide excellent myocardial protection but there is concern about 
maldistribution of the solution especially to the right ventricle. Careful 
monitoring of coronary sinus pressure during the administration of RCP is 
required to avoid coronary sinus rupture. 
Routes of delivery of cardioplegia should be complementary and not 
exclusive. Contrast echocardiography has demonstrated left ventricular 
perfusion to be better with warm antegrade delivery than retrograde delivery. 
Delivery to the right ventricle is poor with either approach especially in right 
coronary artery occlusion [51]. 
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In patients undergoing elective coronary artery bypass grafting, retrograde 
continuous infusion of cardioplegia by gravitational force combined with 
antegrade cardioplegia has been shown to provide satisfactory myocardial 
protection and to eliminate the need for inotropic support when compared with 
antegrade delivery alone [55]. 
 
4.2.5 Cardioplegia additives 
A variety of medications that might potentially be cardioprotective when given 
in the cardioplegia solution have been studied. Those showing the greatest 
promise include the Na+-H+ exchange inhibitors (such as cariporide), 
adenosine and L-arginine. Aspartate and glutamate are Krebs’ cycle 
intermidiates that have been used to improve myocardial energy metabolism 
with variable success. Other drugs include procainamide, magnesium (which 
has been shown to reduce arrhythmias) and free-radical scavengers. The 
insulin cardioplegia trial involved use of tepid cardioplegia enriched with 
glucose and insulin. This demonstrated metabolic and functional benefits to 
patients undergoing elective but not urgent surgery [51]. 
 
4.3 Cardioplegia Strategy 
Variations in cardioplegia strategies and solutions have made it difficult to 
ascertain which specific element provides true benefit. The extent of coronary 
disease and coronary flow can significantly impact the efficacy of both 
antegrade and retrograde flow and confound any analysis. Clinical studies 
have not demonstrated the superiority of one type of cardioplegia in routine 
cases but have suggested patients with more advanced left ventricular 
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dysfunction fare better with blood cardioplegia especially given both 
antegrade and retrograde. 
Studies suggest that in low-risk groups, multidose cold crystalloid, or cold or 
warm blood cardioplegia, whether given antegrade and/or retrograde, produce 
relatively comparable clinical results. In general, protection of the right 
ventricle is suboptimal with all strategies, especially in patients with right 
coronary artery disease. In high-risk cases a combination of ACP and RCP 
cold or tepid blood cardioplegia may offer the best results [51]. 
 
4.4 Blood vs. crystalloid cardioplegia 
A meta-analysis of 34 RCTs (18/34 undergoing elective CABG surgery) found 
superior myocardial protection provided by blood cardioplegia, deduced from 
lower low output syndrome rates and CKMB release after surgery at 24hours, 
when compared to crystalloid [56]. Blood cardioplegia provides a closer 
approximation to normal physiology and this most likely translates into the 
measurable clinical benefits and advantage. 
A survey of UK practice has found 56% of surgeons use cold blood 
cardioplegia, 14% use warm blood cardioplegia, 14% use crystalloid 
cardioplegia, 21% use retrograde infusion and 16% do not use any 
cardioplegia [57]. 
Although blood cardioplegia has been shown to be 'superior' to crystalloid this 
advantage is marginal and might explain the continuous use of crystalloid 
cardioplegia by some surgeons [58]. 
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4.5 Directed cardioplegia 
To eliminate the steal of cardioplegia, during nonselective antegrade 
cardioplegia, from severely stenosed vessels by other less diseased arteries 
‘direct cardioplegia’ is a novel approach that is being developed. To protect 
poorly perfused myocardial regions the surgeon occludes the other main 
branches and directs a certain volume of cardioplegic solution into the 
severely diseased coronary artery. Early results in severe left main coronary 
artery disease have been promising [59]. 
 
5.0 Volatile anaesthetics 
5.1 Introduction to volatile anaesthetics 
Volatile anaesthetic agents have been shown to have direct protective 
properties against ischaemic myocardial injury by a mechanism termed 
'anaesthetic preconditioning' [60][61]. The cardioprotective effects occur at 
therapeutic doses and are independent of anaesthetic and haemodynamic 
effects [62]. 
It is suggested that the cardiac depressant effects of volatile anaesthetics 
decrease myocardial oxygen demand and may thus improve the myocardial 
oxygen balance during ischemia whilst also directly protecting from ischemic 
myocardial damage [63]. 
 
5.2 Enflurane, Sevoflurane, Desflurane and Isoflurane 
Both Enflurane [64] and Sevoflurane have been shown independently to 
enhance postischaemic functional recovery in patients undergoing coronary 
surgery. Sevoflurane decreases postoperative release of brain natiuretic 
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peptide, the sensitive biochemical marker of myocardial contractile 
dysfunction [65]. 
Preischaemic administration of isoflurane also protects against prolonged 
ischaemia with functional recovery after CPB, increases mean cardiac index 
and reduces necrosis (cTnI) in patients undergoing coronary artery bypass 
graft surgery. Experimentally isoflurane has been shown to provide 
myocardial protection through a signal transduction cascade that is similar to 
the pathways identified in ischaemic preconditioning [66]. 
Meta-analysis’ have demonstrated that desflurane and sevoflurane reduce 
postoperative mortality and incidence of myocardial infarction following 
cardiac surgery with advantages in postoperative cardiac troponin release, 
need for inotrope support, time on mechanical ventilation, intensive care unit 
and overall hospital stay [61][62][63]. In support of current evidence The 
American College of Cardiology/American Heart Association have 
recommended volatile anaesthetic agents to be used during non-cardiac 
surgery for the maintenance of general anaesthesia in patients at risk for 
myocardial infarction [61][62][63]. 
 
5.3  Volatile vs. non-volatile anaesthesia 
The advantage of volatile anaesthesia, against total intravenous anaesthesia, 
on cardiac troponin release in off-pump coronary artery bypass grafting 
(OPCAB) has been found in multicenter randomized controlled studies [67]. 
This benefit has also been shown to extend to patients undergoing CABG with 
CPB with reduced cardiac troponin release, reduced need for postoperative 
inotropic support and trends toward a reduction in number of Q-wave 
22 
 
myocardial infarction, time on mechanical ventilation, intensive care unit and 
overall hospital stay [68]. 
A systematic overview and meta-analysis of all randomized trials comparing 
volatile with non-volatile anaesthesia in CABG surgery identified 27 trials that 
included 2979 patients. Post-bypass, patients randomized to receive volatile 
anaesthetics had 20% higher cardiac indices, lower troponin I serum 
concentrations and lesser requirement for inotropic support. Duration of 
mechanical ventilation was reduced by 2.7 h and there was a 1 day decrease 
in hospital length of stay [69]. 
 
6.0 Ischaemic conditioning 
‘Conditioning’ of the heart to harness its endogenous cardioprotective 
capabilities using either brief ischaemia or pharmacological agents provides a 
potentially novel approach to myocardial protection during cardiac surgery by 
limiting myocardial injury, preserving left ventricular systolic function and 
potentially improving morbidity and mortality in patients with CHD [70][71]. 
The conditioning stimulus can give be given locally or distant to the organ and 
before or after a prolonged period of ischaemia. 
Ischemic postconditioning by brief episodes of ischemia performed just at the 
time of reperfusion has been shown to reduce infarct size in animal models, in 
the clinical settings of percutaneous coronary intervention and in adult 
patients undergoing valve replacement [72].  
Brief episodes of non-lethal ischaemia and reperfusion to an organ or tissue 
remote from the heart, thereby obviating the need to 'condition' the heart 
directly has been termed remote ischaemic conditioning and it is suggested 
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there is potential for widespread systemic protection to other organs which are 
susceptible to acute ischaemia-reperfusion injury such as the brain, liver, 
intestine or kidney [71]. 
 
7.0 Nicorandil 
This potassium channel activator in intravenous preparation has been shown 
to have beneficial effects. When administered during CABG surgery with CPB 
lowers concentrations of cTnT were observed [73] suggesting its potential for 
myocardial protection. 
 
8.0 Statins 
The perioperative use of statin therapy has demonstrated improved short and 
long-term cardiac outcomes following noncardiac surgery. Its beneficial 
effects have been attributed to its positive effects on plaque stability 
(pleiotropic) [74], lipid lowering effects and anti-inflammatory properties [75]. 
In cardiac surgery, one series found pretreatment with statins to reduce the 
incidence of death and myocardial infarction following coronary artery bypass 
grafting surgery [76] supporting its role as a cardioprotective agent. 
 
9.0 Aprotinin 
Aprotinin, a serine protease inhibitor, can limit systemic inflammation, and has 
been associated with myocardial, pulmonary and cerebral protection in 
addition to its proven haemostatic efficacy [77]. It has antithrombotic, 
antifibrinolytic, and antiinflammatory effects and is effective in reducing 
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bleeding and the need for blood transfusions after cardiac surgery with 
cardiopulmonary bypass [77][78]. 
Recent controversy has started since a large randomized controlled trial 
comparing antifibrinolytics in patients undergoing cardiac surgery was 
stopped after a preliminary analysis suggested a trend toward an increase in 
all-cause 30-day mortality associated with aprotinin [78]. Further investigation 
is currently under way. 
 
10.0 Conclusions  
The dangers of insufficient myocardial protection during cardiac surgery 
represents a real worry to surgeons as our population ages and the patient 
presenting have more severe comorbidities. A number of techniques have 
been identified to tackle this issue and continue to be tested and refined. 
The topic of investigation of this thesis and the consecutive chapters is the 
applicability of remote ischaemic preconditioning as a novel technique to aid 
in the armamentarium of the surgical team to reduce myocardial injury and 
enhance myocardial preservation. 
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Section 3: The current status of coronary artery bypass graft 
surgery (CABG) 
 
1.0 Adult Cardiac Surgical Database Report 2008 
The Society of Cardiothoracic Surgeons of Great Britain and Ireland 6th 
National Adult Cardiac Surgical Database Report (2008) [1] documents the 
nature of adult cardiac surgical practice in the United Kingdom and Ireland. It 
provides an invaluable resource for the extraction of data, analysis and 
comment on the current practice of coronary artery surgery. 
 
1.1 Patient populations treated by CABG 
In the financial year ending 2008 22,846 patients underwent isolated CABG. 
Analyses of patients' risk profiles show quite marked changes, with surgeons 
operating on progressively higher-risk patient year-on-year: 
A recent review confirms the feelings that a higher-risk population has started 
to develop. The most current data reports 75% of patients undergoing isolated 
CABG are overweight & about one-third are obese. The number of elderly 
patients presenting for surgery is increasing with the over 75s now making up 
more than 20% of all cardiac surgery and the over 80s making up over 5%. 
The average age of patients undergoing isolated CABG between 1991and 
2007 has increased from 58 to 66 years.  
There are marked changes in the proportion of female patients with increasing 
age: in patients under the age of 51 years of age 13% of patients are female, 
in those over the age of 80 it rises to nearly 30%. 
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The incidence of comorbidities of patients presenting for coronary surgery 
between 2001 and 2008 has increased: 33% in diabetics and more than 15% 
in hypertensives. While left main stem (LMS) disease rates appear to have 
stabilised now, they did increase between 2001 and 2006. Approximately half 
the patients have had a previous myocardial infarction (MI) and the proportion 
of patients who have suffered a heart attack within the previous 30 days has 
gone up from under 19% in 2004 to over 34%in 2008.  
An increase to over 8% of patients presenting for CABG have had prior 
percutaneous coronary intervention (PCI) with the vast majority having 
undergone PCI during a previous hospital admission. There has also been a 
small increase in the proportion of patients with preoperative dialysis-
dependent renal failure, extra-cardiac arteriopathy and a greater proportion of 
urgent cases. 
There is suggestion that an increase in the longevity of conduit used is being 
observed. Fewer patients are requiring repeat operations and the time 
between first- and second-time operations is increasing. 
 
1.2 Survival following CABG 
The outcomes for patients undergoing coronary artery bypass surgery as an 
elective operation are excellent, with low mortality, low morbidity and good 
medium-term survival. Operative mortality rates for isolated CABG fell from 
2.3% in 2001 to 1.5% in 2008. In those patients with no history of previous MI 
in the year to March 2008 the mortality rate was 0.8% and for those who had 
2 or more previous MIs it was 3.6%. 
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The operative mortality of elective surgical patients under the age of 70 years 
is less than 1%. Survival appears to be worse for patients who are older, 
female, undergoing urgent surgery, diabetic, suffering from impaired cardiac 
function or in renal failure. In terms of improving outcome, surgical procedures 
have seen a trend towards increased usage of arterial grafts.  
Following surgery body habitus plays a role in outcome as the extremes of 
weight (under and morbidly obese) have prolonged in-hospital stays. Those 
that are underweight fair poorly with an observed mortality rate of 4.1%. 
Obese and morbidly obese patients have the same medium-term survival 
rates as patients of normal weight. 
As an indicator of improved care and treatment strategies the operative 
mortality has continued to fall whilst the proportion of patients over 75 and 80 
has continued to increase. The mortality rate for patients over the age of 75 
has also fallen from 5.0% in 2004 to 3.4% in 2008. Kaplan-Meier survival rate 
at 5 years post-operatively for the under 66 year age group is over 90% and in 
the over 80 group is 69%. Gender has been shown to affect outcome as 
women have an in-hospital mortality that is nearly twice that of their male 
counterparts and worse medium-term survival.  
The impact of comorbidities on prognosis remains significant. Patients who 
have had a previous heart attack are twice as likely to die at the time of 
surgery compared to patients who have not had a heart attack. However, the 
in-hospital mortality rate of diabetics has decreased in spite of a 50% increase 
in the diabetic proportion between 2001 and 2008. The mortality for diabetics 
remains higher than for non-diabetic patients. Diabetics have a longer length-
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of-stay and a medium-term survival rate of 85% compared to 90% of non-
diabetics. 
In the most recent year of study there is no significant increase in operative 
mortality on inpatients with hypertension. Hypertension does remain 
associated with longer in-hospital stay and worse medium-term survival. 
Severe angina remains an important risk factor for operative mortality. Those 
with LMS disease have significantly higher rates of mortality. LMS disease is 
associated with a significantly greater length of in-hospital stay and a worse 
medium-term survival. 
Priority is an important predictor of operative mortality with urgent and 
emergency cases having mortality rates of 2.2% & 8.3% respectively. 
Positively, in-hospital mortality in this group has fallen inspite of an increase in 
proportion presenting compared to elective cases. Urgent and emergency 
patients consistently stay in hospital longer than elective patients.  
Patients undergoing isolated CABG within 24 hours of a PCI have an overall 
mortality rate of 7.9%. Moderate and severe dyspnoea and extra cardiac 
arteriopathy are associated with an increased operative mortality and the 
mortality associated with redo surgery is nearly four times that of first-time 
surgery.  
Any degree of renal disease is associated with a marked increase in length-
of-stay. Renal disease is a powerful predictor of poor post-operative survival: 
for patients on dialysis the medium-term survival rate at 5 years after surgery 
is 50% compared to 90% for those without renal disease. 
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2.0 Revascularisation vs. medical therapy 
Three multicentre randomised controlled trials demonstrated early on the 
benefit of CABG over medical therapy: Veterans Administration Coronary 
Artery Bypass Surgery (VA) Study [79], Coronary Artery Surgery Study 
(CASS) [80] and the European Coronary Surgery Study (ECSS) [81]. 
Following these studies, there has been impetus to refine understanding and 
identify the best responders to CABG. 
In CASS [80] 780 patients with stable ischaemic heart disease were randomly 
assigned equally to receive surgical or nonsurgical treatment and quality of 
life was assessed. At ten year follow up these patients were found to have no 
difference in cumulative survival, percentage free of death and nonfatal 
myocardial infarction. Patients with an ejection faction (EF) <50% exhibited a 
better survival with initial surgery whilst those with EF ≥50% exhibited a higher 
proportion free of death and myocardial infarction with initial medical therapy. 
The 10 year follow up results of CASS confirmed the early reports that 
patients with left ventricular dysfunction have long-term benefit from surgery 
[82].  
In the European Coronary Surgery Study 768 men under 65 with mild to 
moderate angina, at least two-vessel disease and good left ventricular 
function were recruited. CABG was shown to significantly improve survival in 
patients with three-vessel disease and in those with stenosis in the proximal 
third of the left anterior descending artery constituting a component of either 
two or three vessel disease [81][83].  
To secure the position of CABG as a beneficial treatment strategy, an 
overview of seven randomised trials over ten years found those patients with 
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stable coronary heart disease receiving initial CABG (n=1324) had lower 
mortality at 5, 7 and 10 years than those receiving initial medical therapy 
(n=1325) [84]. Risk reduction was greater in those with left main artery 
disease than in those with three vessel disease or one or two vessels. The 
absolute benefits of CABG were more pronounced in patients in the highest 
risk categories.  
  
3.0 Revascularisation vs. percutaneous intervention 
3.1 CABG vs. balloon angioplasty 
Coronary-artery bypass grafting (CABG) and percutaneous transluminal 
coronary angioplasty (PTCA) are alternative methods of revascularization in 
patients with coronary artery disease. A number of large trials exist comparing 
the two treatment strategies: 
Randomised Intervention Treatment of Angina (RITA) trial compared the long-
term effects of PTCA with CABG in patients with one, two, or three diseased 
coronary arteries and randomised 1011 patients. Although recovery after the 
more invasive CABG took longer than PTCA it did result in less risk of angina 
and fewer additional diagnostic and therapeutic interventions in the first 2 
years with no significant difference in risk of death or myocardial infarction 
[85]. 
The Bypass Angioplasty Revascularisation Investigation (BARI) in patients 
with multivessel disease found PTCA did not significantly compromise five-
year survival in patients with multivessel disease, however once again 
subsequent revascularization was required more often with this strategy. For 
treated diabetics five-year survival was significantly better after CABG [86]. 
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The multinational, multicentre Coronary Angioplasty versus Bypass 
Revascularisation Investigation (CABRI) in 1054 patients with symptomatic 
multivessel coronary disease found PTCA patients more likely to have 
reinterventions [87].  
In another study the 5-year prognosis of patients with isolated proximal left 
anterior descending coronary artery stenosis was good and both PTCA and 
CABG improve clinical status, but revascularization was needed more 
frequently after PTCA. [88] 
To draw together the experiences a meta-analysis of eight randomised trials 
including 3371 patients comparing CABG (n=1161) with PTCA (n=1710) was 
performed. Overall there was a substantial similarity in outcome across the 
trials. The combined evidence showed no difference in prognosis between 
these two initial revascularisation strategies. However, the treatments differed 
markedly in the subsequent requirement for additional revascularisation 
procedures and in the relief of angina [89]. 
In terms of long-term mortality, pooled patient data (n=7812) from ten 
randomised trials with PCI achieved with balloon angioplasty in six trials and 
with bare-metal stents in four trials found it to be similar after CABG and PCI 
in most patient subgroups with multivessel coronary artery disease [90]. More 
recently the SYNTAX trial , a  noninferiority comparison of 1800 patients with 
three-vessel or left main coronary artery disease for the primary endpoint of a 
major adverse cardiac or cerebrovascular event (MACCE) (i.e., death from 
any cause, stroke, myocardial infarction, or repeat revascularization) during 
the 12-month period after randomization was performed. It was recommended 
that CABG remain the standard of care for patients with three-vessel or left 
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main coronary artery disease, since the use of CABG, as compared with PCI, 
resulted in lower rates of the combined end point of major adverse cardiac or 
cerebrovascular events at 1 year [91]. 
 
3.2 CABG vs. coronary stenting 
Following the arrival of coronary stenting as a method of coronary 
revascularisation studies have been performed to evaluate its efficacy as 
compared to the longer established conventional CABG:  
ERACI II found in symptomatic 450 patients with multivessel coronary artery 
disease randomly assigned to stenting (225) or CABG (225) during the first 30 
days, stented patients had lower major adverse events (death, myocardial 
infarction, repeat revascularization procedures and stroke [92]. 
ARTS (Arterial Revascularization Therapies Study) trial assessed the 
relationship between completeness of revascularization and adverse events 
at one year. In 1,205 randomly assigned patients with multivessel disease, 
complete revascularization was found to be more frequently accomplished by 
bypass surgery than by stent implantation. One year after bypass, there was 
no significant difference in event-free survival between surgically treated 
patients with complete revascularization and those with incomplete 
revascularization, but patients randomized to stenting with incomplete 
revascularization had a greater need for subsequent bypass surgery. [93]  
The Stent or Surgery (SoS) trial assessed the effect of stent-assisted 
percutaneous coronary intervention (PCI) (n=488) versus CABG (n=500) in 
the management of patients with multivessel disease. The use of coronary 
stents reduced the need for repeat revascularisation when compared with 
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previous studies that used balloon angioplasty, though the rate remained 
significantly higher than in patients managed with CABG [94]. The six-year 
follow up from the Stent or Surgery Trial (SoS) demonstrated a continued 
survival advantage for patients managed with CABG [95]. 
It was felt by some clinicians that the above trials and others individually were 
underpowered to properly assess safety end points like death, stroke, and 
myocardial infarction in stented patients. Since pooling data from randomized 
controlled trials increases the statistical power and allows better assessment 
of the treatment effect in high-risk subgroups a meta-analysis with 5-year 
patient level data from the ARTS, ERACI-II, MASS-II and SoS trials was 
performed [96]. 
The pooled analysis of 3051 patients in 4 randomized trials evaluating the 
relative safety and efficacy of PCI with stenting and CABG at 5 years for the 
treatment of multivessel coronary artery disease found PCI with stenting was 
associated with a long-term safety profile similar to that of CABG. However, 
as a result of persistently lower repeat revascularization rates in the CABG 
patients, overall major adverse cardiac and cerebrovascular event rates were 
significantly lower in the CABG group at 5 years [97]. 
Stents themselves have evolved since their initial application with the arrival 
of drug-eluting stents to add to the armamentarium, along with bare metal 
stents, of the Cardiologist. 
A randomized, double-blind trial comparing a sirolimus-eluting stent with a 
standard stent in 1058 patients found it to reduce the rates of restenosis and 
associated clinical events in all subgroups analyzed [97]. A further study has 
found that Sirolimus eluting stents (SES) are not inferior to CABG or bare 
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metal stents for the treatment of patients with multivessel coronary disease 
including involvement of the proximal LAD [98]. 
Reports continue to be promising with dug-eluting stents. Paclitaxel when 
compared to bare metal stents in a patient population with complex lesions 
reduces reduces clinical and angiographic restenosis [99].  
A significant body of longer term data comparing revascularisation techniques 
is awaited. However some data is becoming available. In a series of patients 
undergoing revascularisation between 2000 and 2007 (n=363) for unprotected 
left main stem coronary artery stenosis, CABG (n=216), PCI with drug eluting 
stents (n=94) and PCI with bare-metal stent (n=53) were compared. It was 
found that CABG patients had higher target lesion revascularisation (TLR)-
free survival and revascularisation-free survival than rival PCI groups. Cardiac 
death did not significantly differ between the 3 groups [100]. 
More long term data on the safety and outcomes of these techniques is still 
required and will certainly mark a turning point in the future of coronary 
revascularisation therapies on offer to specific patient populations. 
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CHAPTER 2:  ISCHAEMIC PRECONDITIONING  (IP) IN CARDIAC 
SURGERY: A SYSTEMATIC REVIEW OF 
EXPERIMENTAL AND CLINICAL LITERATURE  
 
1.0 Introduction 
1.1 Local (or ‘Cardiac’) Ischaemic Preconditioning  
In 1986 Reimer et al found that ATP levels in dog hearts subjected to serial 
ischaemia were higher than in those exposed to a single ischaemic event. 
This finding was the first description of ischaemic preconditioning (IP) [101]. 
This initial breakthrough by Reimer was confirmed by the finding by Murray et 
al in the same year that paradoxically intermittent ischaemia may not have an 
additive effect but rather a protective affect against subsequent ischaemia. 
[102]  
Murray et al described that myocardial ATP concentrations, on canine hearts, 
fell during the first brief episode of ischaemia. These concentrations were then 
preserved during further identical coronary artery occlusions and no necrosis 
occurred. They demonstrated that pre-treatment with repeated periods of 
ischaemia triggered adaptive changes that protected the myocardium from the 
effects of subsequent prolonged ischaemic insult “ischaemic preconditioning 
(IP)” [102]. 
Murray et al established that 4 cycles of 5 minutes coronary occlusion and 5 
minutes of reperfusion were sufficient to precondition the dog heart. They 
reported that the infarct size produced by 40 minutes of sustained coronary 
artery occlusion in anaesthetized open-chest dogs averaged approximately 
30% of the myocardium at risk. In contrast, in dogs that received 4 cycles of 5 
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minutes episodes of brief ischaemia immediately before the sustained test 
occlusion only 7% of the myocardium at risk became necrotic. Thus, despite a 
longer cumulative duration of coronary occlusion, infarct size in 
preconditioned dogs averaged only one fourth of that seen in controls. 
Reduction of infarct size is now considered the “gold standard” of IP. 
Yellon et al were the first to report that IP protects the human heart during 
cardiac surgery by demonstrating conservation of myocardial adenosine 
triphosphate (ATP) content in biopsy specimens. [103] They showed that 2 
cycles of 3 minutes ischaemia with 2 minutes reperfusion was effective during 
CABG surgery in preconditioning the human myocardium. They found that, as 
in the experimental canine model, myocardial ATP stores after 10 minutes of 
sustained ischaemia, in this case induced by aortic cross clamping and 
fibrillation during coronary artery bypass surgery, were significantly preserved 
in patients who first received two 3 minute episodes of intermittent 
crossclamping when compared with controls who received the sustained 
ischaemia alone. Subsequent studies by these investigators further 
documented a reduction in the release of cardiac troponin T (an index of 
cellular injury) in patients initially preconditioned before undergoing bypass. 
[104] 
The majority of surgeons today utilise cardioplegic arrest for cardioprotection. 
The first study during cardiac surgery with cardioplegia was performed with 
warm blood cardioplegia and the investigators found that preconditioning 
increased the early release of creatine kinase MB and the transmyocardial 
lactate gradient shifted toward production, this would suggest that 
preconditioning may increase the injury. This study initiated several studies, 
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some of which found a positive effect of preconditioning whereas others either 
found no effect or even a worsened postoperative outcome indicated by 
increased inotropic support. [105] 
Perrault et al reported that in the presence of cardioplegic arrest, there was no 
difference in the release of biochemical markers (CK-MB) between 
preconditioned and control groups. This lack of additional protection conferred 
by IP was further confirmed by the absence of difference in the post-arrest 
myocardial levels of ribonucleic messengers coding for cardioprotective heat 
shock proteins between the 2 groups. Similar negative results were reported 
by Kaukoranta, DiSalvo et al, who went on to report that in the presence of 
hypothermia, no beneficial effect of preconditioning was observed in similar 
patients undergoing surgery with intermittent fibrillation techniques. [106] 
 
1.2 Remote Ischaemic Preconditioning (RIPC) 
More than 20 years on since the breakthrough by Reimer et al the effect of 
intermittent upper limb ischaemia during coronary artery bypass surgery on 
the human heart has been investigated [107]. This technique has been coined 
“Remote Ischaemic Preconditioning (RIPC)”. 
RIPC was first suggested by Przyklenk et al after demonstrating that brief 
circumflex artery occlusion preconditioned the area of myocardium perfused 
by the left anterior descending artery. [108] 
Subsequent animal studies have expanded on the principle of RIPC to show 
that ischaemia of different organs such as the kidney, mesenterium, intestine 
and brain can also protect the heart. At the same time all organs tested 
demonstrate the presence of the preconditioning response. Furthermore, 
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RIPC of the brain appears not only to protect the heart but also preserves 
endothelial function of aortic rings in vitro. [105][109] 
IP is a powerful protective mechanism that appears to have immediate and 
delayed protective effects, the importance of which varies between species 
and organ systems. It is a multifactorial process requiring the interaction of 
numerous signals, second messengers and effector mechanisms. Stimuli 
other than ischaemia, such as hypoxic perfusion, tachycardia and 
pharmacological agents, including isoflurane have preconditioning-like effects. 
Currently IP is used during minimally invasive cardiac surgery without 
cardiopulmonary bypass to protect the myocardium against ischaemic injury 
during the anastomosis. [109] 
Other situations in which ischaemia occurs naturally or is induced by 
therapeutic manipulations include unstable angina before infarction, 
percutaneous transluminal coronary angioplasty and coronary artery bypass 
surgery with intermittent cross-clamp fibrillation. [110] 
The data accruing thus far for RIPC in both the medical and surgical 
cardiological arenas is promising and at present it appears to be one of the 
most important potential myocardial protective adjuncts so far identified.[111] 
Progress has been made in elucidating the mechanistic pathways underlying 
‘conditioning’ cardioprotection, and have resulted in the identification of novel 
targets for pharmacological preconditioning.[70] Future clinical applications of 
IP and RIPC will depend on the clarification of the underlying biochemical 
mechanisms, the development of pharmacological methods to induce 
preconditioning, and controlled trials in humans showing improved 
outcomes.[109]  
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2.0 Mechanisms Involved in Conditioning 
2.1.1 Ischaemic Preconditioning 
The underlying mechanism of IP remains to be unravelled in its entirety. 
Hypotheses have been postulated and relative mimetics have been identified 
but the clear underlying pathway is still not known. 
Once the molecular mechanisms of IP and the conditions that confer optimal 
protection in the human heart are defined then pharmacological intervention 
that mimic IP may be developed and used as an adjunct, rather than 
alternative to cardioplegia.[109] 
The first reported corollary of infarct size reduction with preconditioning is the 
observation by Murray et al that the rate of depletion of adenosine 
triphosphate (ATP) during the initial minutes of the sustained test occlusion 
was markedly attenuated in preconditioned dogs versus controls.[102] 
IP appears to provide ischaemia protection by a variety of physiological 
mechanisms. Energy requirements are reduced, conserving substrates and 
diminishing metabolism. Acid base and electrolyte homeostasis is therefore 
better controlled. Preconditioned tissues also demonstrate reduced oxidative 
stress, neutrophil activation and cytokine production and apoptosis.[112] 
Prolonged myocardial ischaemia, in addition to inflicting lethal injury on 
myocytes, also has a deleterious effect on the coronary vasculature, typically 
manifesting as a loss in both endothelium-dependent and endothelium-
independent coronary vasodilator reserve. However, whether the benefits of 
IP extend beyond the myocyte and protect the vasculature from sustained 
ischaemia is a topic of some controversy.[113] 
More relevant to cardiothoracic surgical practice, Yellon et al showed that IP 
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had positive effects on reducing ATP utilisation by cardiomyocytes during 
cardiopulmonary bypass.[103] Patients with angina within 24 hours of 
myocardial infarction had smaller infarct size. Improved left ventricular 
function and enhanced survival after reperfusion therapy.[112] 
It is suggested that the cardioprotection achieved with preconditioning is a 
receptor-mediated phenomenon. In the simplest terms, brief antecedent 
ischaemia is thought to stimulate one or more receptors on the myocyte 
membranes, thereby initiating one or more signal transduction pathways that 
culminate in the phosphorylation of an effector protein and ultimately render 
the myocytes resistant to subsequent sustained ischaemia. However, 
definitive identification of the receptor, the end effector, and most notably the 
intermediate signal transduction pathway evoked by brief antecedent 
ischaemia has proven to be far from simple.[113]  
 
2.1.2 Cellular Events 
IP is a powerful mechanism in reducing post-ischaemic myocardial injury. 
Brief periods of myocardial ischaemia result in the breakdown of ATP and so 
releasing adenosine. Adenosine receptor occupancy has been implicated to 
serve as both a trigger and a mediator of infarct size reduction with 
preconditioning.[113]  
A1 receptors are located on myocardial cells and A2 receptors are located on 
coronary endothelial and leucocyte/platelet membranes. Pretreatment of dog 
heart with selective A1 receptor agonists prior to an ischaemic event mimics 
the protection derived from IP, hence A1 receptors play a role in IP.  
Adenosine infusion prior to CABG surgery has been shown to improve 
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haemodynamics after cardiopulmonary bypass and decreases CPK 
release.[105] Adenosine has demonstrated a role in infarct size reduction with 
preconditioning in the rabbit, dog and swine models, however the rat is the 
exception, suggesting adenosine receptor activation is not the sole trigger for 
infarct size reduction with preconditioning.[113] 
The mechanisms of preconditioning probably vary between acute and delayed 
models and between local versus remote.[105] The initial phase of 
preconditioning may be similar between classic and delayed models and may 
start by release of a trigger substance during the brief episodes of ischaemia 
and reperfusion that may bind to surface receptors coupled to G1 proteins.  
Preconditioning–induced cardioprotection can be initiated by more than one 
receptor. Adenosine, α1adrenergic receptors, muscarinic M2, angiotensin II, 
bradykinin B2, σ-opiod receptors have been shown to play a contributory or 
additive role, or in some cases redundant roles. The common theme is that all 
receptors implicated are coupled to pertussis toxin-sensitive inhibitory G 
proteins. It appears that the stimulation of G1 protein-coupled receptors during 
brief antecedent ischaemia serves as a trigger for preconditioning-induced 
cardioprotection.[113] Other trigger substances have been identified as 
prostanoids, nitric oxide and low doses of reactive oxygen intermediates and 
natiuretic peptides. Tumour necrosis factor alpha has been indicated as a 
trigger of the preconditioning response.[105][113] 
The intracellular message in IP is generated through coupling of agonists of 
G-proteins that span the cell membrane. Adenosine, norepinephrine and 
bradykinin receptors are coupled to G proteins which when stimulated 
increase activity of phospholipase C and D. These enzymes catalyse 
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hydrolysis of membrane phospholipids, increasing diacylglycerol and inositol 
triphosphate levels. 
Diacylglycerol, a second messenger, activates protein kinase C (PKC), an 
enzyme believed to play a key role in the biochemistry of IP through its 
phosphorylation of effector proteins.[113] 
PKC is a hotly debated second messenger implicated to play a role in 
preconditioning. Brief episodes of myocardial ischaemia also result in 
transient increase in cytosolic calcium concentration and calcium is known to 
participate as a second messenger in many signalling pathways.[113] 
Tyrosine kinases as well as mitogen activated protein kinases appear 
involved in the signalling cascade in several species, although which kinase 
cascade is upstream or downstream is currently an issue of debate.[105] 
The next step in the signalling pathway is activation of transcription factors by 
protein kinases, reactive oxygen species, and nitric oxide, of which particularly 
nuclear factor κ-B (NFκB) has been investigated in both classic and delayed 
models. NFκB is a redox sensitive transcription factor that regulates 
transcription of battery of genes most of which are associated with 
proinflammatory effects such as cytokines, chemokines, and leucocyte 
adhesion molecules. Some candidate genes for organ protection in 
preconditioning are also regulated by NFκB. Pharmacologic blocking of NFκB 
translocation inhibits preconditioning in both classic and delayed models.[105] 
The importance of transcription factors is easy to grasp in models of delayed 
preconditioning in which the time frame for translation of protective 
substances is ample. However, the fact that transcription factors appear 
important for protection in classic models is less easy to grasp. The 
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cardioprotective effect of NFκB in immediate models may be due to an 
upregulation of its own inhibitor IκBα thus contributing to reducing a NFκB-
dependent inflammatory response during sustained ischaemia. However, 
abolishing classic preconditioning effects through employing the 
transcriptional inhibitor actinomycin D indicates that the process is complex. 
Other endogenous cardioprotective substances that are suggested as 
upregulated and protective are heat shock proteins of the 70kDA or 27kDA 
families. These have their own regulatory factors but do influence the 
activation of NFκB. Antioxidants, inducible nitric oxide synthase and inducible 
cyclooxygenase, all regulated by NFκB, have furthermore been indicated as 
organ effectors of protection. A last possible route of NFκB mediated 
cardioprotection is through the antiapoptotic effect of preconditioning. NFκB 
regulates several antiapoptotic molecules, such as Bcl-2, surviving, and 
inhibitor of apoptosis protein-1, as well as X-linked inhibitor of apoptosis 
protein-1.[105] 
In 1992 Gross et al proposed that opening of KATP channel may be involved in 
the reduction in infarct size seen in preconditioned myocardium. They found 
the selective KATP channel antagonist glibencamide in dogs either before, or 
immediately after, the brief preconditioning stimulus gave infarct sizes greater 
than those observed in preconditioned dogs. They also found that KATP 
agonists including bimakalin and aprikalim mimicked, the reduction in infarct 
size achieved by preconditioning and demonstrated a connection or synergy 
between adenosine receptor activation, opening of KATP channels, and 
cardioprotection.[113][114] 
Opening of the KATP channel is initiated by low intracellular concentrations of 
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ATP (i.e. as seen during ischaemia). The resultant efflux of potassium from 
the myocytes into the interstitium has thus been suggested to protect the cells 
via local “cardioplegia”. Opening of the KATP channel also results in membrane 
hyperpolarisation and shortening of the action potential duration. These 
electrical responses have further been associated with a reduction in calcium 
influx via voltage-sensitive calcium channels, and thus may attenuate myocyte 
death by attenuating calcium overload. KATP channels thus do not mediate 
infarct size reduction with preconditioning solely via more rapid or pronounced 
shortening of the action potential.[113] Activation of KATP channel causes 
release of reactive oxygen species and one may speculate that their role in 
preconditioning is linked to this.[105] 
There is only general agreement that G protein-coupled receptors initiate and 
KATP channels mediate infarct size reduction with preconditioning. The 
sequence of cellular events occurring between receptor activation and 
eventual cardioprotection are subject of considerable controversy.[113] 
In anaesthetized rabbits, transient systemic ischaemia, followed by HD with 
D-HES, can enhance early cardiac functional recovery following coronary 
artery occlusion and reperfusion, functioning as a powerful mechanism of IP. 
Transient systemic ischaemia is associated with increased endogenous nitric 
oxide (NO) production or release during reperfusion, which may have 
contributed to the improved early myocardial functional recovery in the 
rabbits.[115] 
In summary, stimulation of G protein-coupled receptors (most notably the 
adenosine A1 and A3 receptors) trigger or initiate the adaptation to later 
ischaemia and KATP channels appear to play role in “end effector” (Figure 
45 
 
2.1).[113] 
 
2.1.3 cAMP 
Reduction of cAMP has been implicated in the protection of IP against 
myocardial necrosis. Evidence for this is even in the absence of ischaemia, 
elevations in cAMP have been shown to produce myocardial necrosis. High 
levels of cAMP increase sarcolemmal calcium entry and increase the 
activation of cardiac lipases, effects that are known to aggravate ischaemic 
injury. 
In a rabbit heart model, 10 to 30 minutes of sustained regional ischaemia is 
accompanied by a nearly twofold increase in cAMP levels. IP induced in this 
model with a single cycle of transient ischaemia and reperfusion (IR) prior to 
sustained ischaemia, caused the increase in cAMP to be reduced. 
Furthermore three cycles of IR preceding the sustained ischaemia prevented 
the increase in cAMP.[116] 
How IP prevents the ischaemia-induced elevation in cAMP levels remains 
unclear. It has been suggested that the mechanism of cAMP reduction by IP 
does not involve activation of protein kinase C (PKC) or reduced 
responsiveness of the β-adrenergic effector pathway. It is suggested that the 
lack of elevation in cAMP levels observed during sustained ischaemia in IP 
hearts is mediated by an attenuation of norepinephrine release.  
Activation of adenylyl cyclase with NKH477 increases cAMP levels during 
sustained ischaemia but does not increase necrosis in control hearts or block 
the protection of IP against necrosis. It has been shown that the 
administration of either adenosine A1 receptor agonists or muscarinic M2 
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receptor agonists can mimic the positive effect of IP. In cardiac myocytes, 
both these receptors are coupled to adenylyl cyclase through β-adrenergic G1 
proteins and stimulation of these receptors inhibit cAMP formation.[116] 
Evidence has emerged that activation of PKC is the final effector pathway 
responsible for the protection of IP against necrosis and postischaemic 
dysfunction. Activation of PKC is also known to produce several effects on the 
cAMP-generating and degrading pathways. However, the net effect of PKC 
activation on myocardial cAMP levels is difficult to predict from available 
studies, because one of these effects would be expected to decrease cAMP 
(e.g. uncoupling of adenylyl cyclase-coupled receptors from Gs protein), 
whereas others would be expected to increase cAMP (e.g. ablation of G1 
function and direct sensitisation of adenylyl cyclase).[116] 
IP has also been shown to protect against arrhythmias in several species, 
including the conscious rabbit. High levels of cAMP are casually linked to the 
occurrence of arrhythmias and reducing cAMP levels with drugs such as β-
adrenergic receptor blockers have antiarrhythmic effects. Elevating cAMP 
levels with NKH477 have been shown to significantly increase the occurrence 
of fibrillation in both control and IP groups, thereby suggesting that high levels 
of cAMP are proarrhythmic.[116] 
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Figure 2.1:  Ischaemic preconditioning cascade. The first window of 
protection is shown on the left and the second window of protection on 
the right. AlRed = aldose reductase; Bcl-2 = antiapoptotic protein; DAG = 
diacylglycerol; COX-2 = cyclooxygenase 2; endothelial nitric oxide 
synthase; G-protein = protein that contains cell membrane receptors; 
HSP27 and HSP70 = heat shock proteins; iNOS = inducible nitric oxide 
synthase; KATP Mito and KATP SARC = ATP-dependent potassium 
channels in the mitochondria and sarcolemma respectively; MnSOD = 
manganese superoxide dismutase; NFKβ = nuclear factor Kβ; NO = nitric 
oxide; PKC = protein kinase C; PLC/PLD = phospholipases C and D; 
ROS = reactive oxygen species [334]. 
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2.2 Remote Ischaemic Preconditioning 
RIPC appears to involve adenosine, bradykinin, nitric oxide, protein kinase C, 
and inducible nitric oxide synthase. The apparent general effect of IP may be 
mediated by humoral or neurogenic factors or through substances in blood 
released from the preconditioned organ.[105] 
Previous studies in animals have indicated that remote preconditioning seems 
to involve release of adenosine, bradykinin or norepinephrine and activation of 
KATP channels and bears mechanistic resemblance to local preconditioning. In 
addition to humoral factors, remote preconditioning may also involve the 
autonomic nervous system or modulate the functions of circulating cells such 
as platelets.[117] 
There is evidence that endothelial dysfunction and reduced NO bioavailability 
are important components of IR injury, possibly limiting the extent of 
reperfusion after ischaemia and amplifying IR injury. RIPC might therefore 
reduce tissue injury by limiting endothelial damage during ischaemia 
reperfusion. Ventricular function during ischaemia has been seen to improve 
in preconditioned animals, suggesting a direct effect on the myocardium, 
possibly modifying the metabolic response to ischaemia. Whether endothelial 
preconditioning contributes directly to the reduction in myocardial IR injury 
remains to be determined, but results suggest that RIPC prevents tissue injury 
in animal and human models.[117] 
Data from a randomized controlled trial investigating the effects of RIPC on 
children undergoing cardiac surgery were consistent with an acute 
modification of inflammatory pathways. No significant difference in the mean 
level of IL-6, IL-8, IL-10 or TNF-alpha was found but there were significant 
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differences in variance of levels of IL-10 and TNF-alpha. High levels of TNF-
alpha are known to have a deleterious effect e.g. myocardial depression, 
capillary leak and pulmonary dysfunction.[118]  
In a human forearm model, RIPC has been shown to reduce neutrophil 
activation and endothelial dysfunction. Neutrophil activation leads to release 
of proteases and oxygen radical species that impair mechanical properties of 
the lung.[118] 
In a wild-type mouse hind limb model, RIPC protected left ventricular function 
and reduced infarct size during reperfusion. It was concluded that delayed 
cardioprotection induced by hind limb preconditioning involved signalling 
through nuclear factor kappa-B (NF B) and inducible nitric oxide synthase 
(iNOS).[119] 
Although the mechanism of both IP and RIPC has begun to be unravelled 
there still remains much that is not clear or well-defined. This represents an 
area that would benefit from large scale studies. 
 
2.3 Mitochondrial Transition Pore Opening  
Mitochondrial permeability transition (mPT) is a key event in cell death after 
ischaemia-reperfusion. Opening of the non-specific mitochondrial permeability 
transition pore (mPTP) in the inner mitochondrial membrane results in the 
collapse of the membrane potential, uncoupling of the respiratory chain, and 
efflux of cytochrome c and other proapoptotic factors that may lead to either 
apoptosis or necrosis. Ca2+ overload and excessive production of reactive 
oxygen species (ROS) in the early minutes of reflow trigger opening of the 
mPTP and are crucial events in reperfusion injury.[120] 
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A study on anaesthetised open-chest rabbits who underwent ischaemia-
reperfusion and control hearts that underwent no additional intervention found 
that postconditioning, preconditioning, and NIM811 (mPTP inhibitor) 
significantly limit infarct size.[120] 
The Ca2+ load required to open the mPTP in postconditioning, preconditioning 
and NIM811 was significantly higher than in controls and the study concluded 
that postconditioning inhibits opening of the mPTP and provides a powerful 
anti-ischemic protection. The data strongly suggested that mPT is an 
important mediator of cardioprotection.[120] 
In an adult rat myocyte model, known inhibitors of mPT (cyclosporine A and 
N-methyl-4-valine-cyclosporin A) demonstrated an increase in time taken to 
induce the mPT compared with control groups. Hypoxic preconditioning (HP) 
and pharmacological preconditioning, using diazoxide or nicorandil also 
increased the time taken to induce mPT compared with control groups. The 
effects of HP, diazoxide and nicorandil were shown to be abolished in the 
presence of mitochondrial ATP-sensitive K+ (KATP) channel blockers 
glibencamide and 5-hydroxydecanoate but were maintained in the presence 
of the sarcolemmal KATP channel blocker HMR-1098.[121] 
This evidence suggested that preconditioning protected the myocardium by 
reducing the probability of the mPT, which normally occurs during ischaemia-
reperfusion in response to oxidative stress.[121]   
Further studies on isolated rat hearts have promoted the theory that IP and 
mitochondrial KATP channel activation may protect the myocardium by 
inhibiting mPTP opening at reperfusion.[122]  
An isolated rat heart study concluded diazoxide (pharmacological 
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preconditioning) and mitochondrial uncoupling requires transient mPTP 
opening also and ROS to mediate protection.[123] 
Furthermore, in open-chest beagle dogs, mitochondrial and sarcolemmal KATP 
channels have been shown to independently play an important role in the 
limitation of infarct size in the heart by IP.[124] 
However, in one study on male Wistar rat hearts it was found that mPTP 
opening in mitochondria occurred more readily than control mitochondria, 
implying that mPTP inhibition by IP in situ was secondary to factors such as 
decreased calcium overload and oxidative stress. In addition, the hearts 
perfused with inhibitors of mPTP, also recovered better from ischaemia than 
controls. These agents were less effective than IP at preventing mPTP 
opening. The data suggested that protection from reperfusion injury was 
better achieved by reducing factors that induce mPTP opening rather than by 
inhibiting mPTP directly.[125] 
The evidence seems to indicate that the inner mitochondrial membrane ATP-
sensitive K+ channels (mitoKATP) appear to be activated during preconditioning 
and the mitochondrial and cellular consequences of this activation promote 
ischaemic protection. The effects seen include decreased loss of tissue ATP 
through reverse activity of ATP synthase due to increased mitochondrial 
matrix volumes and lower transport of adenine nucleotides into the 
matrix.[126] 
MitoKATP also decreases the release of mitochondrial ROS by promoting mild 
uncoupling in concert with K+/H+ exchange. Finally, mitoKATP activity may 
inhibit mitochondrial Ca2+ uptake during ischaemia, which, together with 
decreased reactive oxygen release, can prevent mPT, loss of organelle 
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function, and loss of physical integrity.[126] 
 
2.4 Postconditioning 
Brief episodes of myocardial ischemia-reperfusion employed during 
reperfusion after a prolonged ischemic insult may attenuate the total ischemia-
reperfusion injury. This phenomenon has been termed ischemic 
postconditioning. 
In humans, preservation of flow mediated dilatation by postconditioning is 
consistent with increased nitric oxide availability during reperfusion, either due 
to decreased nitric oxide inactivation and/or increased nitric oxide synthesis. 
In one study IR-induced endothelial injury resolved spontaneously within 60 
minutes of reperfusion, consistent with ‘endothelial stunning’ rather than 
necrosis in response to 20 minutes of ischaemia.[127] 
Postconditioning was initially proposed to act by reducing neutrophil-mediated 
damage in postischaemic myocardium but this cannot be the sole mechanism 
of action, because it is protective in isolated perfused hearts and cell culture 
systems that are neutrophil free. There may be effects to reduce reactive 
oxygen series production and calcium overload. Moreover evidence indicates 
that protection may be dependent on adenosine receptor stimulation, opening 
of mitochondrial KATP channels, activation of the prosurvival kinases PI3K-Akt 
and MEK½-Erk½, and inhibition of mitochondrial permeability transition pore 
opening, key factors implicated in ischaemic preconditioning-induced 
protection. These observations suggest that postconditioning and IP have 
common signalling pathways, which may explain why these protective 
phenomena are equally effective in protecting against IR injury.[127] 
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2.5 Cardiopulmonary bypass  
Cardiopulmonary bypass (CPB) is known to induce a systemic inflammatory 
reaction that is believed to be responsible for increased morbidity. More 
recent studies have demonstrated that CPB can also trigger preconditioning 
and be cardioprotective. 
CPB has been shown to trigger an activation of the kinase cascade that is 
mechanistically linked to opening of potassium channels.[128] It has been 
shown to stimulate alpha adrenergic and adenosine-1 receptors. It is 
implicated in a general inflammatory response involving generation of reactive 
oxygen species and increase of cytokines such as tumour necrosis factor 
alpha that may also be triggers of the preconditioning response.[105] 
The generation of free radical species occurs soon after the institution of CPB 
and so free radicals have been implicated as the primary cause of 
cardioprotection. The administration of oxygen free radicals scavengers 
during the first reperfusion period has been shown to block the beneficial 
effect of preconditioning on infarct size in dogs. The generation of low 
amounts of free radicals during the short ischaemic episode is not sufficient to 
cause cell necrosis but enough to modify cellular activity and induce 
preconditioning.[129] 
The opening of mitochondrial KATP channels triggers protection through the 
generation of free radicals that activate protein kinase C, an obligatory step in 
the signal transduction mechanism of IP.[130] 
Interleukin-1 and tumour necrosis factor-α, the production of which is 
increased by CPB, cause an elevation in tissue manganese-superoxide 
dismutase, which was demonstrated when brief sublethal ischaemia or anoxic 
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insults were induced. However, this thesis is unlikely, because the production 
of cytokines is a late event in response to CPB that requires more than 
10minutes.[131][132] 
The induction of CPB affects the body haemodynamics that may provoke a 
number of tissue responses. The loss of atrial and ventricular filling may 
stimulate a sympathetic-receptor-mediated release of local catecholamines, 
whereas the interruption of pulsatile systolic and diastolic blood flow to the 
adrenal glands may stimulate a systemic catecholamine release. Therefore, 
an altered adrenergic state may also be partially responsible for CPB-
associated preconditioning in human myocardium. Several investigators have 
observed that norepinephrine or phenylephrine triggers preconditioning and 
that this protection is prevented by adrenergic blockade.[133] 
Certainly, more studies are required to elucidate the mechanism of 
cardioprotection effected by CPB.  
 
2.6 Neural Factors 
One of the most intriguing questions regarding RIPC is how the transfer of the 
protective signal from the site of preconditioning to remote tissue occurs. 
There is evidence for humoral mediators that may include endogenous 
opioids. In addition, a neurogenic pathway has also been suggested, with 
evidence for involvement of the autonomic nervous system in the mechanism 
of the early phase and sensory C-fibres in the late phase.[134] 
One study, infusing the NN-cholinergic antagonist trimetaphan camsylate, 
demonstrated in humans in vivo that RIPC prevents endothelial injury in 
conduit vessels with two temporally distinct phases of protection. An early 
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(short) phase is activated immediately and disappears within 4h; a second 
late (prolonged) phase presents 24h after the application of the RIPC stimulus 
and is sustained for at least 48h. Both phases of RIPC are dependent on an 
intact autonomic function.[134] 
Time-control studies confirmed that trimetaphan, an autonomic ganglion 
blocker, had no direct effect on FMD, or the endothelial response to IR injury. 
However, when administered during RIPC, it blocked early and late protective 
effects on endothelial IR injury. It is possible that release of local triggers of IP 
(including bradykinin and adenosine) activate the autonomic nervous system 
either directly or via sensory nerves, and transfers the signal to the 
myocardium or other remote tissues. The present study data does not indicate 
which component of autonomic function (muscarinic or adrenergic) is 
involved.[134] 
One potential limitation of this study was the lack of specificity of trimetaphan 
which also has alpha-adrenoceptor blocking properties and induces the 
release of histamine. Moreover, trimetaphan has direct vasodilator actions, 
although the mechanisms of this effect are not currently known. Although 
these additional actions are unlikely to account for these effects described in 
the study, unknown effects of the drug that alter the response of the vascular 
endothelium to RIPC cannot be excluded.[134] 
In a further study to examine if brief anterior mesenteric artery occlusion 
(MAO) protects against myocardial infarction, involvement of a neurogenic 
pathway was suggested. The effect of ganglion blockade on the protection by 
MAO as well as CAO was examined. Ganglion blockade abolished the 
protection by 15-minute MAO during both normothermia and hypothermia but 
56 
 
had no effect on infarct size produced by 60-minute CAO and protection by IP 
at either temperature.[135] In addition, permanent MAO failed to limit 
myocardial infarct size produced by 60minute CAO indicating that reperfusion 
of the small intestine was mandatory to activate the neurogenic pathway. 
These results demonstrated the involvement of a neurogenic pathway in the 
protection by 15-minute MAO, indicating that protection by remote organ 
ischaemia may be different from that by IP. Because sustained MAO failed to 
produce cardioprotection it was suggested that the activation of the 
neurogenic pathway occurred during reperfusion after 15-minute MAO. The 
data could be interpreted to suggest that at reperfusion, substances released 
in the mesenteric bed (e.g. oxygen-derived free radicals, cytokines) stimulate 
afferent neurofibers. 
A study on male Wister rats treated with an HOE-140(bradykinin B2 receptor 
antagonist) demonstrated an important role for bradykinin in RIPC by MAO. 
Results supported the hypothesis that RIPC acts through sensory nerve 
stimulation in the ischaemic organ.[136] 
Further studies to support a neurogenic pathway include a study in rats 
preconditioned with a 15-min MAO that reduced infarct size produced by a 60-
min CAO. Pretreatment with a ganglion blocker abolished the protection by 
MAO15 and the cardioprotection of an intramesenteric artery infusion of 
adenosine. The findings demonstrated that locally released adenosine during 
small intestinal ischaemia stimulates afferent nerves in the mesenteric bed 
during early reperfusion, initiating a neurogenic pathway that leads to 
activation of myocardial adenosine receptors.[137] 
A study on rats found that RIPC significantly reduced infarct size which was 
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completely blocked by a PKC inhibitor The study concluded that RIPC 
activates myocardial PKCє, an essential mediator of classical IP, through a 
neuronal and bradykinin-dependent pathway. It was assumed that PKCє 
activation is an important step in cardioprotection induced by remote 
preconditioning. [138] 
 
2.7 Humoral Factors 
The combined body of knowledge to date suggests that either a neuronal or 
humoral trigger signal is released from distant ischaemic tissue, in effect 
preparing non preconditioned myocardium of the potential ischaemic insult to 
come. Isolation of the trigger signal responsible for preconditioning at a 
distance has obvious therapeutic potential as a stimulant of the patients own 
protective mechanisms. If the trigger signal responsible for preconditioning at 
a distance is humoral in nature then it should be transferable from one animal 
to another of similar species. 
Humoral and neuronal mechanisms are not necessarily mutually exclusive. 
One can envision a combined neuronal/humoral signal such that a humoral 
signal released by ischaemic tissue is detected by the CNS, leading to 
protective neuronal output. 
A study on rabbits paired by crossmatching and placed into preconditioned 
(P) or control sets and then further divided into preconditioned donor (PD) and 
preconditioned acceptor (PA) animals underwent a whole blood exchange 
between PD and PA animals before and after preconditioning [139]. The 
control rabbits underwent the same surgical procedures and time-sequenced 
transfusion without preconditioning. All animals then underwent prolonged 
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circumflex occlusion (60minutes) followed by reperfusion (30minutes). The 
percent infarct within the risk area was significantly lower in the PA and PD 
groups as compared with controls. There was no significant difference 
between the PA and PD groups. This study demonstrated the IP effect can be 
transferred to non-preconditioned animals via whole blood transfusion, 
suggesting a humoral mechanism for preconditioning at a distance. 
 
3.0 Clinical Benefits of Preconditioning  
The demographics of patients presenting for cardiac surgery is progressively 
shifting towards increased risk and so a need for enhanced myocardial 
protection has arisen. Due to the potential complications of repeated aortic 
cross clamp application the inclusion of classical IP in the armamentarium of 
surgical myocardial protection has been frustrated. The possibility of a method 
of overcoming the hazards yet still harnessing the potential benefit of 
modifying ischaemia-reperfusion injury in the form of RIPC is warmly 
welcomed. It is advertised as a cheap, effective, non-invasive, practical 
method with the ability to improve outcome and recovery with health resource 
incentive and multiple applications. 
 
3.1 Clinical benefits of Ischaemic Preconditioning 
The evidence for utilising IP as a myocardial protective regimen in the clinical 
cardiothoracic setting began in 1993 when Yellon et al investigated whether it 
was possible to precondition the human heart in coronary artery bypass 
surgery [103]. 14 patients undergoing CABG were randomised equally into 
two groups; IP and control. After establishing cardiopulmonary bypass (CPB), 
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those in the preconditioning group underwent two 3-min periods of 
crossclamping interspersed with 2 min of reperfusion. A slowing of the rate of 
adenosine triphosphate (ATP) depletion in biopsy specimens of those patients 
who had prior controlled IP was observed demonstrating that it may be 
possible to precondition and protect the human myocardium with short 
controlled periods of intermittent ischaemia and reperfusion. 
Further evidence for the myocardial protective properties of IP in humans was 
provided by a RCT into 33 patients with three vessel coronary artery disease 
and stable angina undergoing elective coronary artery bypass surgery [104]. 
After instituting CPB the IP group received a stimulus of two three-minute 
periods of myocardial ischaemia, by cross clamping the aorta, separated by 
two minutes of reperfusion. This was performed before the ischaemic period 
for the first coronary artery bypass graft distal anastomosis. All patients had 
an undetectable serum troponin T (<0.1 microgram/l) before CPB which was 
raised postoperatively. At 72 hours the serum troponin T release was lower 
(P=0.05) in the preconditioned group than in controls (median 0.3 vs. 1.4 
micrograms.L-1). The direct application of a preconditioning stimulus in clinical 
practice had been shown to protect patients against irreversible myocyte 
injury. 
The purported benefits of IP do not appear limited to coronary artery bypass 
surgery alone. In 1997 Lu et al published their study investigating the effects 
of preconditioning on myocardial ischemia-reperfusion injury in thirty patients 
with rheumatic heart disease requiring both aortic and mitral valve 
replacement undergoing prolonged cold crystalloid cardioplegic arrest [140]. 
Patients were randomly divided into two equal groups; preconditioned and 
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control. Preconditioning was achieved using two cycles of 2-minute occlusion 
of the vena cava and aorta followed by 3 minutes of reperfusion under CPB. 
All hearts were arrested with 40C St. Thomas' Hospital cardioplegic solution.  
IP protected the human ischaemic myocardium by maintaining ATP content 
90 minutes after ischemia (p<0.05), reducing the release of the myocardial-
specific isoenzyme of creatine kinase, improving markers of myocardial 
contractility: first derivative of left ventricular developed pressure 30 minutes 
after reperfusion (1490±102 vs. 1250±97 mmHg.s-1; p<0.05), and reducing 
the incidence of ventricular fibrillation, electric defibrillation time and elevation 
of ST segments.  
More evidence for the benefit of IP during valve surgery was published in 
1999 by Li et al. Forty patients requiring double valve replacement were 
randomised into two equal groups after the institution of CPB; IP and control. 
The IP stimulus was delivered as two cycles of 3 min ischaemia by occlusion 
of the vena cava and aortic crossclamping (effective left ventricular 
decompression by intracardiac drainage) followed by 2 min of reperfusion 
(removing all the occlusions) under CPB [141]. Hearts were arrested with 40C 
cold-blood cardioplegia and sampling from the coronary sinus and radial 
artery measured calcitonin gene-related peptide (CGRP) and creatine kinase-
MB (CK-MB) levels. Right atrial myocardial tissue was collected to measure 
superoxide dismutase/malondialdehyde (T-SOD/MDA) and to observe 
myocardial ultrastructure. 
IP was observed to enhance cardioplegic protection by decreasing the 
production of oxygen free radicals. At 30 minutes after reperfusion IP reduced 
myocardial MDA formation (2.6±0.2 vs. 3.8±0.3 nM.mg-1) and the 
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consumption of myocardial T-SOD (13.1±12.1 vs. 9.2±1.2 IU.mg-1) as 
compared to controls. The production of the endogenous myocardial 
protective substance CGRP (protein kinase C pathway) was increased just 
after preconditioning (92.0±4.1 vs. 52.3±4.5 pg.ml-1) and at the beginning of 
reperfusion (95.3±3.8 vs. 61.2±4.9 pg.ml-1). Preconditioning reduced the 
release of CK-MB at 12 h post-reperfusion (77.5±9.2 vs. 136.5±8.9 IU.l-1) and 
improved cardiac function at 30 min and 12 h (cardiac index 2.8±0.3 vs. 
2.3±0.2 and 2.9±0.1 vs. 2.4±0.2 L.min-1.m-2). 
As the evidence for the benefit of IP accrued, in a bid to refine myocardial 
protective strategy, a prospective randomised study compared IP with two 
established methods of protection, namely cold crystalloid cardioplegia and 
intermittent cross-clamp fibrillation (ICCF) [142]. 30 CABG patients were 
randomised to receive: (a) St Thomas' cardioplegia solution no. 2; (b) ICCF; 
or (c) IP. After establishing CPB, patients were preconditioned at 
normothermia using two 3-min periods of aortic cross-clamping with epicardial 
pacing, separated by 2 min of reperfusion (unpaced).  The coronary grafts 
were then performed as in group (b).  
IP was found to be superior at limiting myocardial necrosis but no difference 
was found to exist between cold crystalloid cardioplegia and ICCF. Mean 
troponin T at 72 h was significantly lower in the IP group compared with the 
cardioplegia and ICCF groups (0.5 vs. 2.1 vs. 1.3 microg.L-1; p=0.05).  
Another technique designed as a myocardial protection strategy is off-pump 
surgery. Ghosh et al investigated whether IP was able to protect against 
myocardial tissue damage in patients undergoing CABG with CPB and on the 
beating heart [133]. 120 patients were divided into 3 groups: (1) CPB with 
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ICCF; (2) CPB with cardioplegic arrest using cold blood cardioplegia; and (3) 
surgery on the beating heart. In each group (n=40) patients were randomly 
subdivided (n=20/subgroup) to controls and IP (1 cycle of 5 minutes of 
ischaemia and 5 minutes of reperfusion before intervention). IP was induced 
by clamping the ascending aorta in groups (1) and (2) or by clamping the 
coronary artery in group (3). 
IP was found to be protective in patients undergoing CABG on the beating 
heart but offered no additional benefit when associated with CPB regardless 
of the mode of cardioprotection used. Total troponin T release and the release 
profile was similar in the patients undergoing surgery with CPB (groups (1) 
and (2)); they were unaffected by IP. In contrast, the total troponin T release 
for the first 48 hours was significantly reduced by IP in the patients 
undergoing surgery without CPB (group (3)) (3.1±0.1 to 2.1±0.2 ng.h.ml). 
Furthermore the release profile that peaked at 8 hours in the control group 
shifted to the left at 1 hour.  
As further evidence for the lack of additional benefit of IP in patients on-CPB 
in vitro studies using atrial muscles obtained before CPB were found to be 
protected by IP however muscles obtained 10 minutes after CPB were 
already protected and IP did not result in further improvements. 
 
3.2 Clinical Benefits of Remote Ischaemic Preconditioning 
Several clinical reports of the potential of RIPC to modify ischaemia-
reperfusion have now been published.  
In 37 children undergoing congenital heart defect repairs utilising CPB, lower 
limb RIPC (four 5min cycles blood pressure cuff inflation; n=17) has been 
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demonstrated to reduce troponin I release, inotrope requirements and airway 
resistance [118].  
In abdominal aortic aneurysm surgery (RIPC n=41; Control n=41), RIPC, 
induced by 2 cycles of intermittent crossclamping of the common iliac arteries 
with 10mins ischaemia followed by 10mins reperfusion reduced the incidence 
of myocardial injury (troponin I) by 27% (p<0.01), MI by 22% (p<0.01) and  
renal impairment by 23% (p<0.01) [143]. 
In adults undergoing CABG, intermittent upper limb ischaemia has been 
followed by reductions in post-operative release of lactate dehydrogenase 
[144] and troponin [103].  
Further evidence that RIPC may improve myocardial protection in humans is 
provided in a single centre randomised trial investigating RIPC or no 
intervention in 45 patients undergoing CABG with or without concomitant 
aortic valve replacement (AVR) as an adjunct to antegrade±retrograde blood 
cardioplegia myocardial protection [145]. Patients with diabetes, renal, hepatic 
or pulmonary dysfunction were excluded as were those with unstable angina 
or myocardial infarction within 4 weeks of surgery. The remote preconditioning 
stimulus comprised of three 5-minute cycles of forearm ischaemia, induced by 
inflating a blood pressure cuff on the upper arm to 200mmHg with an 
intervening 5 min reperfusion. The control group had a deflated cuff placed on 
the upper arm for 30 min. On parametric analysis, RIPC was found to reduce 
AUC serum cTnT release by >40%. The magnitude of the effect was similar to 
that observed in a cohort of patients undergoing intermittent ischaemic arrest 
as a mode of myocardial protection reported by the same group previously 
[107]. Unfortunately, clinical outcomes are not reported.  
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A deeper examination of the study design by Venugopal et al, reveals blinding 
of treatment allocation was applied to patients and surgeons only; 
anaesthetists (who administer agents capable of preconditioning or affecting 
myocardial protection) and investigators were not blinded. Similar proportions 
of patients received isoflurane or sevoflurane for anaesthetic maintenance but 
dosages are not reported. As such volatile anaesthetic agents may induce a 
dose dependent conditioning effect [146] a potential for inadvertent bias 
arises. The study was small and contained only half of the estimated number 
of patients to detect the initially anticipated difference in AUC cTnT of 15 µg.L-
1
.72hrs (standard deviation 25 µg.L-1.72hrs) quoted in the statistical 
methodology. Statistical significance was actually attained with a smaller 
mean difference and sample size and this is attributable to the lower than 
anticipated variance observed in the RIPC group. The study also included 
patients requiring AVR; whether RIPC was effective in the CABG alone 
patients is not reported. The larger number of combined AVR/CABG cases 
contributed to a longer mean bypass time in the control group and bypass 
time was an independent predictor of greater troponin release. Despite this 
potentially confounding effect, an inter-group statistically significant difference 
was maintained after correction for bypass time using a generalised linear 
model. Many of the important variables in the study e.g. bypass time, cross-
clamp time and AUC cTnT had unequal variances yet were analysed 
parametrically unlike the authors’ previous report.  Although the drug history is 
reported, whether potentially relevant medications e.g. atorvastatin, potassium 
channel blockers [147][148] administered in the 24 hours pre-operatively is 
not clear.  
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Nevertheless, the effect of RIPC on troponin release was large and the data 
are very encouraging. In particular, the troponin effect was observed despite 
the use of halogenated anaesthetic gases in the majority of patients. Several 
studies have demonstrated that such volatile anaesthetic agents may reduce 
evidence of myocardial injury during CABG via what is thought to be a pre-
conditioning mechanism [66][68][149]. Thus, this study is important as it 
suggests that the effect of RIPC is, at least additive to any protective effect 
afforded by iso- and sevo-flurane.    
On the basis of this and other work, there is now a need to determine (i) the 
efficacy of RIPC in promoting protection in other forms of cardiac surgery (ii) 
to ascertain whether the changes in troponin release are reproducible in other 
studies and (iii) to establish if these changes are reflected in improved clinical 
outcomes and that RIPC independently reduces risk.  
 
4.0 Conclusion 
With the acknowledged shift to more severe disease within the patient 
population undergoing cardiovascular surgery, the cardiothoracic surgeon 
must reinforce his armoury with more robust, economically viable methods of 
myocardial protection. With the limitations of IP in mind, the initial experience 
of RIPC seems to suggest a novel method of protection that could be 
realistically harnessed and refined so as to meet the demands posed. A large 
randomised controlled study into the effects of RIPC in human cardiac surgery 
is thus demanded. In addition, a greater understanding of the mechanisms 
involved in IP and RIPC would offer a welcome hope for pharmacological 
agents to be developed and assist in the role of myocardial protection. 
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CHAPTER 3: CORE METHODOLOGY 
 
1.0  Introduction 
The work of this thesis reports the outcomes of a single centre, prospective, 
double blind, randomised, placebo-controlled trial and investigates the effects of 
intermittent upper limb ischaemia prior to cardiac ischaemia on the indices of 
myocardial injury (biochemical, functional and arrhythmic) and early renal and 
lung outcomes in patients undergoing first time isolated coronary artery bypass 
grafting (CABG) between January 2007 and March 2009. 
This study was conducted at the Department of Cardiothoracic Surgery, 
University Hospital Birmingham NHS Trust with the assistance of the Wellcome 
Clinical Research Facility and local NHS and University Laboratories. Patient 
recruitment was from the operating lists of two Consultant Cardiothoracic 
Surgeons. 
Research and ethics approval was sought (LREC reference number 
06/Q2702/7) and funding was provided by the British Heart Foundation (BHF 
Project Grant PG/05/125). The trial was registered with the UKCRN (4659). 
A sample of patient data collection, information and consent forms are included 
in Appendix A. 
Procedures that have been standardised across a number of trials including 
protocols for departmental postoperative management of patients are 
referenced in Appendix B. 
Below follows the study flow and methodology specific to the REMOTE Trial. 
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1.1     Study Flow 
1. Informed consent  
2. Preoperative investigations (incl. Spirometry; echocardiography) 
3. Final consideration of exclusion and inclusion criteria 
4. >12 hrs preoperatively Continuous Holter ECG monitor applied. To 
continue until 48 hrs post-operatively 
5. Randomisation 
6. Anaesthesia according to protocol 
7. PA catheter flotation in anaesthetic room 
8. Baseline cardiac function and biochemical markers pre-sternotomy 
9. Remote ischaemic preconditioning (RIPC) stimulus or placebo applied 
during the LIMA harvest (approx 45 mins prior to CPB, aortic clamping 
and cardioplegia arrest). 
10. Cardiopulmonary bypass management according to protocol 
11. Coronary artery bypass surgery conducted using intermittent antegrade 
cold blood cardioplegia administered according to protocol 
12. Serial post-operative studies of haemodynamic performance and 
biochemical markers 
13. Follow-up of post-operative events and timings 
 
2.0 Recruitment  
2.1 Patient selection  
All patients undergoing elective or urgent isolated, first time coronary artery 
bypass grafts with intention to use cardiopulmonary bypass were considered for 
recruitment in this study.  
68 
 
Patients were invited to participate in the study at the preadmission clinic or on 
the ward in the case of in-patients. Patient Information sheet was provided 
(Appendix A) and those that agreed to the trial consented on a standard form 
(Appendix A). Patients were under the care of either Surgeon A or B.  
Patient demographics and operative details were recorded in a standardised 
data collection sheet (Appendix A). 
 
2.2 Inclusion and Exclusion Criteria 
Both elective and urgent patients (post-acute coronary syndrome) adult non-
diabetic patients undergoing first time multi-vessel CABG utilising CPB were 
included in the trial. 
Excluded patients were those >80 years, pregnant, renal impaired requiring pre-
operative renal support therapy, diabetics, intended non-coronary surgery,  
episodes of angina or ischaemia within 48 hours of procedure, intention to use 
the left radial artery or cephalic vein as a bypass conduit and chronic AF. 
Patients with ST-elevation myocardial infarction within 30 days were also 
excluded. All referred patients were considered for entry and all eligible 
patients were approached for consent.  
Pre-medication, anaesthesia, perfusion, cardioplegia and surgical techniques 
were standardized.  
 
2.3 Randomisation  
Prior to the start of the trial recruitment a computer generated block 
randomisation method with blocks of size 6 was used to prepare two boxes of 
envelopes labelled to ‘Surgeon A’ and ‘Surgeon B’. Each box contained pre-
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coded opaque envelopes containing instruction on treatment protocol (RIPC or 
control). Subjects were randomised on a 1:1 basis to receive RIPC (3 x 5min 
cycles of upper limb (or dummy arm) 9cm cuff inflation to 200mmHg separated 
by 5 min periods of cuff deflation. Trial staff, operating surgeons, anaesthetists 
and ITU personnel were all blinded to patient group allocation. The envelopes 
were accessed confidentially by the operating department practitioner (ODP) at 
anaesthetic induction.  
The REMOTE technique ensured blinding of trial staff, anaesthetist and 
surgeons intraoperatively.  
Each envelope contained a form which was signed by the ODP to confirm 
treatment had been performed successfully and then was sealed inside a pre-
prepared envelope and returned to the Research Fellow.  
 
3.0 Pre-operative medications 
All anti-anginal medication (β-blockers, Ca2+channel blockers, nitrates) were 
continued up to and including the morning of surgery to prevent recurrence and 
to provide for a more stable anaesthetic course.  
Antihypertensive medications were given the morning of surgery to prevent 
rebound hypertension and provide for a more stable anaesthetic course. As 
patients taking ACE inhibitors tend to have a lower systemic resistance on 
bypass and in the immediate postoperative period this medication was withheld 
the day prior to surgery. [150] 
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3.1 Permitted drugs 
3.1.1 Statins 
Patients on a statin(oral) received their standard dose on the evening prior to 
surgery because of the beneficial effect (Chapter 1: Section2; 8.0) 
 
3.1.2 Ca2+ channel antagonists (oral) 
Patients receiving calcium channel antagonists on admission received a 
standard dose on the day of surgery. 
 
3.1.3 β-receptor antagonists (oral) 
Patients receiving beta-blockers on admission received a standard dose on the 
day of surgery. The use of preoperative β-blockers has been shown to lower the 
mortality rate of coronary bypass surgery.[151][152] 
 
3.1.4 Long acting nitrates (oral) 
Patients receiving long acting nitrates on admission received a standard dose 
on the day of surgery. 
 
3.2 Drugs to be omitted 
3.2.1 Anti-platelet agents 
Aspirin and other anti-platelet therapy were routinely stopped 7 days before 
admission or in the pre-admission clinic. The day that the aspirin was stopped 
was recorded. Failure to stop aspirin therapy did not exclude patients from this 
study but was recorded for data interpretation purposes.  
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In patient transfers with stable symptoms clopidogrel and aspirin was stopped 
for at least 1 week prior to surgery. If symptoms were unstable or there was 
significant (>50%) LMS stenosis aspirin was continued (or clopidogrel was 
converted to aspirin) for at least 7 days prior to surgery. 
Aspirin has been shown to be associated with increased perioperative blood 
loss by superimposing impaired platelet function on numerous derangements in 
the clotting mechanism caused by CPB. Aspirin irreversibly acetylates platelet 
cycloxygenase, impairing thromboxane A2 formation and inhibiting platelet 
aggregation for the lifespan of the platelet (7-10 days) [150]. 
 
3.2.2  Angiotensin converting enzyme (ACE) inhibitors 
ACE inhibitors were stopped 24 hours prior to surgery or on admission in line 
with departmental policy. 
 
3.2.3 Angiotensin-II receptor antagonists ‘Sartans’  
Angiotensin-II receptor antagonists 'Sartans' were stopped for 24 hours prior to 
surgery or on admission. 
 
3.2.4 Diuretics  
Diuretics were omitted on the day of surgery. 
 
3.2.5 Potassium channel activators 
Nicorandil was not administered for 24 hours pre-operatively so as not to bias 
the results of the trial (Chapter 1; Section 2; 7.0). 
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3.3 Scheduled drugs 
3.3.1 Premedication 
90 minutes before surgery Temazepam 20-30mg (oral), Ranitidine 150 mg 
(oral) and Metoclopramide 10 mg (oral) was administered  
 
4.0 Treatment Groups 
4.1 Control Group 
A dummy arm was placed beside the left upper arm. Both dummy arm and left 
upper arm were connected to a tourniquet machine with two independent 
tourniquet cuffs (Figures 3.1, 3.2). 
Connection of the cuffs was conducted after the patient was anaesthetised, 
prepped and draped on the surgical table by the Operating Department 
Practitioner (ODP). The ODP would follow the instructions in the randomisation 
envelope when connecting the two cuffs and at all times would ensure blinding 
of trial staff, anaesthetists, surgeons and theatre staff remained. 
Figure 3.1: Tourniquet machine  
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Figure 3.2: Dummy arm and cuff adjacent to cuffed upper limb 
 
                                                                 
Dummy arm cuff inflation was commenced at left internal mammary artery 
(LIMA) harvest. 3 cycles of cuff inflation (5minutes) and deflation (5minutes) 
were performed.  
A pulse oximeter placed on the left middle finger and connected to a concealed 
monitor below the draped operating table was checked to ensure no change in 
arterial trace took place. 
 
4.2 RIPC Group 
Both dummy arm and left upper arm were connected to a tourniquet machine 
with two independent tourniquet cuffs.  
Connection of the cuffs was conducted after the patient was anaesthetised, 
prepped and draped on the surgical table by the ODP. The ODP would follow 
the instructions in the randomisation envelope when connecting the two cuffs 
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and at all times would ensure blinding of trial staff, anaesthetists, surgeons and 
theatre staff remained. 
Upper arm cuff inflation was commenced at left internal mammary artery (LIMA) 
harvest. 3 cycles of cuff inflation (5minutes) and deflation (5minutes were 
performed. In this study, we used an identical stimulus as previous reports that 
demonstrated a >40% reduction in cTnT release [107][145]. 
A pulse oximeter placed on the left middle finger and connected to a concealed 
monitor below the draped operating table was checked to ensure a change in 
arterial trace took place (Figure 3.3, 3.4, 3.5).  
 
Figure 3.3: Cuffed left upper limb with attached pulse oximeter probe 
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Figure 3.4: Pulse oximeter monitor concealed below operating table 
 
Figure 3.5: Cuffs attached once patient prepped and draped 
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5.0 Anaesthetic Protocols 
5.1 Induction of anaesthesia 
Anaesthesia was induced in the anaesthetic room with the following regimen: 
• Fentanyl 10-15 mcg.kg-1  
• Etomidate 0.1-0.2 mg.kg-1 
• Pancuronium 0.1 mg.kg-1 
 
5.2 Central venous cannulation 
All patients received a: 
• Quadruple lumen central venous line 
• Pulmonary artery catheter and sheath, fully floated into the pulmonary 
artery prior to sternotomy.  
Baseline haemodynamic measurements were performed prior to sternotomy. 
 
5.3 Maintenance of anaesthesia 
• Propofol 2% infused at 4-8 mg.kg-1.hr-1 
• Alfentanil 25mg in 50ml used for maintenance infused at 50mcg.kg.h-1 
• Enflurane 0-2% or Sevoflurane volatile anaesthesia was used to 
supplement the propofol-based anaesthesia (Figure 3.6). 
n.b. isoflurane volatile anaesthesia was not permitted to supplement propofol-
based anaesthesia as it has a potential pre-conditioning effect on the 
myocardium (Chapter 1: Section 2; 5.2). 
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Figure 3.6: Anaesthetic machine 
 
                             
5.4 Other medications 
• Mannitol 20% 0.5g.kg-1 was administered into the central line and not the 
heart-lung machine reservoir, prior to cardiopulmonary bypass (CPB) 
• GTN (50mg made up to 50ml) was administered intra-operatively at a 
minimum dose of 0.1ml.hr-1 
• Dopamine (low dose) as “renal dopamine” was not used in this study. 
However dopamine (high dose) was the first choice inotropic agent 
• Isoflurane was NOT used for anaesthetic maintenance 
• Tranexamic acid was used, not aprotinin, as the antifibrinolytic agent. 
Aprotinin has beneficial myocardial protective effects (Chapter 1:Section 
2;9.0). Initial bolus of 30mg.kg-1; pump prime 2mg.kg-1; infusion 
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16mg.kg.h-1 until the end of surgery. Tranexamic acid has a better risk 
benefit profile than aprotinin in low to moderate risk cases.[153] 
• Patients with moderately impaired renal function (Cr 130-200) received 
frusemide 250mg in 25ml (10mg.ml-1) neat infused at 0.2 ml.hr-1 
 
6.0 Perfusion Protocols 
6.1 Bypass schedule 
All patients underwent surgery utilising cardiopulmonary bypass (Table 3.1; 
Figure 3.7): 
 
Table 3.1: Bypass schedule 
Prime 2 L Hartman’s saline + 10000 units heparin 
Pump Roller Pump 
Oxygenator Capiox.SX Membrane Oxygenator 
Flow range 2.4 L.min-1.m-2 
Mean perfusion pressure Radial artery 50-60 mmHg 
Vasoactive drugs Phenylephrine (1mg in 10ml. N/Saline) administered in 0.5-
1.0ml aliquots and titrated to effect. 
Not metariminol (aramine). If phenylephrine fails to 
maintain perfusion pressure, noradrenaline may be used  
Cooling/rewarming Blood/water temperature gradient to be ≤ 7° C 
α-stat standardisation of the blood gases 
Cooling active cooling to 34OC in all cases 
Protection Antegrade intermittent cold blood cardioplegia 
 
Perfusionists were requested to enter the time and dose of each administration 
of phenylephrine onto the perfusion chart. The effect of each test solution on 
haemodynamic stability during CPB was assessed as part of the study.  
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Figure 3.7: Cardiopulmonary bypass machine 
 
 
6.2 Cardioplegia composition 
• St. Thomas A stock solution: 
1L of Ringer’s compound sodium chloride 
102 ml of cardioplegia infusion  
16.6 MgCl2.L-1 
6.0843 KCl.L-1 
Procaine hydrochloride 1391.28 mg.L-1 
• St. Thomas B stock solution:  
1L of Ringer’s compound sodium chloride  
32 ml of cardioplegia infusion 
5.2 MgCl2.L-1 
1.9 KCl.L-1 
Procaine hydrochloride 435.68 mg.L-1 
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6.3 Cardioplegia administration (Table 3.2) 
Intermittent antegrade cold blood St Thomas’ cardioplegia (Martindale 
pharmaceuticals Essex, UK) was used for myocardial protection with an 
induction dose of 12ml.kg-1 followed by maintenance administration each 15-
20 minutes 
Table 3.2: Cardioplegia protocol 
Temperature 4° C 
Delivery Aortic root 
Pressure 120-150 mmHg 
Induction St Thomas A stock at AXC at 12 ml.kg-1 (800 ml blood + 200 ml stock A 
solution)  
Maintenance St Thomas B stock after max 30 minutes or between anastomoses at 
surgical discretion 300ml doses (400 ml blood + 100 ml stock B 
solution). Hot shot was not permitted 
 
6.4 Discontinuation of CPB 
On rewarming once the nasopharyngeal temperature reached 35°C the 
heater/chiller temperature was set to 37°C 
CPB separation occurred at 36oC-37oC nasopharyngeal temperature using 
atrial or dual-chamber epicardial pacing to achieve a target heart rate of 
90min-1.  
 
7.0 Surgical Protocol 
7.1 Conduct of operation 
The technique to be adopted is as follows in the operating theatre: 
• Institution of cardiopulmonary bypass 
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• Aortic cross-clamping and completion of all proximal and distal 
anastomoses during a single clamp period. Planned bypass conduits 
would be internal mammary artery and saphenous vein. 
• Rewarming should commence during the penultimate anastomosis. 
 
7.2 Surgical technique (Table 3.3) 
Table 3.3: Surgical technique 
Heparinisation timing Heparin should be requested and administered following 
procurement of all conduit just prior to commencing the 
aortic purse string insertion 
Heparin dose 300 units.kg-1 
Cannulation Standard cannulation 
Cooling Active cooling to 34°C in all cases 
 
7.3 Myocardial protection (Table 3.4) 
Table 3.4: Myocardial protection 
Technique Antegrade intermittent cold blood cardioplegia 
Induction dose St Thomas ‘A’ stock at AXC at 12 ml.kg-1 (800 ml blood + 200 ml 
‘A’ solution) 
Maintenance dose St Thomas ‘B’ stock in all cases after 20 minutes or between 
anastomoses at surgical discretion (400 ml blood + 100 ml ‘B’ 
solution) for intermittent administration of 300ml doses. 
Hot shot is not permitted 
De-airing  
 
7.4 Myocardial Biopsy 
Patients underwent myocardial biopsy studies. Biopsies (LV) were full thickness 
and taken from a non-scarred area of the anterior wall.  
Biopsies (x1 core) were taken from: 
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• Right atrium    ↔ at cannulation within boundaries of the 
atrial purse string  
• LV 1 (pre-ischaemia) ↔ just before AXC on CPB using 
fibrillation if preferred 
• LV2 (ischaemia)  ↔ immediately before AXC release 
• LV3 (reperfusion)  ↔ 10 minutes after the AXC release  
Atrial and trucut biopsies were snap frozen in liquid nitrogen and stored at -
700C. The biopsy sites required 5’O’ prolene suture oversewn to ensure 
haemostasis.  
 
8.0  Operating department practitioner protocol 
8.1 Checklist prior to commencing (Table 3.5) 
Table 3.5: ODP checklist 
Anaesthetic drugs as per protocol Placebo group: Dummy arm 
Quad-lumen and Swan-Ganz catheter + 
injectate coil 
Stimulus group: Patient LEFT 
arm 
Air splitter device Portable saturation monitor 
Tourniquet machine with two cuffs Stopwatch 
 
8.2 Conduct of ODP 
1. ODP action randomisation - boxes Surgeon A or Surgeon B 
2. Prepare anaesthetic drugs as per protocol 
3. Insert RIGHT radial arterial line and ABG 
4. 20 ml blood for 2x yellow top bottles (cTnT and routine biochemistry), 
1x purple and 1x blue (haematological indices) top withdrawn 
5. Quad-lumen and Swan-Ganz catheter + injectate coil insert and float 
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prior to draping 
6. Urine (for ACR and α-1 microglobulin) 
7.  Connect air splitter to AIR port in theatre  
8. Air splitter device in AIR port in operating theatre to supply 
anaesthetic and cuff inflation machine 
9. Apply tourniquet cuffs to LEFT arm and dummy arm. Keep tourniquet 
hoses detached 
10. Apply Pulse oximeter to LEFT index finger from separate monitor 
(blinded to all except ODP). Check trace 
11. Drape patient 
12. Connect tourniquet hose A and hose B  to either LEFT arm or dummy 
arm (as per randomisation instructions) 
13. Ensure  RED LIGHT on tourniquet machine (cuff is deflated) 
14. Document 1st systolic blood pressure (SBP) from either RIGHT radial 
or RIGHT femoral arterial line 
15. At beginning of LIMA harvest, blinded anaesthetist to inflate 
tourniquet A to 200mmHg (1st cycle of STIMULUS). Start stopwatch 
for 5 mins. 
16. GREEN LIGHT will show on tourniquet machine (cuff is inflated) 
17. ODP check pulse oximeter trace lost if patient arm inflated.  
18. After 5 mins of ischaemia deflate tourniquet A. RED LIGHT will show 
19. Time 5 mins of reperfusion with stopwatch  
20. Document 2nd SBP 
21. Reinflate cuff to 200mmHg for 5 mins (2ND cycle of STIMULUS). 
GREEN LIGHT will show. 
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22. Deflate cuff for 5 mins reperfusion. RED LIGHT will show 
23. Document 3rd SBP 
24. Reinflate cuff to 200mmHg for 5 mins (3rd cycle of STIMULUS). 
GREEN LIGHT will show 
25. Deflate cuff for reperfusion. RED LIGHT will show 
26. ODP to check pulse oximeter trace returned once patient arm 
deflated and document on sheet 
Stimulus now complete. 
27. Disconnect tourniquet hoses from cuffs and remove dummy arm 
28. On de-draping, safeguard the Holter monitor leads and monitor on the 
patient 
 
9.0 Biochemical monitoring protocol 
9.1 Cardiac Troponin T [154] 
Biochemical estimation of myocyte injury was deduced from cardiac Troponin T 
(cTnT). Samples were taken pre-sternotomy (in anaesthetic room), 6h, 12h, 24h 
and 48h after aortic cross clamp release and sent for analysis to the 
Department of Biochemistry at the University Hospital Birmingham NHS FT. A 
commercially available assay (Elecsys 2010; Roche Diagnostics, UK) was 
utilised in conjunction with an automated clinical analyser (Roche Modular 
E170). 
Troponin T (TnT) is a component of the contractile apparatus of the striated 
musculature. Although the function of TnT is the same in all striated muscles, 
TnT originating exclusively from the myocardium (cardiac TnT, molecular 
weight 39.7kD) clearly differs from skeletal muscle TnT. As a result of its high 
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tissue-specificity, cTnT is a cardio specific, highly sensitive marker for 
myocardial damage.  
The Elecsys Troponin T assay employs two monoclonal antibodies 
specifically directed against human cardiac troponin T. The antibodies 
recognise two epitopes (amino acid position 125-131 and 136-147) located in 
the central part of the cardiac troponin T protein, which consists of 288 amino 
acids. Elecsys Troponin T assay detects free troponin T as well as binary and 
ternary complexes of troponin. 
 
9.2 Test Principle – Sandwich principle [154] 
The total duration of the assay was 18 minutes.  
• 1st incubation: 15µl of sample, a biotinylated monoclonal troponin T-
specific antibody and a monoclonal troponin T-specific antibody 
labelled with ruthenium complex react to form a sandwich complex. 
• 2nd incubation: After addition of streptavidin-coated microparticles, the 
complex becomes bound to the solid phase via interaction of biotin and 
streptavidin. 
• The reaction mixture is aspirated into the measuring cell where the 
microparticles are magnetically captured onto the surface of the 
electrode. Unbound substances are then removed with ProCell. 
Application of a voltage to the electrode then induces 
chemiluminescent emission which is measured by a photomultiplier. 
• Results are determined via a calibration curve which is instrument-
specifically generated by 2-point calibration and a master curve (5-
point calibration) provided by the reagent barcode. 
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The measuring range defined by the lower detection limit and the maximum of 
the master curve is 0.010-25.00 µg.L-1 or ng.mL-1. Values below the detection 
limit are reported as <0.010 µg.L-1 (ng.mL-1). Values above the measuring 
range are reported as >25.00 µg.L-1 or ng.mL-1 (or up to 250 µg.L-1 or ng.mL-1 
for 10-fold diluted samples). 
 
10.0 Haemodynamic monitoring  
10.1.1 Initial pre-bypass studies (Baseline/pre-sternotomy) 
Time was taken for a good wedge trace. Full cardiac output studies were 
obtained prior to sternotomy but after cleaning and draping and with the legs 
horizontal and the patient flat in the neutral position. 
 
10.2 Post-bypass haemodynamic studies (pre-protamine) 
Cardiac output studies were performed following discontinuation of bypass after 
volume and pressor adjustment was complete but prior to protamine 
administration. 
Volume adjustment was at discretion of the surgeon. The aim was to establish 
comfortable filling pressures with a MAP of 65-85mmHg at the time of cardiac 
output studies. 
 
10.3 Post-protamine haemodynamic studies 
Cardiac output studies were repeated between 5 and 15 minutes after the 
completed administration of protamine but at an appropriate time convenient to 
the surgeon performing haemostasis. The patient was flat.  The chest was 
open, preferably without the retractor in position 
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10.4 Post-sternal closure haemodynamic studies 
Cardiac output studies were repeated 2 minutes following sternal re-
approximation  
 
10.5 Haemodynamic studies on the intensive care unit 
Haemodynamic studies were performed 2, 4, 6, 9 and 12 hours post-
reperfusion.  
During this 12 hour period, need for IABP and the usage and dosage of any 
inotropic support was noted.   
 
10.6 Low cardiac output episodes 
Low cardiac output episodes (defined as a CI ≤2.2 L.min-1.m-2 with CVP 
≥12mmHg and/or PCWP ≥14mmHg in the presence of a native or paced 
synchronised rhythm and heart rate of 90-110min-1) were recorded. 
 
11.0 Protocol for post-operative inotropic support and vasoconstrictor 
The haemodynamic aims were as follows: 
• M.A.P. of 65-85 mmHg  
• C.I. ≥ 2.2 L.min-1.m-2 
• Sinus rhythm (Pacing) 
In the ideal situation inotropes were not administered until post-bypass 
haemodynamic studies were complete but sometimes this was not possible.  
Inotropic support, initially with dopamine (200mg.50 ml-1 D5%W) at 5-10ml.hr-
1
 was commenced if the cardiac index(CI) was ≤2.2 L.min-1.m-2 in the 
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presence of a central venous pressure(CVP) of ≥12mmHg, pulmonary 
capillary wedge pressure(PCWP) of ≥14mmHg, and  heart rate of ≥90min-1 in 
a coordinated rhythm(sinus, AAI pacing or DDD pacing in order of 
preference). Escalation of inotrope therapy with adrenaline or noradrenaline 
or intra-aortic balloon pump (IABP) insertion was then at clinician discretion. 
Introduction of support was also permitted if the operating surgeon identified 
poor contractility at separation of CPB or if marginal haemodynamics were 
noted by attending physicians on the intensive care unit (ICU). 
Intra-operative boluses of phenylephrine were used to maintain a mean 
arterial pressure of ≥55mmHg during CPB and ≥65mmHg following separation 
in the context of a low systemic vascular resistance. Phenylephrine was also 
used as a post-operative vasoconstrictor at 0-0.4µg.kg-1.min-1 and substituted 
as necessary noradrenaline.  
Extubation, ICU and hospital discharge criteria and post-operative atrial 
fibrillation management were standardised. 
 
12.0 Echocardiography  
A comparison was made between left ventricular function assessed on 
echocardiography 1-3 days before surgery with post-operative results 5-7 
days after surgery in patients undergoing first time coronary artery bypass 
surgery with or without RIPC. Patients were studied using a Vivid 7 ultrasound 
machine (GE Vingmed Ultrasound, Horten, Norway) with a multifrequency 
transducer (3V2c) and second harmonic imaging with presets available for 
contrast and tissue Doppler imaging. Left ventricular dimensions and function 
were assessed by standard M-mode and 2D according to current American 
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Society and European Society of Echocardiography Guidelines [155]. Studies 
were performed by two accredited echocardiographers but analysed off-line 
by a single observer (Ectopic PC Version 108.x.x, GE Medical System, 
Horten, Norway). 
 
12.1 Contrast Echocardiography for EF 
The current method recommended for quantification of LV volumes and 
function is the Simpsons biplane estimation [155]. Accuracy of this technique 
is reduced if there is difficulty in endocardial border definition and in obtaining 
true perpendicular views of the LV in apical four and two chamber views. 
Inter-study variability may be up to 10% ejection fraction points between two 
studies as a result of these technical issues [156]. Difficulty in obtaining an 
optimal acoustic window becomes more acute in the post-operative period 
due to pain from the median sternotomy and as patients may not be able to lie 
in a left lateral decubitus position. The use of contrast opacification 
overcomes the issue of endocardial border definition and enables the 
echocardiographer to identify the true apex of the LV more reliably. As a 
consequence, reproducibility of LV volumes and function using contrast 
opacification during 2D echocardiography is equivalent to that of 
cardiovascular magnetic resonance imaging [157]. Contrast-enhanced 2D 
Simpson’s biplane was therefore used as the main method for estimation of 
LV volumes and ejection fraction in this study. SonoVue (Bracco, Italy) was 
used as the transpulmonary contrast agent, which is a suspension of 
microspheres filled with perfluorocarbon gas that has a similar size to red 
blood cells. 3D echocardiography was not used in this study as the 
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technology available at our institution requires the stitching of pyramids of 
data acquired over 4-7 RR intervals to cover larger volume ventricles, which 
may be inaccurate in irregular post-operative rhythms such as atrial fibrillation. 
Patients were cannulated before study with a 20 gauge cannula located in the 
left antecubital fossa. A three-way tap was attached to the cannula with a Luer 
lock syringe containing 10mls saline and another Luer lock syringe containing 
1-4 ml Sonovue contrast. After optimisation of the 2D image in the apical four 
chamber view, a pre-specified contrast pre-set was activated to deliver low 
mechanical index imaging (MI 0.2) and contrast was injected with a prompt 
saline flush. Focus, compression and gain settings were optimised to 
delineate LV endocardial borders. 
 
12.2 Isovolumic Acceleration 
Although widely used, LV ejection fraction is of most use when studying 
populations or identifying individual risk at any one point in time. LV ejection 
fraction is a method for assessment of LV contractility that is altered 
significantly by change in loading conditions. As a result of this, it is less 
useful as a method of tracking outcomes in an individual patient before and 
after CABG surgery - whether 2D, contrast-enhanced or 3D.  In order to 
attempt to overcome this, load-independent indices of LV function were 
studied. In experimental models, myocardial acceleration during isovolumic 
contraction (IVA) is a sensitive index of left ventricular contractile function 
which is unaffected by changes in loading conditions within a physiological 
range [158]. 
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After acquisition of standard 2D and M-mode measurements and before 
injection of LV opacification contrast, the tissue Doppler preset was activated. 
Tissue Doppler presets are required to introduce low pass filters to exclude 
low amplitude, high velocity blood signal, thereby optimising image acquisition 
to high amplitude, low velocity signal from myocardium. The image sector was 
narrowed to the wall of interest to optimise frame rate. During suspended 
respiration following exhalation, images were acquired of the inferoseptal, 
anterolateral, inferior and anterior walls after optimisation of baseline and 
scale to exclude aliaising. IVA was derived by measurement of the slope of 
the time-velocity profile from tissue Doppler data acquired by a sample 
volume placed within 1 cm of the insertion point of the mitral valve at the base 
of all 4 walls. Images were optimised to minimise the angle between the 
direction of annular motion and the ultrasound beam. Post-processing of this 
signal enabled calculation of the slope of the acceleration during isovolumic 
contraction, that part of the cardiac cycle when the LV is contracting to 
increase pressure without change in volume before aortic valve opening. [159] 
The ∆isovolumic acceleration (∆IVA) was an average from basal septal (A4C), 
basal lateral (A4C), anterior (A2C) and inferior (A2C) tissue Doppler images 
demonstrating change postoperatively as compared to before surgery. 
 
12.3 Tissue Velocity Imaging 
Left ventricular function is now thought to depend upon both radial and 
longitudinal function in a fashion analogous to the wringing of a cloth. 
Histopathological studies have clearly demonstrated that longitudinally-
orientated fibres predominate in the endocardium, while both the mid- and 
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epicardial layers share longitudinal, helical and circumferential fibres [160]. As 
the myocardium is perfused from epicardium to endocardium, the longitudinal 
fibres of the endocardium are most at risk from hypoperfusion. Longitudinal 
function therefore declines before fall in radial function in ischaemia [161]. 
There is good evidence that the fall in longitudinal function with ischaemia is 
initially compensated for by an increase in radial contraction, leading to 
apparent hyperdynamic EF. Hence both basal systolic myocardial velocities 
(s’) and early myocardial relaxation velocities (e’) both provide incremental 
prognostic information to ejection fraction in ischaemic heart disease [162]. 
Moreover, early myocardial relaxation velocities can be used to give an 
estimate of LV filling pressure in patients with normal EF and assessment of 
transmitral to mitral myocardial relaxation velocity ratio (E/e’) is a strong 
prognosticator in ischaemic heart disease.  
After acquisition of standard 2D and M-mode measurements and before 
injection of LV opacification contrast, the tissue Doppler preset was activated. 
The image sector was narrowed to the wall of interest to optimise frame rate. 
During suspended respiration following exhalation, the pulsed Doppler sample 
volume was placed at the base of the inferoseptal, anterolateral, inferior and 
anterior walls after optimisation of baseline and scale to exclude aliaising. The 
size of the sample volume was altered to cover longitudinal displacement of 
the annulus (5-10mm) and placed within 1 cm of the insertion point of the 
mitral valve. Images were optimised to minimise the angle between the 
direction of annular motion and the ultrasound beam. Gain was then set to 
provide clear tissue velocity traces from which s’, e’ and a’ were recorded 
(Figure 3.8).  
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Figure 3.8: Tissue velocity imaging 
 
 
13.0 Arrhythmia Assessment    
Three lines of investigation were employed to assess and compare 
perioperative arrhythmias between the groups:  
 
13.1 Continuous Holter ECG recording 
A continuous Holter ECG recording device was attached by three leads to the 
patient ≥ 12 hours prior to aortic crossclamping and was kept in-situ until 48 
hours postoperatively. Leads were applied to the right shoulder, left shoulder 
and left lower chest in the anterior axillary line. Leads ran behind the patient, 
and not across the chest, so as not to obstruct the operative field (median 
sternotomy). (Figures 3.9, 3.10, 3.11, 3.12). 
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Ventricular tachyarrhythmia quantitation was undertaken at the following time 
periods; pre-operative 12 hours (Pre-12h), the10 minute period after 
reperfusion (Post-10min), the next 2 hours of reperfusion (Post-120min), 2-24 
hours post-operative (Post2-24h) and 24-48 hours (Post 24-48h). 
                    
Figure 3.9: Continuous Holter ECG Monitor 
 
 
 
 
 
 
 
95 
 
Figure 3.10: Anterior view of applied Holter leads 
 
Figure 3.11: Lateral view of applied Holter leads 
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Figure 3.12: Posterior view of applied Holter leads 
Note leads do not obstruct operative (median sternotomy) field 
 
                         
13.2 12 lead electrocardiograms (ECGs) 
12 lead ECGs were recorded in patients preoperatively, immediately 
postoperatively, on postoperative day 1 and day 4. 
Perioperative myocardial infarction (PMI) defined by the presence of new left 
bundle branch block (LBBB) or new Q waves of 2mm in depth in 2 contiguous 
leads by postoperative day 4 was assessed by an independent cardiologist. 
 
13.3 Atrial Fibrillation – Treated 
The incidence of atrial fibrillation (AF) that required treatment with either/or 
amiodarone, digoxin, DCCV during the postoperative period was recorded. 
 
 
97 
 
14.0 Renal outcomes protocol 
Changes in serum creatinine, urinary albumin:creatinine ratio, urinary α-1 
microglobulin, and requirement for diuretics or haemofiltration were used as 
outcome measures  to assess the effect of renal protection by RIPC on peri-
operative renal injury in this  double-blind, randomised controlled trial. 
 
14.1.1 Creatinine  
Post-operative creatinine was measured on days 0 and 4. 
In muscle metabolism, creatinine is synthesized endogenously from creatine 
and creatine phosphate. Under conditions of normal renal function, creatinine 
is excreted by glomerular filtration. Serum creatinine measurements are used 
as a marker of glomerular filtration in diagnosis and monitoring of acute and 
chronic renal disease as well as for the monitoring the efficacy of renal 
replacement therapies such as haemofiltration, haemodialysis and chronic 
ambulatory peritoneal dialysis.  
Because urine excretion of creatinine is constant unless there is an acute 
change in renal function, it can be used to correct for variations in urine flow 
rate by expressing analytes such as urine albumin or alpha 1 microalbumin as 
the urine protein/creatinine ratio. The method used is based on the Jaffe 
reaction as described by Popper et al., Seelig and Wust and modified by 
Bartels [163][164]. This modified version has a higher sensitivity and better 
precision than the original Jaffe method. Serum and urine creatinine were 
measured by the Clinical Biochemistry Department using a kinetic, blanked 
and compensated method  using Roche Modular automated clinical chemistry 
analysers.[165][166][167][168][169] 
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14.1.2 Test principle – Kinetic colorimetric assay 
In alkaline solution, creatinine forms a yellow-orange complex with picrate. 
The colour intensity is directly proportional to the creatinine concentration and 
can be measured photometrically. Assays using rate-blanking minimize 
interference with bilirubin.  
• Sample and addition of R1(Sodium hydroxide: 0.20 mol/L) 
• Addition of R2(Picric acid: 25 mmol.L-1) and start of reaction: 
creatinine + picric acid     →  creatinine-picric acid complex 
The reference range for 24 hr urine creatinine is 9-21 mmol.24h-1 (1040-2350 
mg.24h-1) and for women is 7-14 mmol.24h-1 (740-1570 mg.24h-1). 
 
14.2.1 Albumin 
Albumin is a non-glycosylated protein with a molecular weight of 66,000 
daltons. Albumin is quantatively the most important protein component in 
plasma normally representing about 50% of the total protein content.   
However, in normal urine albumin only contributes <30mg.24h-1 of the total 
urine protein which is normally <150 mg.24h-1.  Low level but pathologically 
significant albuminuria, undetectable by chemical dipstix, called 
‘microalbuminuria’ is a sensitive marker of renal injury, and may reflect 
glomerular or renal tubular dysfunction.   
A variety of methods, such as radial immunodiffusion, nephelometry and 
turbidimetry, are available for the determination of albumin. 
[170][171][172][173][174] Immunoturbidimetric assay for the in vitro 
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quantitative determination of albumin in human urine on Roche Modular 
automated clinical chemistry analyzers was performed in this series. 
 
14.2.2 Test principle – Immunoturbidimetric assay 
Urine albumin was measured by automated immunoturbidimetry using an 
antibody to human albumin. 
• Sample and addition of R1 (buffer; TRIS (Tris(hydroxymethyl)-
aminomethane) buffer: 50mmol.L-1, pH 8.0 (25oC); PEG: 4.2%; EDTA: 
2.0mmol.L-1; preservative) 
• Addition of R2 (anti-albumin antibodies; Polyclonal anti-human albumin 
antibodies (sheep): dependent on titre; TRIS buffer: 100mmol.L-1, pH 
7.2 (25oC); preservative) and start of reaction: Anti-albumin antibodies 
react with the antigen in the sample to form antigen/antibody 
complexes which, following agglutination, are measured 
turbidimetrically. 
• Addition of R3 (human albumin; Albumin (human): 200mg.L-1; 
phosphate buffer: 50mmol.L-1, pH 7.0 (25oC); sodium chloride: 
150mmol.L-1; preservatives): Human albumin is added and the 
resulting additional turbidity change is evaluated for detection of 
antigen excess. 
The 24 hr urine expected values in adults are <20 mg.L-1 (0.304 µmol.L-1) 
albumin or <30 mg.24h-1 (0.456 µmol.24h-1) albumin. 
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14.3.1 Urine ACR 
Urine was collected pre-sternotomy (in anaesthetic room), 4h, 8h, 12h and 
24h after aortic cross clamp release and sent to the Department of 
Biochemistry for analysis. Urinary albumin-creatinine ratios (ACR) were 
assessed at 0, 12 and 24 hours. The normal urine ACR reference range for 
women is <3.5 and men is < 2.5 mg.mmol-1. 
 
14.4.1 Urine for α-1 microglobulin 
Urine was collected pre-sternotomy (in anaesthetic room), 4h, 8h, 12h and 
24h after aortic cross clamp release and sent to the Department of 
Biochemistry for storage of aliquots that were then sent to East Kent Hospitals 
for analysis.  
Measurement of alpha-1-microglobulin in urine aids in the diagnosis of kidney 
tubular damage. A1M reagent when used in conjunction with the Beckman 
Coulter IMMAGE® Immunochemistry Systems and Urine Protein Calibrator 
was utilised for quantitative determination of Alpha-1-Microglobulin (A1M) in 
human urine by rate nephelometry. 
 
14.4.2 Test principle – Rate nephelometry 
The A1M test measures the rate of increase in light scattered from particles 
suspended in solution as a result of complexes formed during an antigen-
antibody reaction. 
Alpha-1-microglobulin(sample) + Antibody → [Alpha-1-microglobulin(sample)- 
                Antibody (aggregates)] 
The 24 h urine expected values are <1.28 mg.dL-1. 
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15.0 Lung outcomes protocol  
15.1 Spirometry 
Patients underwent preoperative simple spirometry to assess FEV1, FVC and 
FEV1/FVC ratio (Figure 3.13). 
 
Figure 3.13: Spirometer 
 
15.2 Positive End Expiratory Pressure 
As Positive End Expiratory Pressure (PEEP) has been shown to increase right 
and left ventricular stroke volume variation both during open and closed chest 
conditions in addition to reducing right ventricular end-diastolic volume 
indicating a preload reductive effect, [175] its use in ventilator management was 
standardised to 5cm H2O. Changes in arterial blood partial pressure of oxygen 
(PaO2) / fractional inspired oxygen (FiO2) ratio and intubation times were used 
as outcome measures. 
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15.3 Arterial PaO2 / fractional inspired oxygen ratio (PaO2:FiO2 ratio) 
Arterial blood was sampled preoperatively from a right sided radial arterial line 
in the anaesthetic room prior to induction and assessed for PaO2 (kPa) (Bayer 
RapidLab865 Analyser). PaO2:FiO2 ratio was recorded and the process 
repeated for measurements at 6hr and 12hr postoperatively. 
 
15.4 Intubation time 
Intubation time (or time to extubation) was recorded as the time from arrival to 
the Intensive Care Unit to extubation (minutes). Extubation was nurse-led and 
performed according to standard departmental criteria (>36oC, normal and 
stable acid base balance, chest output <100ml.h-1). 
 
16.0 Analysis of myocardial samples 
During a small mechanistic study in patients undergoing on-pump coronary 
artery bypass grafting randomised to RIPC (three 5 min cycles left upper limb 
ischaemia) and Control groups, left ventricular myocardial Tru-cut biopsies 
were collected: (a) ‘pre-ischaemia’ (‘LV1’ – just prior to application of aortic 
cross clamp); (b) ‘end-ischaemia’ (‘LV2’ – just prior to removal of aortic cross 
clamp); (c) ‘post-reperfusion’ (‘LV3’ – 10 minutes after removal of aortic cross 
clamp). Biopsies were snap frozen in liquid N2 and stored at –80OC for batch 
analysis using standard techniques.  
Myocardial samples were transported on dry ice to the University of Oxford for 
analysis. 
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The left ventricular apical biopsy samples, taken 10 minutes after the 
cessation of the extra-corporeal circuit, were homogenised and protein 
extracted for Immunoblotting (see below).  Quantification was done by 
densitometry and all samples were normalised to beta-tubulin.  Comparisons 
between control (n=6) and RIPC (n=7) was by unpaired t-testing. 
 
16.1 Tissue homogenization and protein quantification  
All samples were stored at -80ºC until use. Tissue samples were 
homogenized using a Polytron rotor (GlenMills) in RIPA buffer (50 mM 
TrisHCl pH7.6, 150 mM NaCl, 2 mM EDTA, 1% NP-40, 0.1% SDS) containing 
1x complete protease inhibitor tablet (Roche Applied Sciences), 1x PhosSToP 
phosphatase inhibitor cocktail tablet (Roche Applied Sciences) and 0.5mM 
PMSF.  
Protein content was quantified using the colorimetric BCA protein assay kit 
(Thermo Scientific).  Briefly assay reagents A and B supplied were mixed in a 
ratio of 50:1. Bovine serum albumin at concentrations of 0, 50, 100, 200, 400 
and 800µg.ml-1 was used to create a standard curve.  10µl of each sample of 
homogenate was diluted in 40µl of ddH2O. 1ml of mixed assay reagent was 
then added to each sample and then samples were incubated at 37ºC for 
30mins.  
Samples were transferred to cuvettes and then colorimetric density was 
assessed using a spectrophotometer (Ultrospec 2000, Pharmacia Biotech) set 
at 562nm. By comparison against the standard curve all samples were 
normalised to 200µg.ml-1 before the addition of SDS-Page running buffer (4% 
SDS, 20% glycerol, 10% 2-mercaptoethanol, 0.004% bromphenol blue, 0.125 
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M Tris HCl) to give a 6:1 dilution. All samples were subsequently heated to 
95ºC for 5 minutes prior to immunoblotting. 
 
16.2 Western Blotting  
Protocol for ECL Western blotting
Flow diagram Separate protein sample by 
electrophoresis
Transfer to membrane
Block non-specific sites
Incubate in primary antibody
Incubate in HRP-labelled conjugate
ECL detection reagents
Expose to film
 Pre-cast 4-12% 1.5mm Bis-Tris Gels were utilised (Invitrogen) in a standard 
electrophoresis tank containing MOPS buffer (200mM MOPS free acid, 50mM 
sodium acetate, 10mM EDTA, and 10mM EGTA) and 500 µl of NuPage 
antioxidant (Invitrogen) in the central section only.  
Into each well was loaded 20µl of sample with 12 µl of Full Range Rainbow 
Marker (GE Healthcare) in the outside lane.  
Gels were run at 200V for a minimum of 50mins or until the forward protein 
marker was seen to have run off the gel. Once completed, gels were removed 
from the tank and placed into cooled transfer buffer (4ºC) (48mM Tris Base, 
390mM Glycine, 0.1% SDS, 20% Methanol). Transfer stacks were formed 
with a layer of fibre pad and pre-cut blotting paper (both soaked in transfer 
buffer) as the base for the gel. A PVDF membrane (Bio-Rad) (activated by 
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soaking in 100% methanol for 10 min prior to rinsing in transfer buffer) was 
placed on top of the gel and the stack completed with further layers of blotting 
paper and fibre pad, prior to rolling to remove any air bubbles. Transfers were 
conducted overnight at 20mA, in a 4ºC cold room with constant stirring using 
a magnetic flea.  
After transfer PVDF membranes were placed in 50ml Falcon tubes and 
incubated with constant rolling for 1 hour at room temperature in 5% fat free 
milk in TBST (50 mM tris-HCl, 10 ml 0.5 M tris-HCl, 150 mM NaCl, 75 ml 2 M 
NaCl and 0.05 % Tween 20) as a blocking  agent. The blocking solution was 
then replaced with 10ml of the same solution containing the primary antibody 
at a dilution of 1:1000. After incubation at room temperature for 2 hours, the 
antibody was removed and the PVDF membrane washed 3 times for 5 minute 
periods in 15ml TBST. Secondary antibody in the 5% milk and TBST solution 
at a dilution of 1:4000 was then added and the membrane incubated at room 
temperature for 40 min, prior to a final 3 washes in TBST as above.   
ECL advance solution (Amersham Biosciences) reagents A+B were mixed in 
a 1:1 ratio and pipetted onto the PVDF membrane, allowing it to incubate at 
room temperature for 5 mins. The resulting chemoluminescence was detected 
in a Chemi-Doc molecular imaging system (Bio-Rad) and band densitometry 
performed using the QuantityOne software package. (Figure 3.14; Table 3.6). 
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Figure 3.14: Gel tank assembly for SDS-polyacrylamide gel 
electrophoresis 
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Table 3.6: Antibodies used in Western Blotting 
 
17.0 Statistics 
17.1  Primary outcome measure and estimation of sample size 
If RIPC is an effective adjunct to myocardial protection it would be expected to 
reduce evidence of myocardial ischaemic injury. The optimal biochemical 
measurement of myocyte injury remains unclear [176][177]. It is not known 
whether a peak, timed or serial measure (ANOVA, AUC) is the most appropriate 
predictor of biochemical injury but serial measures contain greater information 
about the total injury and until further comparative studies become available we 
believe AUC represents the best predictor of mid-term survival post CABG. 
At first, cTnI was considered as the biochemical measurement of myocyte 
injury.  
  
17.1.1 Estimation of sample size using cTnI 
Single time point comparisons and cumulative area-under-the-curve 
comparisons of creatine kinase MB fraction (CK-MB) [149] and Troponin I 
(cTnI) [178] are currently accepted standards [179][180][181]. In our previous 
studies GIK therapy reduced cTnI by 3.07ng.ml-1. (population SD 6.905) [182]. 
Antibody Species/Ig class Dilution Manufacturer/catalogue No. 
Phospho-Akt (Ser 473) Rabbit/Ig G/polyclonal 1:1000 Abcam/ab28821 
Pan-Akt Rabbit/Ig G/polyclonal 1:1000 Abcam/ab8805 
Phospho-GSK3 beta (S9) Rabbit/Ig G/polyclonal 1:1000 Abcam/ab30619 
GSK3 beta Rabbit/Ig G/polyclonal 1:1000 Abcam/ab31366 
β-catenin Rabbit/Ig G/polyclonal 1:1000 Abcam/ab6302 
β-tubulin Rabbit/Ig G/polyclonal 1:1000 Abcam/ab6046 
Rabbit IgG (HRP) Goat/ Ig G/polyclonal 1:4000 Abcam/ab6721 
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If this difference were replicated in the current study this will be detectable 
with a total sample size of 162 patients (α 0.05. 1-β 0.8). Previous studies of 
ischaemic preconditioning in myocardial protection have suggested that the 
reduction in peak or AUC CK-MB or cTnI approximates ≥0.5SD. For instance, 
Belhomme et al. reported a difference of 250ng.ml-1.h-1 (population SD 404) 
for AUC CKMB, a difference of 80 ng.ml-1.h-1 (population SD 140) for cTnI 
AUC, a difference of 29µg.L-1 (control SD 33) for 6 hour CKMB and a 
difference of 1.9ng.ml-1 (population SD 3.64) for 6 hour cTnI [149]. Replication 
of these differences for the proposed study with a total sample size of 162 
patients would yield the following power and alpha (Table 3.7). 
 
Table 3.7: cTnI sample size calculations 
Parameter & 
study 
Estimated 
difference 
Population 
standard 
deviation 
Total 
sample 
size 
α 1-β 
6h cTnI [183] 3.07 6.905 162 0.05 0.8 
*6h cTnI [183] 3.453 6.905 162 0.05 0.85 
6h cTnI [149] 1.9 3.64 162 0.05 0.9 
6h CK-MB [149] 29 33 162 0.01 >0.95 
AUC CK-MB [149] 250 404 162 0.025 0.95 
AUC cTnI [149] 80 140 162 0.05 0.9 
AUC cTnI [183] 105 210 162 0.05 0.85 
*GIK study (postulated 0.5SD difference) 
Thus, using cTnI the primary end-point of 6 hour and 48 hour AUC cTnI 
estimation with sampling at 0, 6, 12, 24 and 48 hours post-operatively 
[181][184]would be achieved with a total sample size of 162 patients.   
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17.1.2 Estimation of sample size using cTnT 
48h AUC cTnT release was finally selected as the primary endpoint 
biochemical measurement of myocyte injury for the following reasons: (1) 
more available assay; (2) only one assay exists from a single provider; (3) as 
used in previous similar studies this study would then be comparable. 
Previous studies suggested a large treatment effect; a standardised difference 
of 0.8.  We hypothesised that RIPC would reduce cTnT AUC by a 
standardised difference of 0.6 at 90% power and 5% alpha. This required a 
sample size of 120 subjects which we increased by 33% to accommodate 
withdrawal or missing data points.  
 
17.2 Secondary outcome measures 
Secondary cardiac end points were 6hour and peak cTnT, incidence of 
myocardial injury on 12-lead ECG, serial cardiac and left ventricular stroke 
work indices (CI, LVSWI), low cardiac output episodes (LCOE) incidence, 
inotrope usage and dosage, reperfusion ventricular fibrillation and peri-
operative ventricular tachyarrhythmia incidence and functional 
echocardiographic change, ICU and hospital length of stay(LOS) and the 
renal and lung data listed above.  
 
17.3 Statistical analysis for cardiac, renal and lung outcomes 
Data were analysed with statistical package (SPSS 15.0, Chicago, Ill). 
Categoric or ordinal data were compared by using χ2 tests or Kendall tau b, 
respectively. Continuous data are presented as mean±standard deviation or 
median(interquartile range). Normally distributed data were compared using 
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independent two-sided t tests. Repeated-measures analysis of variance 
(RMANOVA) was used for serial measurements. Skewed data were either 
logarithmically transformed or analysed non-parametrically (Mann-Whitney U 
test).  
To assess cTnT AUC, we estimated missing troponin values (6% 
measurements) from the group and sampling time using a general linear 
model. 
 
17.4 Statistical analysis of echocardiographic parameters 
The primary end-point for the echocardiographic assessment of the functional 
outcome from RIPC was IVA. With a sample size of 73 patients in each group, 
this study would be able to detect a difference in IVA ≥0.5SD between groups 
(α 0.05, 1-β 0.85) [158][159][185][186]. Secondary end-points were change in 
contrast-enhanced LVEF and change in myocardial tissue systolic and early 
myocardial relaxation velocities. 
Data were analysed with statistical package (SPSS 15.0, Chicago, Ill). 
Categoric or ordinal data were compared by using χ2 tests or Kendall tau b, 
respectively. Continuous data are presented as mean±standard deviation or 
median(interquartile range). Normally distributed data were compared using 
independent two-sided t tests. Repeated-measures analysis of variance 
(RMANOVA) was used for serial measurements. Skewed data were either 
logarithmically transformed or analysed non-parametrically (Mann-Whitney U 
test).  
18.0 Demographic and intraoperative variables 
Both groups were well matched (Table 3.8). 
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Table 3.8: Pre-operative and intra-operative patient characteristics. CCS 
= Canadian Cardiovascular Society; NYHA = New York Heart 
Association; TIA = Transient ischemic attack; CVA = Cerebrovascular 
accident; ACE-I = Angiotension converting enzyme inhibitor; IABP = 
intra-aortic balloon pump. 
 
Control  
(n=82) 
RIPC 
(n=80) 
p 
Age  65(60-73) 63(57-71) 0.19 
Male gender (n(%)) 72(88) 71(89) 0.59 
CCS Angina Class 2(1-2) 1(1-2) 0.54 
NYHA Class 2(1-2) 2(1-3) 0.25 
Body mass index (kg.m-2) 28(25-31) 27.5(26-30) 0.80 
Elective (n(%)) 38(46) 42(52) 0.53 
Urgent (n(%)) 44(54) 38(48) 0.53 
Current Smokers (n(%)) 7(9) 12(15)  
0.15 Ex-smokers (n(%)) 52(63) 39(49) 
Never smoked (n(%)) 23(28) 29(36) 
High risk lung status (n(%)) 17(21) 22(28) 0.36 
Hypercholesterolemia (n(%)) 59(72) 61(76) 0.59 
Hypertension (n(%)) 52(63) 44(55) 0.34 
Past history of TIA (n(%)) 4(5) 3(4) 1.00 
Past history of CVA (n(%)) 1(1) 1(1) 1.00 
Statins (n(%)) 71(87) 76(95) 0.10 
Aspirin (n(%)) 70(85) 73(91) 0.33 
Diuretics (n(%)) 16(20) 10(13) 0.29 
Potassium channel blocker (n(%)) 18(22) 12(15) 0.31 
Angiotensin II Antagonist (n(%)) 7(9) 6(8) 1.00 
ACE I (n(%)) 57(70) 48(60) 0.25 
β-blocker (n(%)) 68(83) 63(79) 0.55 
Oral Nitrates (n(%)) 30(37) 18(23) 0.06 
Ca2+ channel blockers (n(%)) 31(38) 26(33) 0.51 
Pre-CPB IABP (n(%)) 1(1) 0(0) 1.00 
Fasting glucose >7mmol.L-1 (n(%)) 0(0) 3(4) 0.33 
Fasting triglycerides (mmol.l-1) 1.4(1.1-1.7) 1.3(1.0-1.7) 0.81 
Fasting cholesterol(mmol.l-1) 3.6(2.9-4.3) 3.6(3.2-4.4) 0.20 
Creatinine (mg.dL-1 ) 1.09±0.18 1.11±0.18 0.44 
Pre-operative pO2:FiO2 ratio  53(47-61) 55(48-63) 0.31 
Euroscore  3(2-5) 3(2-4.5) 0.10 
Logistic Euroscore 2.5(1.5-4.3) 1.9(1.3-3.4) 0.78 
Intra-operative factors  
Enflurane (n(%)) 65(79) 64(80)  
0.46 Sevoflurane (n(%)) 15(18) 15(19) 
Propofol (n(%)) 2(2) 1(1) 
Bypass time (min) 96±22 100±23 0.25 
Cross-clamp time (min)  71±18 76±21 0.08 
Number of grafts  3.5(3-4) 3(3-4) 0.88 
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CHAPTER 4 THE EFFECT OF RIPC ON CARDIAC OUTCOMES IN 
PATIENTS UNDERGOING CORONARY ARTERY 
BYPASS SURGERY 
 
1.0 Introduction 
In remote ischemic pre-conditioning (RIPC) short cycles of repeated limb (or 
other organ) ischemia provoke a protective effect that can halve the mass of 
infarction caused by substantive vessel occlusion and reperfusion [70]. In 
coronary artery bypass grafting (CABG), adverse outcomes predominantly 
relate to cardiomyocyte injury due to myocardial protection failure and there is 
experimental and clinical evidence that RIPC could attenuate such injury 
[187]. The adequacy of myocardial protection can be assessed using an array 
of measurements that are indicative of cardiomyocyte death, injury or 
dysfunction [188]. These include cardiac troponin (cTn) release, the incidence 
of post-operative low cardiac output episodes and ventricular arrhythmias, the 
need for inotropic support and functional assessment by haemodynamic 
monitoring and echocardiography. These measures contribute to an 
assessment of reversible and irreversible myocardial injury.   
Experimental models have demonstrated a first window (1-4 hours) followed 
by a second window (24-72 hours) of protection against infarction afforded by 
ischaemic preconditioning. In rabbit models the second window also protects 
against infarct and arrhythmias [189] and this has been corroborated by rat 
models where repeated left coronary artery occlusions have been shown to 
reduce infarct size by >40% [190] and the incidence of ventricular fibrillation 
[191].  
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Human ventricular myocytes [192] and atrial appendages taken during CABG 
[193] have also been shown to exhibit protection at both windows with 
preconditioning protocols followed by prolonged ischaemia and reperfusion. 
Suppression of proinflammatory gene transcription in leukocytes within 15 
minutes and 24 hours of an intermittent forearm ischaemic stimulus highlights 
evidence for first and second windows in human models following RIPC 
protocols [194]. 
In elective percutaneous coronary intervention(PCI), RIPC has been 
associated with reduced cTnI release, less electrocardiographic ST elevation 
and a reduced incidence of major adverse cardiovascular events [195]. In 
abdominal aortic aneurysm repair, RIPC induced by intermittent iliac artery 
occlusion reduces the incidence of myocardial injury and may reduce post-
operative renal impairment [143].  
In cardiac surgery, the first clinical report of a protective RIPC effect was in 
children. RIPC, induced by four 5-min cycles of lower limb ischemia-
reperfusion resulted in lower cTnI release, reduced inotrope requirements and 
lower airway resistance implying a possible protective effect on myocardial 
injury, function and bypass-related lung injury, a finding also demonstrated in 
experimental models [107][118][196].  
Two studies in CABG patients, one investigating RIPC in CABG undertaken 
using predominantly intermittent ischemic arrest and a second utilising 
cardioplegia have reported [107][145]. Both were single blinded, used a 3-
cycle upper arm RIPC stimulus and both demonstrated a significant reduction 
of cTnT area-under-the-curve(AUC) release of over 40%. Clinical and 
hemodynamic outcomes were however not reported. Much of the cardiac 
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injury associated with CABG appears to be a reversible phenomenon 
manifest as transiently subnormal cardiac output and a temporary need for 
inotropic support. The role of RIPC in affording protection against such post-
ischemic dysfunction is far less clear [197]. 
The aims of this study were to confirm the role of RIPC in reducing troponin 
release and to ascertain if this is accompanied by an enhanced protection 
against post-operative cardiac, renal and pulmonary dysfunction.   
 
2.0 Methods 
Biochemical and haemodynamic assessment of cardiac outcomes followed 
methodology set out in Chapter 3; Section 9.0 to 11.0. Statistical analysis was 
performed as per Chapter 3; Section 17.0 to 17.2. 
 
3.0 Results 
Of 313 possible subjects, 206 met the inclusion criteria, 170 consented and 
were initially enrolled, 8 of which were withdrawn pre-randomisation for 
logistical reasons (Figure 4.1) leaving a study population of 162. All patients 
had the appropriate signal on pulse oximetry during RIPC or placebo stimulus 
delivery with no inadvertent crossover. The stimulus was applied in the 74±16 
minutes between incision and aortic cross clamping (AXC). Demographic and 
intra-operative variables were similar (Table 3.8).  
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Figure 4.1: Consort diagram of trial recruitment. 
313 assessed for 
eligibility 143 excluded
95 diabetics
36 refused to participate
4 unstable angina
8 other
162 randomly assigned
80 underwent
RIPC on upper arm
82 underwent 
Control stimulus 
on dummy arm
170 consented for study
8 withdrawn pre-randomisation 
for logistical reasons
 
All patients survived 30 days. There was one in-hospital death in the control 
group at day 109 due to pneumonia, a hospital mortality of 0.6%. There was 
no difference in ITU or hospital length of stay (Table 4.1). 
 
Table 4.1: Post-operative data. cTnT = Cardiac Troponin T; IABP = intra-
aortic balloon pump; LCOE = low cardiac output episode; LOS = length 
of stay. 
 Control 
(n=82) 
RIPC 
(n=80) 
p= 
 
6 hour cTnT (ng.ml-1) 0.93(0.59-1.35) 1.01(0.72-1.43) 0.522 
Cmax cTnT (ng.ml-1) 1.02(0.74-1.44) 1.04(0.78-1.51) 0.789 
Postoperative IABP (n(%)) 7(9) 6(8) 0.52 
12h LCOE incidence (n(%)) 20(24) 27(34) 0.225 
Inotrope usage (n(%)) 32(39) 40(50) 0.155 
Vasoconstrictor usage (PhE or NE) (n(%)) 54(66) 51(64) 0.870 
ITU LOS (days) 3(2-4); 3(2-5) 0.287 
Hospital LOS (days) 8(6-11); 8(6-12) 0.392 
116 
 
3.1 Myocardial Injury 
Of 810 possible cTnT measurements, 758(94%) were assayed. Using a 
generalised linear model, there was no difference in 48 hour AUC cTnT (RIPC 
30.1(22.2-38.1) vs. 27.7(18.9-39) ng.48h.ml-1; p=0.721) (Figure 4.2). When 
completely sampled patients (n=123; 76%) were considered, the results were 
similar (RIPC 29.3(20.8-39.2) vs. 27(17.4-39.6) ng.48h.ml-1; p= 0.451). Other 
cardiac injury indices were not different (Table 4.1; Figure 4.3).  There was no 
difference between the groups when AUC cTnT release was considered for 
elective (RIPC 31.7(23.4-40.9) vs. 27.6(17.4-39.5) ng.48h.ml-1; p= 0.260) or 
urgent patients (RIPC 28.0(18.1-35.3) vs. 28.4(19.4-36.3) ng.48h.ml-1; p= 
0.765).   
 
Figure 4.2: Cardiac troponin T release over 48 hours.  Medians and 
interquartile ranges are presented. No difference in release profiles was 
identified on area-under-the-curve analysis (p=0.721) 
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Figure 4.3: 6 hour and Peak Cardiac troponin T release.  Medians and 
interquartile ranges are presented. No difference in release profiles was 
identified.
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3.2 Hemodynamic Effects 
Over the measurement period, the CI increased in both groups but there was 
no significant difference between groups (Figure 4.4). Similar numbers in 
each group experienced LCOEs or required IABP (Table 4.1; Figure 4.5). 
Serial LVSWI was not different (p=0.844; RMANOVA; Figure 4.6). 
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Figure 4.4: Serial cardiac index measurements in each group 
(mean±SD). Cardiac index increased from pre-operative values in both 
groups (p<0.001) but was not different between groups (p=0.620; 
RMANOVA)
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Figure 4.5: Incidence of Low Cardiac Output Episode (LCOE), Intra-
aortic balloon pump (IABP) and Inotrope usage. 
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Figure 4.6: Serial left ventricular stroke work index in each group 
(mean±SD). 
 
 
 
 
 
 
 
 
 
 
 
 
3.3 Inotrope and vasoconstrictor requirements 
Intra-operatively all patients required phenylephrine administration at similar 
dosage (RIPC 0.36(0.22-0.63) vs. 0.43(0.25-0.67) mg.kg-1; p=0.622). A similar 
number of patients in each group required inotropes (Table 4.1; Figure 4.7) at 
equivalent dosages (Figure 4.8). 
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Figure 4.7: Incidence of individual inotrope usage in the first two 6 hour 
periods. Dopa. = dopamine, Epi.= epinephrine, NorE. = norepinephrine. 
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Figure 4.8: Cumulative dose(SD) of inotrope received over 6 hours by 
group. For presentation, the doses of epinephrine (Epi.) and 
norepinephrine(NorE.) are multiplied by 10-1. 
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4.0 Discussion 
This double-blind study using an identical RIPC stimulus and cTnT assay has 
not corroborated previous smaller single blind studies that found RIPC to 
reduce troponin release following on-pump CABG. This absence of effect on 
measurable myocardial injury is matched by a failure to demonstrate any 
advantage of RIPC in terms of cardiac performance and inotrope requirement. 
Our study suggests that RIPC, like its predecessor classical cardiac 
ischaemic preconditioning (IP), has not fulfilled the promise of a practically 
useful form of improved myocardial protection. While early studies using 
classical IP reported reduced troponin release [103][104], improvement in 
high energy phosphate conservation and reduced inotrope requirement these 
effects were replicated in some but not all studies [141][142][133][198]. The 
clinical effect was less obvious and in some reports detrimental[106] and this 
frustrated the use of classical IP as surgical myocardial protective adjunct.  
There is debate regarding the site of origin and significance of troponin 
release during on-pump CABG. Troponin release may be indicative of 
myofibrillar damage and myocyte necrosis or changes in sarcolemmal 
permeability with leakage from cytosolic pools [199][200]. RIPC may protect 
against necrosis-related but not cytosolic release. CPB may itself affect 
sarcolemmal permeability or may have a pre-conditioning effect that 
precludes further protection by RIPC [106].  
For assessment of perioperative myocardial infarction and heart failure a 
range of cardiac biochemical and inflammatory markers have been identified 
Although cardiac troponin I (cTnI) is more sensitive and specific than CK-
MB[201][202] it has not shown itself to be a better discriminator when 
122 
 
compared to cardiac troponin T (cTnT)[203]. The release of markers in on-
CPB surgery is now well established and known to be higher than those off-
CPB with the associated sequelae[204][205][206][207]. 
Postoperative cardiac troponin is an independent predictor of in-hospital death 
and high concentrations are associated with a cardiac cause of death and 
major postoperative outcomes[208][209]. The magnitude of release has been 
shown to be related to the type of cardiac surgical procedure[210] In one 
series perioperative elevation of cTnI reliably predicted mortality in infants and 
children undergoing surgical repair of congenital heart defects.[211] 
In this RCT cTnT, as a marker of perioperative myocardial infarction and 
myocardial protective intervention efficacy [212][213][214],  has shown no 
difference between groups when collated up to 48 hours after reperfusion. 
Thus, we have no evidence to suggest the benefit of a ‘first window’ of RIPC 
protection.  
To corroborate the evidence all secondary endpoints of myocardial injury: 
peak cTnT, 6hr cTnT; LCOE incidence; serial cardiac indices; IABP usage; 
inotrope and vasoconstrictor usage failed to show any advantage for RIPC. 
To accommodate for changes in systemic vascular resistance left ventricular 
stroke work indices was compared between groups but again failed to show 
advantage to those receiving RIPC. 
Post-CABG myocardial injury often manifests as a transient period of 
reversible dysfunction, treatable by hemodynamic optimisation and temporary 
inotropic support. This implies a cardiac stunning phenomenon and the role of 
RIPC as a protective measure against stunning is unclear. During clinical PCI, 
RIPC has been shown to not attenuate post-ischemic stunning [197]. Our 
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hemodynamic data suggests there is similar absence of effect on reversible 
dysfunction in CABG.  
In this study, we used an identical stimulus and cTnT assay as previous 
reports that demonstrated a >40% reduction in cTnT release [107][145]. To 
remove inadvertent bias, we developed a scrupulous technique to blind the 
surgeon, anaesthetist and investigators from the group allocation. The 
stimulus was administered within an appropriate time-frame and delivery 
verified by observing disappearance of the oximetry pulse signal. In the 
single-blind studies, statistical significance was attained by the much smaller 
variances observed in cTnT levels in the RIPC group. In the current study, the 
cTnT release in both groups was similar to that of the control groups in the 
previous reports. The study design also had important similarities; most 
patients received a volatile halogenated anaesthetic agent peri-bypass and 
high percentages of patients received pre-operative statins. Isoflurane, a 
known pre-conditioning agent was specifically avoided in the current study.  
When re-examining the data in this study no subtle evidence appears to exist 
to explain the comparability between the two groups. Volatile anaesthetics 
have a known preconditioning effect yet there was no significant difference 
between groups in the incidence of Enflurane (RIPC 64/80(80%) v 
65/82(79%) or Sevoflurane (RIPC 15/80(19%) v 15/82(18%) used. In three 
cases intravenous propofol alone was used as the anaesthetic agent (RIPC 
1/80(1%) v 2/82(2%). No difference between the groups was observed when 
cTnT AUC was adjusted for calculated CrCl or elective/urgent cases. 
Other differences exist between our study and those previously reported. We 
noted a higher pre-operative usage of beta-blockers continued until the 
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morning of surgery. Our bypass and cross-clamp times were slightly longer as 
we used a single clamp technique and we included non-elective patients who 
had angina or an acute coronary syndrome within 30-days of surgery. 
However, no patients had experienced angina within 48 hours of surgery and 
we observed no differences between those admitted electively and more 
urgent cases.    
By excluding the harder to precondition group of diabetics the opportunity to 
observe a real change from RIPC has been improved. And by further 
exclusion of patients who have suffered with recent angina (<48hours) there 
can be confidence that changes observed in primary and secondary 
endpoints can be attributable to the beneficial effects of our treatment. 
As to why the present study did not replicate similar recent studies the answer 
is more difficult. An initial challenge may be the ischaemic stimulus itself. 
Interestingly not only the same stimulus was used by Haunseloy et al where a 
43% decrease in cTnT AUC was observed but also in the present study 
verification of the ischaemic stimulus by loss of pulse oximeter trace was 
confirmed by the ORT. Differences in protocols such as lack of blinding of 
anaesthetists and investigators; lack of data on dosages of volatile 
anaesthetics with proven conditioning effects; concomitant AVR with 
antegrade and retrograde cardioplegia may offer lines of reasoning 
attributable to the purported benefit of RIPC in one study over the other. 
Finally, and perhaps most strongly, the statistical difference in the power 
generated by a study with nearly four times as many patients investigated 
may offer an explanation [111].  
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Thus, we conclude, that RIPC fails to augment myocardial protection in 
patients undergoing CABG. Whether it may have a specific role in higher risk 
patients undergoing surgery with prolonged cross-clamp times or even 
cardiac transplantation warrants further study. 
Future clinical applications of IP and RIPC will depend on the clarification of 
the underlying biochemical mechanisms, the development of pharmacological 
methods to induce preconditioning, and controlled trials in humans showing 
improved outcomes. 
 
5.0 Conclusion 
In contrast to prior smaller studies, RIPC did not reduce troponin release or 
improve post-operative haemodynamics protection in this double-blind study.  
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CHAPTER 5 THE FUNCTIONAL IMPACT OF RIPC ON PATIENTS 
UNDERGOING FIRST TIME CABG 
 
1.0 Introduction 
Coronary artery bypass grafting (CABG) is highly effective in improving life 
expectancy and quality of life in symptomatic patients with multivessel 
coronary artery disease [215]. In patients without left main stem stenosis, the 
major benefit of surgical revascularisation has been demonstrated in those 
with concomitant LV dysfunction. As a result, echocardiographic estimation of 
left ventricular ejection fraction (LVEF) has become the main method used in 
clinical practice to guide surgical management of patients with coronary artery 
disease [216][217].  
 
2.0 Effects of Coronary Artery Surgery on Myocardial Function 
2.1 Coronary Artery Surgery and LV Function 
Increased survival following CABG has only been observed in those with left 
main stem stenosis and in those with three-vessel coronary artery disease, 
particularly in the context of impaired LV function [218][219][220][221]. While 
reduction in LVEF identifies those with most to benefit from revascularisation, 
it is also a predictor both of in-hospital morbidity [222] and mortality [223]. 
Although LVEF above 40% is associated with reduced peri-operative 
complications [224], those with lower values suffer higher in-hospital mortality, 
longer cardiopulmonary bypass time, and longer hospital stays. 
Surgical revascularisation may improve LV function. Hibernation is the 
presence of resting LV dysfunction due to a reduction in myocardial perfusion 
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sufficient to prevent efficient contraction but without cell death. In patients with 
impaired LV function and evidence of myocardial hibernation, CABG 
increases LVEF and improves regional LV function [225]. Furthermore, 
surgical revascularisation of hibernating myocardium reduces mortality 
compared to medical therapy [226]. The improvement in LV systolic function 
following surgical revascularisation of hibernating myocardium is greatest in 
those patients with the lowest preoperative LVEF [227]. 
Although CABG may result in an improvement in LVEF in those with 
preoperative LV dysfunction, standard on-pump CABG for multi-vessel 
disease in patients with normal LV function at surgery does not alter LVEF. 
This has been established in studies comparing multi-vessel arterial 
revascularisation utilising either off-pump CABG (OP-CABG) or on-pump 
CABG (ON-CABG). In the standard ON-CABG surgical cases assessed with 
cine MRI, mean preoperative LVEF was 62 ±12% and mean postoperative 
LVEF was 59 ±11% at a median 6 days following surgery. Surgical technique 
however, can affect post-operative LVEF, since there was an absolute 
difference in post-operative EF between off-pump and on-pump groups [180]. 
 
2.2  Coronary Artery Surgery and RV Function 
There is growing evidence that CABG is associated with right ventricular (RV) 
dysfunction. RV function is a major determinant of outcome following on-pump 
CABG and RV dysfunction is associated with a high mortality [228]. RV 
function post-CABG is markedly reduced 3 months after on-pump surgery 
compared with preoperative measurements [229]. Reduction in RV systolic 
longitudinal function does not improve within the first 3 months after CABG 
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and recovers partially at 1 year, whereas diastolic tissue velocities show no 
improvement [230]. This fall in RV long axis contraction occurs in patients who 
have no obstructive disease within the right coronary artery and who do not 
have surgery on the right heart [229]. RV depression also occurs after bypass 
grafting in patients with a moderate stenosis of the right coronary artery that is 
not revascularized. Revascularization of a more severe stenosis of the right 
coronary artery in this context however, appears to preserve postoperative RV 
function [231].  
Reduction in RV function does not appear to be related to the type of 
cardioplegia used during CABG [230][232][233][234]. The use of on-pump or 
off-pump surgical techniques does not reduce the impact of CABG on RV 
function. RVEF falls significantly whichever technique is used, with a relative 
reduction of 12% in the OPCABG group and 7% in the ONCABG group 
compared to pre-operative values without significant intergroup difference. 
[235]. In this series, preoperative RVEF was 66±6% in the OPCABG group 
and 65±8% in the ONCABG group. After surgery, early RVEF decreased 
significantly in both groups (P<0.05) with a relative reduction of 12% in the 
OPCABG group and 7% in the ONCABG group, but without significant 
intergroup difference (p=0.46). This early reduction in RV function recovered 
completely by 6 months. Because of the number of independent variables 
involved, a model-building strategy was employed to assess the potential 
association between baseline variables and early RV function. First a simple 
regression analysis was performed to examine any potential association 
between baseline variables (e.g. age, sex, body mass index, preoperative 
LVEF and RVEF) and early RV function. Variables with P<0.1 were then 
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included in a multiple linear regression by stepwise selection to assess the 
‘best’ subset in predicting early RV function. This analysis indicated the only 
predictors of postoperative RV function to be preoperative RV and LV function 
[235]. 
Assessment of RV ejection fraction is difficult using 2D echocardiography due 
to the complex anatomical shape, which means that standard geometric 
formula for calculation of volumes do not readily apply. Furthermore, the 
position of the ventricle immediately behind the sternum means that full 2D 
visualisation of the RV endocardial border cannot be achieved from a single 
acoustic window. Assessment of RV function has therefore come to rely on 
alternative methods. The RV myocardium differs in structure and function to 
that of the LV [236]. There is a greater preponderance of longitudinal fibres 
within the RV and contraction in this plane is of relatively greater importance 
to RV function [160]. Methods that rely on assessment of RV long axis 
function such as tricuspid annular systolic plane excursion (TAPSE) and 
systolic tissue velocity imaging of the RV lateral annulus (s’) therefore have a 
close correlation with gold standard measurement of RV function, including 
radionuclide ventriculography and cardiovascular magnetic resonance 
[237][238]. 
 
2.3 Effect of IP and RIPC on LV and RV function 
Early reports of the functional benefit of IP and RIPC have been promising. In 
a porcine model (n=17) RIPC induced by intermittent hindlimb ischaemia (four 
cycles 5 mins tourniquet inflation and 5 mins deflation; n=9) reduced extent of 
myocardial necrosis on histology induced by 40 min balloon occlusion of the 
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LAD compared to controls (n=8) (area of infarction RIPC 26±9% vs. Control 
53±8%; p<0.05) and calculated mass of myocardial infarction (RIPC 3.5g vs. 
Control 7.5g, p<0.05). The effect on LV function was assessed invasively by 
real time left ventricular (LV) pressure-volume loops generated by 8 polar 
conductance catheters with integrated micromanometer. During ischaemia, 
there was a greater fall in LVEF in controls compared to those with RIPC 
(p=0.02) and a greater increase in the time constant of ventricular relaxation 
(Tau) in controls (p=0.02). At reperfusion however, this difference was 
abolished and late effects were not studied. [117] 
Several clinical reports of RIPC in cardiovascular surgery have been 
published. In children undergoing congenital heart defect repairs using 
cardiopulmonary bypass, lower limb RIPC has been shown to reduce troponin 
release and inotrope requirement [118]. In adults undergoing CABG, 
intermittent upper limb ischaemia has been followed by reductions in 
postoperative release of lactate dehydrogenase [144] and troponin T [107]. 
None of these studies assessed the functional consequences of RIPC on LV 
and RV function assessed by echocardiography. To-date there has been only 
one small study of 40 patients listed for CABG for angina assessing the 
functional consequence of RIPC, recruiting 20 patients randomised 
prospectively to Control and 20 to IP arms. Those patients who had 
experienced angina within 48-72 hours (not <48hours) were included [239]. 
After establishing CPB and running the pump to empty the heart, the 
ascending aorta was occluded by cross clamping for 2 min, following 3 min 
reperfusion, the procedure being repeated once. In the control group, the 
pump was also running for 10min before routine operation. The temperature 
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was kept in normothermia during this period. Blood cardioplegia was delivered 
first antegradely and then retrogradely at temperature of 6-90C. Warm 
cardioplegia (370C) was given retrogradely before release of the aortic cross 
clamp. CI and RVEF were measured using a fast–response volumetric 
thermister-tipped pulmonary artery catheter and a microprocessor which 
allowed measurement of the diastolic washout plateaus of a thermodilution 
cardiac output curve using exponential curve analysis. Prior to surgery there 
was no difference in demographics and functional parameters between 
groups (IP CI 2.63±0.29 vs. 2.75±0.58 L.min-1.m-2, p=0.51; IP RVEF 
(41.54±8.22 vs. 44.11±10.8%, p=0.52).  After declamping, CI improved in the 
IP group at 1 hour compared to controls (106% vs. 88% of baseline; p=0.03) 
but this advantage was not maintained at 6 hours and the 1st postoperative 
day (POD) (123% vs. 116% and 121% vs. 114% of baseline). Similarly RVEF 
fared better in the IP group at 1 hour (103% vs. 81%; p=0.02) but not at 6 
hours and the 1st POD (90% vs. 80%; p=0.27 and 94% vs. 81%; p=0.10). 
There was no difference in CI between the groups after the operation (p=0.14) 
but the fall in RVEF was less falling CABG in those exposed to IP (p=0.03). 
Cardiac troponin I and CK-MB levels remained the same. 
In summary, outcome from CABG is dependent upon LV function and RV 
function. Surgical revascularization may improve LVEF in those with pre-
operative dysfunction, dependent in part on surgical technique. CABG is 
associated with a prolonged fall in RV function, predominantly governed by 
pre—operative status. The effect of IP and RIPC on outcome following CABG 
has mainly been studied using biochemical surrogate markers and there are 
no data on an effect on ventricular function beyond the very early post-
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operative period. The primary aim of the present study was to assess the 
effect of remote ischaemic preconditioning during cardiac surgery on left 
ventricular function assessed by transthoracic echocardiography. 
 
3.0  Methods 
Echocardiographic assessment of cardiac outcomes followed methodology set 
out in Chapter 3; Section 12.0 to 12.3. Statistical analysis was performed as per 
Chapter 3; Section 17.4. 
 
4.0  Results 
Of the 162 patients (Control n=82; RIPC n=80) recruited to the trial 76 
patients underwent preoperative echocardiography, the remaining 86 patients 
did not undergo echocardiographic studies for logistical reasons or resource 
availability. Of the 76 patients that did undergo preoperative 
echocardiography 4 patients did not have post-operative echocardiography 
(Prolonged ITU stay n=2; Logistical reasons n=2) and thus preoperative and 
postoperative data was available on 72 patients (Control n=38; RIPC n=34) 
for comparative analysis. Echocardiography was performed with ventricular 
opacification contrast (SonoVue) (Control n=29/38(76%); RIPC 
n=26/34(76%)) to assess left and right ventricular size and function. Both 
groups who did have (n=72) and did not have echocardiography (n=90) were 
well matched for preoperative and intraoperative variables (Table 5.1). Control 
(n=38) and RIPC (n=34) groups who did undergo echocardiography were also 
well matched at baseline (Table 5.2). There were no significant differences in 
LV geometry, LV systolic function or LV diastolic relaxation at baseline 
133 
 
between the patients assigned to Control and RIPC (Table 5.3). There were 
no differences in RV size and function at baseline between Control and RIPC 
(Table 5.3).  
Following surgery, there was no change in LV geometry or function within 
Control or RIPC groups (Table 5.4 and 5.5). The only difference between pre-
operative and post-operative echocardiography was the fall in TAPSE but with 
no other change in RV dimensions or function. There was no difference 
between the groups following surgery or difference in the change (postop-
preop) between Control and RIPC groups (Table 5.6 and 5.7). 
When examining all patients (Control and RIPC) as a group, no markers of 
echo injury was found to correlate with 48 hour cTnT release, (Table 5.8), 
incidence of inotrope at 0-6 hours (Table 5.9) and at 6-12 hours 
postoperatively (Table 5.10). 
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Table 5.1: Comparison for preoperative demographics and 
intraoperative variables of those who did and did not undergo 
echocardiography 
 Echocardiography 
(n=72) 
No Echocardiography 
(n=90) 
p 
Age 65(61-71) 64(56-72) 0.28 
Male gender (n(%)) 82 61 0.31 
Body mass index (kg.m-2) 28(26-31) 27(25-30) 0.59 
Elective (n(%)) 34 46 0.64 
Urgent (n(%)) 38 44 0.64 
Euroscore 3(2-5) 3(2-5) 0.27 
Logistic Euroscore 2.5(1.5-4.1) 2.1(1.3-3.5) 0.21 
Bypass time (min) 98.2±23.5 96.3±19.7 0.58 
Cross-clamp time (min) 75.3±18.4 73.4±18.0 0.58 
 
 
Table 5.2: Comparison for preoperative demographics and 
intraoperative variables of Control and RIPC groups of those who 
underwent echocardiography 
 Control (n=38) RIPC (n=34) p 
Age 68(63-74) 63(59-68) 0.09 
Male gender (n(%)) 33 28 0.75 
Body mass index (kg.m-2) 28(25-31) 29(26-30) 0.91 
Elective (n(%)) 19 15 0.64 
Urgent (n(%)) 19 19 0.64 
Euroscore 4(2-5) 3(2-5) 0.33 
Logistic Euroscore 2.7(1.5-4.3) 2.1(1.4-3.8) 0.28 
Bypass time (min) 98.4±20.1 98.0±26.9 0.93 
Cross-clamp time (min) 74.5±14.4 76.2±22.3 0.71 
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Table 5.3: Analysis of preoperative echocardiographic parameters of LV 
and RV size and function between Control and RIPC groups. IVSd = 
Intraventricular septum in diastole; LVIDd = Left ventricular internal 
dimension in diastole; LVPWd = Left ventricular posterior wall 
dimension in diastole; LVEDV(i) = Left ventricular end-diastolic volume 
(index); LVESVi = Left ventricular end-systolic volume index; LVEF = 
Left ventricular ejection fraction; IVA = Isovolumic acceleration; RVIDd = 
Right ventricular internal dimension in diastole; TAPSE = Tricuspid 
annular plane systolic excursion. 
 
 Control RIPC p 
LV Size  
IVSd (cm) 1.6±0.4 1.5±0.4 0.25 
LVIDd (cm) 4.7±0.6 4.8±0.6 0.51 
LVPWd (cm) 1.1±0.2 1.1±0.3 0.82 
LVEDV Contrast (ml) 117±45 111±40 0.59 
LVEDVi Contrast(ml.m-2) 58.5±19.6 55.3±18.4 0.54 
LVESVi Contrast(ml.m-2) 22.9±13.8 24.2±15.6 0.75 
LV Function  
LVEF Contrast (%) 61.6±13.4 58.5±13.3 0.40 
Average IVA 2.0±0.7 2.0±0.7 0.56 
LVTei 0.6±0.2 0.7±0.3 0.58 
E/A 0.9±0.2 1.0±0.3 0.07 
Deceleration Time (ms) 227±68 203±46 0.09 
e' 0.07±0.04 0.07±0.04 0.37 
E/e' 11.6±8.8 10.9±6.2 0.34 
LA Volume (ml) 33±19 34±17 0.73 
RV Size  
RVIDd (cm) 2.7±0.6 2.7±0.4 0.95 
RV Function  
TAPSE (mm) 21±5 23±5 0.15 
RVTei 0.6±0.3 0.5±0.1 0.17 
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Table 5.4: Within Control group analysis preoperative and 
postoperatively of echocardiographic parameters of LV and RV size and 
function. IVSd = Intraventricular septum in diastole; LVIDd = Left 
ventricular internal dimension in diastole; LVPWd = Left ventricular 
posterior wall dimension in diastole; LVEDV(i) = Left ventricular end-
diastolic volume (index); LVESVi = Left ventricular end-systolic volume 
index; LVEF = Left ventricular ejection fraction; IVA = Isovolumic 
acceleration; RVIDd = Right ventricular internal dimension in diastole; 
TAPSE = Tricuspid annular plane systolic excursion. 
 
 Preop Postop P 
LV Size  
IVSd (cm) 1.6±0.4 1.7±0.3 0.19 
LVIDd (cm) 4.7±0.6 4.7±0.7 0.27 
LVPWd (cm) 1.1±0.2 1.2±0.3 0.42 
LVEDV Contrast (ml) 117±45 111±38 0.27 
LVEDVi Contrast (ml.m-2) 58.5±19.6 55.4±17.1 0.24 
LVESVi Contrast(ml.m-2) 22.9±13.8 23.0±15.4 0.24 
LV Function  
LVEF Contrast (%) 61.6±13.4 61.8±17.0 0.30 
Average IVA 2.0±0.7 2.2±0.7 0.24 
LVTei 0.6±0.2 0.7±0.2 0.24 
E/A 0.9±0.2 1.1±0.3 0.21 
Deceleration Time (ms) 227±68 171±48 0.24 
e' 0.07±0.04 0.07±0.04 0.12 
E/e' 11.6±8.8 12.4±7.6 0.24 
LA Volume (ml) 33±19 37±22 0.26 
RV Size  
RVIDd (cm) 2.7±0.6 2.7±0.5 0.32 
RV Function  
TAPSE (mm) 21±5 12±3 <0.01 
RVTei 0.6±0.3 0.6±0.3 0.25 
 
137 
 
Table 5.5: Within RIPC group analysis preoperative and postoperatively 
of echocardiographic parameters of LV and RV size and function. IVSd = 
Intraventricular septum in diastole; LVIDd = Left ventricular internal 
dimension in diastole; LVPWd = Left ventricular posterior wall 
dimension in diastole; LVEDV(i) = Left ventricular end-diastolic volume 
(index); LVESVi = Left ventricular end-systolic volume index; LVEF = 
Left ventricular ejection fraction; IVA = Isovolumic acceleration; RVIDd = 
Right ventricular internal dimension in diastole; TAPSE = Tricuspid 
annular plane systolic excursion. 
 
 Preop Postop P 
LV Size  
IVSd (cm) 1.5±0.4 1.5±0.2 0.25 
LVIDd (cm) 4.8±0.6 4.9±0.7 0.24 
LVPWd (cm) 1.1±0.3 1.1±0.3 0.21 
LVEDV Contrast (ml) 111±40 101±37 0.09 
LVEDVi Contrast(ml.m-2) 55.3±18.4 51.4±19.9 0.24 
LVESVi Contrast(ml.m-2) 24.2±15.6 22.0±14.0 0.24 
LV Function  
LVEF Contrast (%) 58.5±13.3 58.7±16.7 0.26 
Average IVA  2.0±0.7 2.2±0.7 0.24 
LVTei 0.7±0.3 0.7±0.2 0.24 
E/A 1.0±0.3 1.2±0.4 0.33 
Deceleration Time (ms) 203±46 154±33 0.26 
e' 0.07±0.04 0.07±0.05 0.19 
E/e' 10.9±6.2 13.4±13.1 0.24 
LA Volume (ml) 34±17 35±18 0.20 
RV Size  
RVIDd (cm) 2.7±0.4 2.7±0.5 0.21 
RV Function  
TAPSE (mm) 23±5 12±3 <0.01 
RVTei 0.5±0.1 0.5±0.2 0.24 
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Table 5.6: Analysis of postoperative echocardiographic parameters of 
LV and RV size and function between Control and RIPC groups. IVSd = 
Intraventricular septum in diastole; LVIDd = Left ventricular internal 
dimension in diastole; LVPWd = Left ventricular posterior wall 
dimension in diastole; LVEDV(i) = Left ventricular end-diastolic volume 
(index); LVESVi = Left ventricular end-systolic volume index; LVEF = 
Left ventricular ejection fraction; IVA = Isovolumic acceleration; RVIDd = 
Right ventricular internal dimension in diastole; TAPSE = Tricuspid 
annular plane systolic excursion. 
 
 Control RIPC P 
LV Size  
IVSd (cm) 1.7±0.3 1.5±0.2 0.05 
LVIDd (cm) 4.7±0.7 4.9±0.7 0.32 
LVPWd (cm) 1.2±0.3 1.1±0.3 0.23 
LVEDV Contrast (ml) 111±38 101±37 0.36 
LVEDVi Contrast(ml.m-2) 55.4±17.1 51.4±19.9 0.46 
LVESVi Contrast(ml.m-2) 23.0±15.4 22.0±14.0 0.82 
LV Function  
LVEF Contrast (%) 61.8±17.0 58.7±16.7 0.52 
Average IVA 2.2±0.7 2.2±0.7 0.89 
LVTei 0.7±0.2 0.7±0.2 0.79 
E/A 1.1±0.3 1.2±0.4 0.07 
Deceleration Time (ms) 171±48 154±33 0.09 
e' 0.07±0.04 0.07±0.05 0.52 
E/e' 12.4±7.6 13.4±13.1 0.70 
LA Volume (ml) 37±22 35±18 0.60 
RV Size  
RVIDd (cm) 2.7±0.5 2.7±0.5 0.91 
RV Function  
TAPSE (mm) 12±3 12±3 0.37 
RVTei 0.6±0.3 0.5±0.2 0.31 
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Table 5.7: Analysis of ∆(Postop-Preop) echocardiographic parameters of 
LV and RV size and function between Control and RIPC groups. IVSd = 
Intraventricular septum in diastole; LVIDd = Left ventricular internal 
dimension in diastole; LVPWd = Left ventricular posterior wall 
dimension in diastole; LVEDV(i) = Left ventricular end-diastolic volume 
(index); LVESVi = Left ventricular end-systolic volume index; LVEF = 
Left ventricular ejection fraction; IVA = Isovolumic acceleration; RVIDd = 
Right ventricular internal dimension in diastole; TAPSE = Tricuspid 
annular plane systolic excursion. 
 
 Control RIPC P 
LV Size  
∆IVSd (cm) 0.0±0.4 0.1±0.3 0.89 
∆LVIDd (cm) 0.0±0.6 0.0±0.7 0.70 
∆LVPWd (cm) 0.1±0.3 0.02±0.3 0.24 
∆LVEDV Contrast (ml) -10±30 -14±39 0.69 
∆LVEDVi Contrast(ml.m-2) -4.8±15.3 -4.2±16.2 0.90 
∆LVESVi Contrast(ml.m-2) -0.4±9.3 -2.4±9.9 0.46 
LV Function  
∆LVEF Contrast (%) -0.4±16.7 0.0±15.0 0.64 
∆Average IVA 0.1±0.7 0.2±0.7 0.74 
∆LVTei 0.0±0.3 0.0±0.3 0.42 
∆E/A 0.2±0.3 0.2±0.4 0.67 
∆Deceleration Time (ms) -63±55 -48±50 0.25 
∆e' 0.00±0.03 0.00±0.03 0.73 
∆E/e' 0.4±9.0 1.3±9.9 0.36 
∆LA Volume (ml) 4±13 -1±20 0.22 
RV Size  
∆RVIDd (cm) -0.1±0.7 0.0±0.5 0.63 
RV Function  
∆TAPSE (mm) -9±5 -11±6 0.08 
∆RVTei -0.1±0.4 0.0±0.2 0.33 
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Table 5.8: Correlation of echo injury with 48 hour AUC cTnT release (all 
patients) 
 Value Correlation 
coefficient 
p 
∆LVEF(Contrast) -0.2±15.7 -0.13 0.36 
∆LV Tei 0.0±0.3 -0.02 0.89 
∆RV Tei -0.1±0.3 0.16 0.21 
∆TAPSE -10±6 -0.09 0.53 
∆Average IVA 0.1±0.7 0.17 0.17 
 
Table 5.9: Correlation of echo injury with 0-6hrs inotrope incidence (all 
patients) 
 Value Correlation 
coefficient 
p 
∆LVEF(Contrast) -0.2±15.7 -0.08 0.49 
∆LV Tei 0.0±0.3 -0.01 0.91 
∆RV Tei -0.1±0.3 -0.01 0.90 
∆TAPSE -10±6 -0.03 0.78 
∆Average IVA 0.1±0.7 -0.13 0.20 
 
Table 5.10: Correlation of echo injury with 6-12 hours inotrope incidence 
(all patients) 
 Value Correlation 
coefficient 
p 
∆LVEF(Contrast) -0.2±15.7 -0.03 0.82 
∆LV Tei 0.0±0.3 0.10 0.32 
∆RV Tei -0.1±0.3 0.08 0.43 
∆TAPSE -10±6 0.07 0.55 
∆Average IVA 0.1±0.7 -0.14 0.16 
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5.0 Discussion 
This double-blind study is the first to demonstrate that no functional benefit on 
left or right ventricular function assessed by transthoracic echocardiography 
arises from RIPC during on-pump CABG.  
Early evidence for a benefit from RIPC on LV function had been promising. 
Kharbanda et al in a porcine model undergoing intermittent hindlimb 
ischaemia observed a greater fall in LV function, measured invasively, during 
ischaemia in controls. Unfortunately this was not maintained at reperfusion 
and late effects were not studied perhaps suggesting that benefit in LV 
function is short-lived (minutes) and long term functional benefit is unlikely.  
In the present study markers of left heart function (LVEF with contrast; LV Tei) 
remained comparable between groups when measured following surgery. The 
primary endpoint selected was the load-independent IVA which remained 
unchanged but there were no changes in LVEF using contrast or in global 
measures of systolic and diastolic relaxation. Due to logistical reasons, the 
study did not recruit the planned 146 patients (73 patients in each group) so 
as to achieve the planned power to detect a difference in IVA ≥0.5SD (α 0.05, 
1-β 0.85). Therefore, the lack of effect in this study could have been due to a 
lack of statistical power arising from the failure to perform echocardiography in 
all subjects recruited. With the achieved sample size of 72 patients however 
(Control n=38; RIPC n=34), this study would still have the power to detect a 
difference in IVA ≥0.675SD (α 0.05, 1-β 0.80). The observed difference in 
∆IVA between the two groups was non-significant (p=0.74) and the 95% 
confidence interval of the difference was small (-0.4 to 0.3). From this, it is 
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suggested that should a difference between the two groups exist as a result of 
RIPC, this is likely to be small and offer minimal clinical benefit. 
Another potential reason for the failure to demonstrate an effect could be the 
degree of variability between pre-operative and post-operative measurements 
on echocardiography. Image acquisition is dependent not only on observer 
seniority but also patient morphological variation. Intra-patient variability exists 
particularly in the post-operative setting where “poor acoustic windows” are 
commonplace. Poor pain control, less patient compliance, post-operative fluid 
and ventilation requirements result in a difficulty in obtaining a “good acoustic 
window” postoperatively. This variability may be reflected in the wide standard 
deviations for the LVEF values recorded, albeit similar in both groups. The 
inter-study variability in our population was minimised as far as possible by 
using a single blinded observer to analyse all studies. 
Intraoperative tranoesophageal echocardiography was not performed and so 
comment on any immediate, albeit short lived, benefit on contractility is not 
possible. From a clinical perspective data on longer term functional 
improvement is more relevant and it is clear RIPC failed to achieve this. This 
failure should not be due to inadequate RIPC stimulus, since an identical 
stimulus to that which in previous reports was associated with a >40% 
reduction in cTnT release. The RIPC stimulus was administered in this study 
within an appropriate time-frame and delivery was verified by observing 
disappearance of the oximetry pulse signal. One possibility is that a greater 
effect of RIPC would be documented in patients with abnormal LVEF prior to 
CABG, in whom improvement following revascularisation of hibernating 
segments might be more subject to variation in peri-operative conditions. This 
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study did not directly address the issue of whether RIPC could afford 
additional benefit to improvement in LV function in those undergoing CABG 
with impaired LV function and hibernation, and was restricted to patients with 
normal EF at entry. 
At present there is no data in the literature that has investigated the effects of 
RIPC on RV function however the effect of IP has been studied. In a clinical 
trial Wu et al showed that an IP stimulus (crossclamping of the aorta) with 
antegrade and retrograde cold blood cardioplegia followed by a hot shot 
improves cardiac index and RVEF 1 hour after declamping. Yet again though 
this immediate advantage was not replicated at 6 hours nor on the first 
postoperative day. Indeed multiple samples of cardiac troponin I and CKMB, 
markers of myocardial necrosis, up to the second postoperative day were 
similar between groups. Our study has corroborated the findings that 
preconditioning does not preserve late RV function (TAPSE and RV Tei). 
Within groups, markers of load-dependent (LVEF with contrast; LV Tei) and 
load-independent (IVA) heart function was unchanged following surgery. 
Conversely, reduced TAPSE but unchanged RV Tei in both groups would 
suggest a reduction in RV longitudinal function that is compensated for 
circumferentially as global function remains unchanged. Current myocardial 
protection techniques would appear to be effective in the LV but are sub-
optimal in the RV. This reduced RV function was not related to peri-operative 
myocardial necrosis or inotrope use. Indeed deleterious echocardiographic 
change post-CABG is not predicted by cTnT release or inotrope requirement 
up to 12 hours postoperatively. 
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6.0 Conclusion 
In this double-blind study, RIPC has failed to afford benefit in LV or RV 
contractile function 5-7 days following CABG in spite of manoeuvres designed 
to overcome inherent difficulties: intravenous ultrasound contrast; 
measurement of load-independent IVA. RV longitudinal function is reduced 
post-CABG but overall global RV function is maintained. 
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CHAPTER 6 THE EFFECTS OF RIPC ON ARRYTHMIAS ON 
PATIENTS UNDERGOING FIRST TIME CORONARY 
ARTERY BYPASS SURGERY 
 
1.0 Introduction 
In a porcine model of remote ischaemic preconditioning (RIPC), short cycles 
of repeated limb ischaemia during myocardial ischaemia have reduced 
myocardial infarction by >20% and protected against malignant arrhythmia 
during the reperfusion phase through a K(ATP) channel-dependent 
mechanism [240]. Partial hindlimb occlusion has also delayed the 
development of ischemia-induced ventricular arrhythmias induced by coronary 
artery occlusion [241] in experimental models.  
Although as yet no study of the effects of RIPC on arrhythmias in humans has 
been reported, IP has been investigated. In one series preinfarction angina, a 
clinical form of preconditioning, has been positively associated with protection 
from the development of sustained ventricular tachycardia and ventricular 
fibrillation (VT/VF) after reperfusion (by PCI) following STEMI. [242] VT/VF is 
a significant determinant of long-term major adverse cardiac events. 
Continuous Holter ECG monitoring of patients with variant angina has 
demonstrated that preconditioning by transient ischemia induces protection 
against ischemia-induced complex ventricular arrhythmias [243].  
Ischaemic heart disease carries an increased risk of malignant VF and VT 
and sudden death [244][245][246][247][248][249] and post-CABG both VF 
and VT have been identified as potential life threatening complications. In a 
RCT of 86 patients undergoing CABG only (three vessel disease) IP has been 
146 
 
shown to reduce postoperative VF (48.8% vs. 79.1%; p<0.01) and VT, the 
mechanical ventilation period and need for inotropes [250]. IP has also been 
observed to reduce the QT dispersion provoked by coronary artery occlusion 
and reperfusion during coronary angioplasty.[251] Preconditioning with 
adenosine, which has been implicated in the IP pathway, has been shown to 
suppress the frequency of pre- and post-ischaemic tachyarrhythmia’s against 
an ischaemia-reperfusion insult in human myocardium harvested from CABG 
patients [252]. 
The timing of the conditioning stimulus does not appear to influence effect. In 
a rat model of postconditioning ventricular arrhythmia after regional ischemia 
was markedly attenuated [253]. 
However analyses of the effects of preconditioning on ischaemia and 
reperfusion-induced rhythm disturbances have yielded controversy. In a 
porcine model no changes were observed in the refractory duration, 
ventricular vulnerability or defibrillation energy requirements up to 90 min after 
ventricular ischaemic preconditioning [254]. 
In a prospectively randomised trial (n=35) Ascione et al observed antegrade 
cold blood cardioplegia to be associated with less ischaemic stress and 
myocardial injury than antegrade warm blood cardioplegia in hypertrophic 
hearts of patients undergoing aortic valve surgery. Troponin I release and the 
total incidence of postoperative arrhythmias was higher in the warm blood 
group. As the evidence pointed towards myocardial injury being responsible 
for the occurrence of supraventricular arrhythmias [178], this endpoint 
following reperfusion may be an important index of myocardial protection.  
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The aims of this study were to confirm the role of RIPC in reducing 
perioperative MI (LBBB or new onset Q waves), ventricular tachyarrhythmia 
and treated atrial fibrillation rates in non-diabetic adults undergoing first time 
CABG.    
 
2.0 Methods 
Three lines of investigation were employed to assess and compare 
perioperative arrhythmias between the groups as set out in Chapter 3; Section 
13.0 to 13.3.  
 
3.0 Results 
3.1 Perioperative myocardial infarction (PMI) outcomes  
148 patients (Control n=75; RIPC n=73) underwent 12 lead 
electrocardiography preoperatively through to postoperative day 4. No 
difference in the incidence of LBBB or new onset Q waves 2mm depth in 2 
leads by postoperative day 4 was found between the two groups (Table 6.1). 
 
Table 6.1: Post-operative dysrhythmias. For 12 lead ECG data Control 
n=75, RIPC n=73. AF = atrial fibrillation; LBBB = left bundle branch 
block. 
 Control 
(n=82) 
RIPC 
(n=80) 
p= 
 
New onset LBBB (n(%)) 3/75(4%) 0/73(0%) 0.25 
New onset Q wave (n(%)) 4/75(5.3%) 4/73(5.5%) 1.00 
Incidence of treated AF (n(%)) 30(37%) 28(35%) 0.87 
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3.2 Continuous ECG recording Outcomes 
Continuous ECG monitoring was performed in 146 patients (RIPC n=76 vs. 
Control n=70). Initial heart rate at the start of monitoring in both groups was 
comparable (RIPC 47(43-51) vs. Control 47(43-50) bpm). There was no 
difference in the incidence of reperfusion ventricular fibrillation during the 10 
minutes after AXC release (RIPC 15.8% vs. Control 11.4%; p=0.43). After the 
reperfusion period there were no episodes of sustained ventricular 
tachyarrhythmia requiring treatment. Brief non-sustained tachyarrhythmia’s 
occurred in 48/76(63.2%) RIPC and 43/70(61.4%) Control patients in the first 
post-operative 24 hours. There was no difference in tachyarrhythmia 
incidence at different time points between groups (Figure 6.1).   
 
Figure 6.1: Rates of detected non-sustained ventricular 
tachyarrhythmia’s in each group: -12h to operation (p=0.489); operation 
to reperfusion(p=0.180); post-reperfusion to 2 hours (p=0.124); 2-
24hours(p=0.179); 24-48 hours (p=0.353) 
p=0.489
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3.3 Atrial fibrillation - treated 
The overall incidence of treated atrial fibrillation was 58(36%) (RIPC 28(35%) 
vs. Control 30(37%); p=0.87) (Table 6.1). 
 
4.0 Discussion 
This double-blind study is the first to demonstrate that RIPC has no role in 
reducing arrhythmia rates during on-pump CABG in non-diabetic adults. 
No previous studies have investigated the anti-arrhythmic potential of RIPC in 
humans but reports from experimental models had been promising. In a 
porcine model four 5 minute cycles of lower limb ischaemia by tourniquet 
inflation had reduced myocardial infarction by >20% and protected against 
malignant arrhythmia. The present study, however, has failed to replicate this 
advantage. All markers of arrhythmia: perioperative MI (12 lead ECG); 
ventricular tachyarrhythmia incidence (continuous Holter monitor); treated AF 
incidence have afforded no anti- or pro-arrhythmic potential in humans.  
A difference in protocols may have prevented change. The porcine model 
employed one more cycle of 5 minutes limb ischaemia than the present study 
and selected the lower limb. It is possible that this may have conferred extra 
benefit but seems unlikely as this study utilised an identical stimulus as 
previous reports that demonstrated a >40% reduction in cTnT release on the 
upper limb [107][145]. Whether response to RIPC is species-dependent is 
possible and identical protocols would have to be used as part of a trial to 
deduce the answer. 
The benefit afforded by IP in humans has been documented. In a randomised 
controlled trial by Wu et al postoperative ventricular tachyarrhythmia’s have 
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been reduced by >30% in patients undergoing on-pump CABG following two 
cycles of cross-clamping the aorta for 2 minutes followed by 3 minutes of 
reperfusion[250]. The present study however has been unable to replicate 
these positive findings.  
An explanation in the differences observed may lie in the different cardioplegic 
protocol employed by Wu et al. Using both an antegrade and retrograde 
delivery system for the cold blood cardioplegia and then completing the 
myocardial protection with a further 3 minutes of warm cardioplegia (37oC) 
prior to release of the aortic cross clamp may have offered additional 
protective benefit. A further possibility for the difference between the IP and 
RIPC patients may lie within the level of ischaemia generated by the 
preconditioning stimuli. Crossclamping the ascending aorta may generate a 
more substantial conditioning stimulus as compared to the 3 cycles of 5min 
inflation/deflation peripherally used in the RIPC protocol. This in turn may be 
sufficient to generate a functional change which the RIPC stimulus, although 
able to activate pathways, is simply not strong enough to match and thus 
bring about functional change. 
A much lower overall incidence of reperfusion fibrillation and a lower overall 
rate in the post-operative 48 hour period was found. This suggests important 
differences in protection efficacy between studies but the lower arrhythmia 
incidence in the current study makes it under-powered to exclude a lack of 
protection by RIPC for this end-point. 
Nonetheless at present the evidence is not in favour of any anti-arrhythmic 
potential afforded by RIPC to humans. A randomised controlled trial using a 
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different endpoint with higher quantitation of arrhythmia incidence may be 
more suitable in detecting change between treatment groups. 
  
5.0 Conclusions 
RIPC does not offer any anti-arrhythmic benefit in non-diabetic adult humans 
undergoing first time coronary artery bypass surgery. It has not shown any 
potential for pro-arrhythmia also. 
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CHAPTER 7 THE EFFECT OF RIPC ON RENAL OUTCOMES IN 
PATIENTS UNDERGOING FIRST TIME CORONARY 
ARTERY BYPASS SURGERY 
 
1.0 Introduction 
Acute kidney injury (AKI) is a common and prognostically important 
complication of cardiac surgery. It is independently associated with in-hospital 
mortality, even after adjustment for comorbid disease and other 
complications, all degrees of AKI are associated with increased mortality and 
other adverse outcomes. [255]. 
In a series of 817 patients undergoing on-pump CABG, a discrete alteration in 
renal function (AKI) defined as an increase of 0.3 mg.dL-1 or 50% in baseline 
creatinine was found in 52% of patients and independently predicted death 
within 30 days (p<0.01).  These patients were observed to have higher 30 day 
mortality (12.6% vs. 1.4%; p<0.01), longer intensive care unit (ICU) stay 
(median 2(2-3) vs. 3(2-5) days; p<0.01) and a larger proportion of patients 
with prolonged ICU stay (>14 days) (14 vs. 2%; p<0.01) [256]. 
In a larger series of 2672 patients undergoing CABG, 7.9% patients 
developed acute renal failure(ARF), defined as a rise in serum Cr >1.0mg/dl, 
and 0.7% developed acute renal failure requiring some form of dialytic 
therapy(ARF-D). ARF and ARF-D patients were observed to have increased 
mortality (14% vs. 1%; p<0.01 and 28% vs. 1.5%; p<0.01 respectively). 
Increased age, elevated preoperative Cr, duration of CPB, carotid artery bruit 
and diabetes were associated with development of AFR and ARF-D by 
multivariate analysis. [257] Other risk factors identified for AKI development in 
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a multicenter cohort of 3500 patients undergoing cardiac surgery were left 
ventricular dysfunction, presence of IABP, urgent surgery, preoperative 
anaemia, perioperative RBC transfusions and postoperative re-
exploration[255]. 
The aetiology of renal injury has been linked strongly to preoperative and 
intraoperative factors, in those presenting for cardiac surgery, that result in 
renal cellular ischaemia induced tubular epithelial and vascular endothelial 
injury and activation [258][259]. 
Preoperatively, patients tend to have impaired autoregulation due to pre-
existing comorbidities, (advanced age, atherosclerosis, chronic hypertension 
or chronic kidney disease), renal-injurious medication (NSAIDS, ACEI, 
Angiotensin receptor blockers) or a pro-inflammatory state. Normal renal 
perfusion is autoregulated such that the glomerular filtration rate is maintained 
until the mean arterial blood pressure (MABP) falls below 80mmHg [259]. 
During surgery MABP is often at the lower limits of normal autoregulation and 
especially during periods of haemodynamic instability these patients are 
vulnerable to ischaemic renal injury. 
Intraoperatively, proinflammatory events such as operative trauma, contact of 
the blood components with the artificial surface of the CPB circuit, ischaemia-
reperfusion injury, and endotoxaemia [260][261[262] contribute to injury. The 
generation of free haemoglobin and iron from haemolysis during CPB [260] 
has also been linked.  
Early experimental and human models have reported positively to the 
application of RIPC in cardiovascular surgery. Temporary infrarenal aortic 
occlusion in an animal model, during open thoracoabdominal aneurysm repair 
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has been shown to decrease IR renal injury caused by subphrenic aortic 
cross-clamping [263] and patients undergoing elective open abdominal aortic 
aneurysm repair demonstrate a 23% reduction in the incidence of renal 
impairment with intermittent common iliac artery cross clamping[143].  
More recently, in a RCT of patients undergoing endovascular repair (EVAR) 
for abdominal aortic aneurysms (n=40), 18 patients undergoing sequential 
lower limb ischaemia had a reduced increase in urinary markers of renal injury 
(urinary retinol binding protein and urinary albumin:creatinine ratio(ACR) [264] 
however no differences in the rates of renal impairment or major adverse 
cardiac events were observed. 
Reports of ischaemic preconditioning in experimental models have been 
equally encouraging. Intermittent renal artery clamping (renal IP) has been 
shown to ameliorate ischaemic renal injury as assessed by functional, 
metabolic and morphological methods [265][266][267][268][269][270]. 
Attenuation of NF-kappa B activity, downregulation of IL-18 expression, 
attenuation of NGAL and IKKbeta have been implicated in the renoprotective 
pathways [159][270]. Ischemic postconditioning has also been shown to 
decrease apoptosis and improve renal function, effects possibly related to 
activation of Akt and ERK½ activation.[271] 
In the assessment of renal injury both proteinuria and microalbuminuria have 
an established role in diagnosis and management. The glomerular membrane 
selectively allows passage of water and low molecular weight solutes into the 
tubule and restricts passage of larger molecular weight plasma proteins, 
based on a combination of molecular size, shape and charge. Despite the 
protein-retaining properties of the glomerular membrane, some protein does 
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pass into the proximal tubular fluid. Only a very small proportion of plasma 
proteins with a molecular weight >50 000 Da normally reaches the urine. This 
is primarily due to retention of large molecular weight proteins by the 
glomeruli, and tubular reabsorption of lower molecular weight proteins that 
pass through the glomerular membrane more easily.  Proteins such as 
albumin which do reach the glomerular filtrate are reabsorbed in the proximal 
tubules by a low capacity high affinity mechanism.  
The National Kidney Foundation Guidelines recommends urine albumin as a 
sensitive marker for chronic renal disease due to diabetes, glomerular disease 
and hypertension. Urinary albumin:creatinine ratio (ACR) may also be used as 
a sensitive and early marker of primary and secondary renal 
disease[272][273][274]. A reduction in the 24 h urinary ACR by Walsh et al 
following intermittent lower limb ischaemia (median 5 vs. 8.8; p=0.06) in 
patients undergoing EVAR reconfirms the relevance of this test in a 
cardiovascular setting [264]. 
The glomeruli filter larger amounts of low molecular weight proteins (<50 000 
Daltons). Measurement of the urinary content of low molecular weight proteins 
such as α1-microglobulin can be used as sensitive markers of proximal 
tubular function because.  Under normal conditions filtered low molecular 
weight proteins are almost completely reabsorbed by the proximal tubule, but 
even subtle tubular damage is associated with increased urinary 
excretion[275].  
The aims of this study were to confirm the role of RIPC in reducing markers of 
renal injury (peak creatinine, significant increase in creatinine (>44 µmol.L-1), 
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∆-creatinine (day 0-4), 24h area under the curve (AUC) ACR, 24 h α1-
µglobulin) in non-diabetic adults undergoing first time CABG. 
 
2.0 Methods 
Changes in serum creatinine, urinary albumin:creatinine ratio, urinary α-1 
microglobulin, and requirement for diuretics or haemofiltration were used as 
outcome measures  to assess the effect of renal protection by RIPC on peri-
operative renal injury in this  double-blind, randomised controlled trial. Protocols 
for assessment of renal outcomes are set out in Chapter 3; Section 14.0 to 
14.4.2. Statistical analysis was performed as per Chapter 3; Section 17.3. 
 
3.0 Results 
Of 162 patients (89% males) 80 were randomized to treatment and 82 to 
placebo.  The groups were well matched for pre-operative renal function 
(Serum creatinine: Control 96±16 vs. RIPC 98±16 µmol.L-1). The mean time 
on bypass (96±22 vs. 100±23; p=0.25) mins and aortic cross-clamp times 
(71±18 vs. 76±21; p=0.08) mins were not significantly different (Table 3.8). 
Peak creatinine, day 4 creatinine levels and ∆-creatinine between days 0-4 
were not different. Similar numbers of patients had increases >44 µmol.L-1. 
Three RIPC (3.8%) and one (1.2%) control patient required temporary 
dialysis. There was no difference in 24h AUC urine ACR or 24 hour urine α-
microglobulin levels (Table 7.1).  
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Table 7.1: Post-operative renal outcomes. For creatinine Control n=77, 
RIPC n=75. ACR = albumin:creatinine ratio. 
 Control 
(n=82) 
RIPC 
(n=80) 
p= 
 
Peak creatinine (µmol.L-1) 106(97-123) 106(88-123) 0.61 
>44 µmol.L-1 increase in creatinine (n(%)) 8/77(10) 5/75(7) 0.56 
∆- creatinine (day 0-4) (µmol.L-1) -0.88(-10.6-7.9) -2.6(-8.8-7.9) 0.67 
24h AUC ACR  69(40-112) 58(32-85) 0.08 
Pre-op. α1-µglobulin (mg.L-1) 8(4-16) 8(5-13) 0.75 
24 h α1-µglobulin (mg.L-1) 51(38-71) 45(28-74) 0.42 
Temporary dialysis (n(%)) 1(1) 3(4) 0.36 
Intravenous frusemide infusion (n(%)) 6(7) 8(10) 0.59 
 
4.0  Discussion 
This double-blind study is the first to demonstrate that RIPC has no role in 
reducing rates of acute renal injury following on-pump CABG in non-diabetic 
adults. 
No previous studies have investigated the renal protective effects of RIPC 
following cardiac surgery. Following three relatively small experimental and 
human studies: Lazaris et al (n=26); Walsh et al (n=40); Ali et al (n=82), the 
evidence for a beneficial effect of RIPC on aortic aneursymal surgery 
(including endovascular) has been encouraging.  
However, by failing to reduce 24h AUC urinary ACR, RIPC has delivered no 
detectable protection at the glomerular level from the insult of cardiac surgery. 
There is also no suggestion of protection against damage to tubular 
reabsorptive function as 24 h α1-microglobulin levels between the groups 
were similar. A difference in protocol between the aneursymal studies and the 
present study may offer a clue to the lack of the purported effect. In the rat 
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model of Lazaris et al a vascular clamp was applied on the infra-renal aorta 
just above its bifurcation for 15 minutes and in Ali et al’s human model the 
right iliac vessel was crossclamped for 10 minutes and then released and 
applied to the left iliac vessel for 10 minutes. These invasive methods of 
applying a remote ischaemic stimulus were both longer in duration and 
arguably more likely to provide a significant ischaemic stimulus. Walsh et al 
used two sequential periods of lower limb ischaemia using a tourniquet 
inflated for 10 minutes on one leg and then repeated on the other leg. 
Whether the three  five minute cycles of non-invasive tourniquet cuff inflation 
on an upper limb is just as likely to produce an equal strength or sufficient 
strength stimulus to effect change is difficult to deduce. Certainly this study 
utilised an identical stimulus as previous reports that demonstrated a >40% 
reduction in cTnT release on the upper limb [107][145] and so evidence for 
robustness of ischaemic stimulus exists. A large scale trial comparing the 
effects of intermittent upper limb ischaemia (three 5 min cycles tourniquet 
inflation/deflation) on similar aneursymal surgical procedures would be able to 
clarify whether the shorter non-invasive stimulus is just as effective as the 
reported longer noninvasive and invasive stimuli. Such a trial, if positive, 
would also stimulate discussion on whether similar to reports of IP [133] RIPC 
offers no additional benefit when associated with CPB regardless of the mode 
of cardioprotection used, because CPB per se induces preconditioning. 
Other surrogate markers of renal injury: peak serum creatinine concentration, 
change in serum creatinine, incidence of intravenous frusemide requirement; 
incidence of dialysis requirement also failed to support the improvement of 
renal function by intermittent upper limb ischaemia (RIPC).  
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A sub-analysis of the incidence of those patients who suffered a more severe 
acute kidney injury as defined by >44 µmol.L-1 increase in creatinine once 
again demonstrated no benefit afforded in this group by RIPC (Control 
8/77(10%) vs. RIPC 5/75(7%); p=0.56). 
In spite of early suggestions that RIPC may offer benefit against IR injury of 
the kidneys during coronary surgery this study has failed to offer evidence. 
The morbidity and mortality from renal injury post-CABG remains a concern 
for the surgical community and the search for a more effective treatment 
strategy must continue. 
  
5.0 Conclusion 
In this double blind randomised controlled trial RIPC does not offer any renal 
protection in non-diabetic adult humans undergoing first time coronary artery 
bypass surgery. 
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CHAPTER 8 THE EFFECT OF RIPC ON LUNG OUTCOMES IN 
PATIENTS UNDERGOING FIRST TIME CORONARY 
ARTERY BYPASS SURGERY 
 
1.0 Introduction 
Acute lung injury, presenting as pulmonary oedema and pulmonary gas 
exchange abnormalities such as postoperative hypoxaemia is common after 
cardiac surgery. Pulmonary dysfunction is a frequent complication of CABG 
and is associated with a longer duration of mechanical ventilation, difficulty 
weaning the patient, prolonged hospitalization, major morbidity, mortality and 
health care expenditure [276][277][278][279]. The pathophysiology reflects the 
combined effects of general anaesthesia, surgical injury, median sternotomy 
and CPB to produce hypoxia, atelectasis, pleural effusion and dysfunction of 
the diaphragm [280].  
CPB has been implicated in decreased oxygen and nutrient delivery to the 
alveoli due to a number of factors: microemboli from the ascending aorta may 
become dislodged during placement of cannula [281][282][283][284]; 
haemodilution by crystalloid fluids used to prime the pump reduces oxygen 
carrying capacity[285][286]; hypothermia increases blood viscosity increasing 
the risk of sludging in microvessels and impairing oxygen transfer from 
erythrocytes to alveolar cells; nonpulsatile flow, compared to physiologic 
pulsatile flow, decreases microvascular blood flow and increases the 
expression of inflammatory mediators in blood and vascular cells  
[287][288][289]. 
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However CPB itself may not be the major contributor to the development of 
post-operative pulmonary dysfunction. In a series of 175 patients undergoing 
CABG with CPB (n=150) and without CPB (n=25) changes in postoperative 
gas exchange was similar between groups. These findings were in spite of 
higher levels of markers of systemic inflammatory response in CPB patients 
[280]. These findings have been replicated in other studies [276] 
In a series of 16,847 patients undergoing on-pump CABG, valve, or CABG-
valve surgery patients receiving transfusion (red blood cells; fresh frozen 
plasma) had more risk-adjusted pulmonary complications: respiratory distress, 
respiratory failure, longer intubation times, acute respiratory distress 
syndrome and reintubation [290]. 
Early evidence in experimental models has been reassuring for the existence 
of lung IP. Clamping of the lung hilum (lung IP) in a rabbit model [291] has 
improved markers of lung ischaemia-reperfusion injury. Activation of 
adenosine A(1) receptors,  alteration of the pulmonary vasodilator response to 
histamine, sarcolemmal K(ATP) channels, preservation of endothelial-
dependent vasodilator responses and restoration of surfactant properties 
have been identified in the mediation of the protective properties of lung IP on 
ischemia-reperfusion injury[292][293][294]. Postconditioning has also been 
shown to attenuate lung ischemia-reperfusion injury through upregulating the 
protein expression of HO-1 that leads to reduced post-ischemic oxidative 
damage[295].  
In small scale human models RIPC has been shown to benefit the lungs 
whether the upper or lower limbs undergo intermittent ischaemia. In a 
prospective RCT of infants undergoing repair of ventricular septal defects 
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those randomised to 3 cycles of 5 min cuff inflation of the left upper limb at 24 
h and 1 h before surgery (RIPC n=30; Control n=30) were found to have 
higher calculated static lung compliance, dynamic lung compliance and lower 
respiratory index than controls postoperatively [296].  An attenuation of the 
systemic inflammatory response syndrome and increase in systemic tolerance 
to ischaemia-reperfusion injury enhanced lung preservation. A RCT in 
children undergoing repair of congenital heart defects with four 5 minute 
cycles of tourniquet cuff inflation to the lower limb (RIPC n=17; Control n=20) 
resulted in lower airway resistance 6 hours postoperatively [118]. Cardiac 
ischemic preconditioning has also been shown to improve lung preservation in 
patients having valve replacement, whereby reduction in the accumulation of 
polymorphonuclear leukocytes in lung tissue and the formation of oxygen free 
radicals has been suggested[297].  
Small study experimental models have also produced encouraging results. In 
a sheep model of repeated coronary artery occlusion and reperfusion 
(mimicking multi-vessel off-pump CABG), three episodes of five-minute 
occlusion of the external iliac artery (RIPC n=9; Control n=5) improved gas 
exchange (PaO2; PaO2:FiO2 ratio) and preserved pulmonary vascular 
resistance [298]. A porcine model (n=18) where the external iliac arteries were 
isolated bilaterally and simultaneously clamped for three cycles of 5 minutes 
before a prolonged ischemic period reduced markers of systemic 
inflammation and acute lung injury [299]. Furthermore lower limb ischaemia 
have been observed to reduce lipid peroxidation and lung injury [300][301] 
also when CPB has been used[196].  
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The ratio of the partial pressure of oxygen in arterial blood (PaO2) to the 
inspired oxygen fraction (FiO2) has been utilised as a tool for quantification of 
the degree of abnormality in pulmonary gas exchange[280][302]. The ratio 
has been used in experimental models to quantify pulmonary gas exchange 
before and after therapeutic intervention [303][304][305] and in clinical models 
has aided in the classification of patients’ pulmonary gas exchange status, 
including the definitions of acute lung injury (ALI) (27kPa≤PaO2:FiO2<40kPa) 
and of adult respiratory distress syndrome (ARDS) (PaO2:FiO2<27kPa) 
[306][307]. In the experimental model mimicking CABG by Xia et al RIPC 
increased PaO2 and PaO2:FiO2 reconfirming the relevance of this test in the 
setting of RIPC. Time to extubation according to standardised departmental 
protocols also allows comparative analysis of improvement from lung injury.  
Coronary artery bypass grafting (CABG) is established as a highly effective 
treatment strategy in improving life expectancy and quality of life of patients 
with ischaemic heart disease[215] but its success has been tarnished by a 
‘postperfusion syndrome’ implicated in dysfunction of the kidneys, lungs, heart 
and clotting system frequently found in patients undergoing extracorporeal 
circulation[308]. The activation of the clotting, kallikrein, complement systems 
and neutrophils and monocytes together with other blood elements produce 
the vasoactive and cytotoxic substances that cause myocardial and 
respiratory injury[309]. 
The aims of this study were to confirm the role of RIPC in reducing markers of 
lung injury (6h and 12h PaO2:FiO2 ratio; intubation time) in non-diabetic adults 
undergoing first time CABG. 
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2.0 Methods 
As Positive End Expiratory Pressure (PEEP) has been shown to increase 
right and left ventricular stroke volume variation both during open and closed 
chest conditions in addition to reducing right ventricular end-diastolic volume 
indicating a preload reductive effect, [175] its use in ventilator management 
was standardised to 5cm H2O. Changes in arterial blood partial pressure of 
oxygen (PaO2) / fractional inspired oxygen (FiO2) ratio and intubation times 
were used as outcome measures as set out in Chapter 3; Section 15.0 to 
15.4. Statistical analysis was performed as per Chapter 3; Section 17.3. 
 
3.0 Results 
Of 162 patients (89% males) 80 were randomized to treatment and 82 to 
placebo.  The groups were well matched for incidence of Forced expiratory 
volume in one second (FEV1) / Forced vital capacity (FVC) ratio <0.7 (RIPC 
12/80(15%) vs. Control 13/82(16%); p=0.51), preoperative PaO2:FiO2 ratio 
(RIPC 55(48-63) vs. Control 53(47-61); p=0.31) and smoking history (p=0.15); 
current smokers (RIPC 12/80(15%) vs. Control 7/82(9%)), ex-smokers (RIPC 
39/80(49%) vs. 52/82(63%)), and never smoked (RIPC 29/80(36%) vs. 
Control 23/82(28%)). Mean bypass times (RIPC 100±23 vs. Control 96±22; 
p=0.25)mins and aortic cross-clamp times (RIPC 76±21 vs. Control 71±18; 
p=0.08)mins were not significantly different (Table 3.8). Postoperatively times 
to extubation were not different (RIPC 895(675-1180) vs.  938(766-1403)min; 
p=0.28) and PaO2:FiO2 ratios at 6h (RIPC 37(28-45) vs. 36(29-43); p=0.85) 
and 12h (RIPC 35(28-41) vs. 33(26-43); p=0.56) were also comparable 
(Tables 8.1). Incidence of high risk lung status (preop FEV1:FVC ratio <0.7 
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and/or current smokers) was comparable and no difference postoperatively in 
6h (RIPC 36(32-43)  vs. Control 30(23-38); p=0.70), 12 h (RIPC 35(27-40) vs. 
Control (32(23-40); p=0.50) PaO2:FiO2 ratios and time to extubation (RIPC 
900(713-1940) vs. Control (838(574-1112)mins; p=0.29) was observed. 
 
Table 8.1: Post-operative lung outcomes. LOS = length of stay. 
 Control 
(n=82) 
RIPC 
(n=80) 
p= 
 
Extubation time (min) 937(766-1402) 895(675-1180) 0.28 
ITU LOS (days) 3(2-4) 3(2-5) 0.29 
Hospital LOS (days) 8(6-11) 8(6-12) 0.39 
6h PaO2:FiO2 ratio 36(29-43) 37(28-45) 0.85 
12h PaO2:FiO2 ratio  33(26-43) 35(28-41) 0.56 
 
4.0  Discussion 
This double-blind study is the first to demonstrate that RIPC has no role in 
reducing rates of acute lung injury following on-pump CABG in non-diabetic 
adults. 
No previous studies have investigated the pulmonary protective effects of 
RIPC following CABG in humans. In three relatively small human studies, 
Wenwu et al (n=60), Cheung et al (n=47) and Li et al (n=40) presented 
assuring evidence for the beneficial effect of RIPC in cardiac surgical 
procedures. However in this study, RIPC did not improve lung preservation as 
assessed by 6 and 12 hour PaO2:FiO2 ratio and time to extubation.  
Small sample size, age of population, differences in remote stimulus delivery 
and cardioplegia protocols may help explain why RIPC did not produce effect. 
166 
 
All three human studies investigated a considerably younger population group 
than the present study (median 65 years): Wenwu et al (mean 5 months); 
Cheung et al (mean 1 year); Li et al (mean 36 years). Whether the lung is less 
likely to respond to RIPC with age would be suggested from the evidence but 
could only be truly answered with trials using similar protocols in older age 
groups. Certainly this would be less practical in the case of repairs of 
congenital defects but may be more so in the case of valve replacements. 
Perhaps more significantly a case for the difference in findings attributable to 
strength of ischaemic stimulus used could be presented. Wenwu et al used 3 
cycles of 5 min cuff inflation of the left upper limb twice (at 24 h and 1 h) 
before surgery, Cheung et al employed an extra 5 minute cycle of lower limb 
cuff inflation than the three cycles in the present study and Li et al executed 
two 3 minute cycles of cross-clamping the aorta. Both non-invasive protocols 
were longer in total duration and the invasive stimulus although shorter 
arguably produced a more powerful ischaemic stimulus than the present 
study. At present no test exists to ascertain the ‘strength’ of a stimulus but 
certainly this study utilised an identical stimulus as previous reports that 
demonstrated a >40% reduction in cTnT release [107][145] and so evidence 
for robustness of ischaemic stimulus exists. 
All three positive human studies were conducted on CPB. Cardioplegia 
administered may have played an integral part of the purported benefit of 
RIPC seen but unfortunately lack of information on protocols makes comment 
difficult. Wenwu et al does not qualify what ‘cardioplegic arrest’ was used, 
Cheung et al does not expand on ‘blood cardioplegia’ used. Li et al uses a 
similar ‘intermittent cold blood (40C) cardioplegic arrest’ in valve replacements 
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as the antegrade cold blood (40C) cardioplegic arrest used in the present 
coronary surgery but operative details are limited. 
Experimental models also have observed improvement in markers of lung 
function. Both Xia et al (n=14) and Harkin et al (n=18) occluded the external 
iliac arteries for three 5 minute cycles unilaterally and bilaterally respectively. 
Again these invasive protocols may produce stimuli that the present study is 
not able to match. However, like repeated cross-clamping of the aorta, it is 
unlikely that these invasive procedures will be taken up by the cardiothoracic 
surgical community due to the potential for atheroembolism.   
A sub-analysis did not observe RIPC to improve lung preservation (6h and 
12h PaO2:FiO2 ratio; time to extubation) in those considered as high risk lung 
patients (preoperative FEV1:FVC ratio <0.7 and/or current smokers. 
In spite of early suggestions that RIPC may offer benefit against IR injury of 
the lungs during coronary surgery this study has failed to offer evidence. The 
morbidity and mortality from lung injury post-CABG remains a challenge for 
the cardiothoracic fraternity and the search for a more effective treatment 
strategy must continue. 
 
5.0 Conclusion 
In this double blind randomised controlled trial RIPC does not offer any lung 
protection in non-diabetic adult humans undergoing first time coronary artery 
bypass surgery. 
 
 
168 
 
CHAPTER 9 PILOT STUDY INTO THE EFFECTS OF RIPC ON 
GENES AND PATHWAYS IN PATIENTS 
UNDERGOING FIRST TIME CORONARY ARTERY 
BYPASS SURGERY 
 
1.0 Introduction 
Changes in gene expression and signal transduction pathways have been 
reported to be involved in ischaemic conditioning mediated myocardial 
protection. 
In experimental models RIPC has been shown to modify myocardial gene 
expression by upregulating cardioprotective genes and suppressing 
proinflammatory genes potentially involved in the pathogenesis of ischemia-
reperfusion injury [311]. Genes encoding key proteins involved in cytokine 
synthesis, leucocyte chemotaxis, adhesion and migration, exocytosis, innate 
immunity signalling pathways, and apoptosis have been shown to be 
suppressed within 15 mins of the RIPC stimulus and these findings are more 
pronounced after 24 hours (second window)[194]. In one model, 24 hours 
following RIPC, the expression of genes known to be associated with the 
stress response, redox regulation, growth and metabolism, DNA repair and 
other cellular functions was increased [312].  
Hypoxic conditioning of atrial trabeculae harvested from patients undergoing 
cardiac surgery has been observed to protect myocardium following 
prolonged ischaemia-reperfusion.  Protection has been shown to be 
dependent on activation of the Reperfusion Injury Salvage Kinase (RISK) 
pathway [313].  
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The RISK-pathway represents a group of pro-survival protein kinases, 
including Akt and Erk½, and has been seen to be recruited by IP to mediate 
cardioprotection in a series of animal models.   
In an isolated perfused rat heart model two 5 min cycles of global ischaemia 
(IP) prior to prolonged ischaemia-reperfusion increased prosurvival kinase 
(Akt, Erk½, p70S6K) phosphorylation and reduced histological infarct risk-to-
volume ratio [314] In an isolated rabbit heart model, one 5 min period of 
ischaemia followed by 10 min of reperfusion (IP) prior to lethal ischaemic 
insult reduced histological infarct risk-to-volume ratio and binding of 
adenosine (A1 and/or A2B) receptors during reperfusion was observed to 
initiate the protective signal transduction cascade [315]. IP-mediated 
activation of prosurvival kinases has been replicated in other studies [316]. 
Akt and Erk½ are activated through phosphorylation by PI3K and MEK½ 
respectively and seem to reduce the cellular damage specifically caused by 
the event of reperfusion [314][317]. Anti-apoptotic pathways are activated by 
phosphorylated Akt and Erk½ but one downstream target of activated Akt has 
been found to be of particular importance in this regard: Glycogen Synthase 
Kinase-3β (GSK-3β) and its association to the mitochondrial permeability 
transition pore (mPTP).  
GSK-3β is inhibited by site-specific phosphorylation and has previously been 
shown to be involved in cardioprotection in rat models [318]. Some evidence 
suggests that GSK-3β-inhibition is the effector mechanism of mPTP-inhibition 
preventing uncoupling of oxidative phosphorylation and mitochondrial swelling 
in the reperfusion period [319]. Moreover GSK-3β-inhibition is associated with 
accumulation of cytoplasmic β-catenin in the cytosol and nucleus.  
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Cytoplasmic β-catenin is a transcriptional regulator of several genes involved 
in cell survival and proliferation [320][321] and has been implicated in the 
process of preconditioning and healing after myocardial infarction (MI). 
Adenovirus mediated gene transfer of β-catenin in a rat model has been 
shown to decrease apoptosis in cardiomyocytes and cardiac fibroblasts. It has 
been suggested that β-catenin plays an important role in the healing process 
after MI by promoting survival and cell cycle in cardiomyocytes and cardiac 
fibroblasts with its differentiation into myofibroblasts [322]. 
Activation of PI3K-Akt, a part of the Risk-pathway, inhibits GSK-3β through 
site-specific phosphorylation. GSK-3β inactivation allows β-catenin 
accumulation and inhibits opening of the mPTP. Together with Erk½ 
activation these mechanisms seem to underlie the cytoprotective effects of 
preconditioning. 
Thus the PI3K/AKT/GSK-3 β/β-catenin cell survival pathway has been 
proposed as key in conditioning pathways (Figure 9.1). 
Invasive and non-invasive models of RIPC in rats have demonstrated nitric 
oxide [323], free radical pathways, heat shock proteins, antioxidant enzymes 
[324] and protein kinase C to be involved in these protective pathways [325].  
The aim of this pilot study was to generate hypotheses: RIPC exerts its 
cardioprotective effect through activation of the PI3K/AKT/GSK-3 β/β-catenin 
cell survival pathway in myocardial specimens of non-diabetic adults 
undergoing first time CABG. 
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Figure 9.1: Activation of PI3K-Akt, a part of the Risk-pathway, inhibits 
GSK-3β through site-specific phosphorylation. GSK-3β inactivation 
allows β-catenin accumulation and inhibits opening of the mitochondrial 
Permeability Transition Pore (mPTP). Together with Erk½ activation 
these mechanisms underlie the cytoprotective effects of 
preconditioning. 
 
2.0 Methods 
Assessment of acquired myocardial specimens followed methodology set out in 
Chapter 3; Section 16.0 to 16.2. 
 
3.0 Results 
Adult non-diabetic patients for CABG were recruited into a trial. All patients 
had three myocardial biopsies harvested intraoperatively (LV1, LV2, LV3). Of 
the 162 patients recruited to the trial 80 were randomised to RIPC and 82 to 
Control groups. From the Control arm of the trial 6 ‘post-reperfusion’ biopsy 
samples were randomly selected and from the RIPC arm of the trial 7 ‘post-
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reperfusion’ biopsy samples were randomly selected and analysed (Control 
n=6; RIPC n=7). RIPC increased expression of p–Akt (p=0.05; Figure 9.2) and 
pan-Akt (p<0.01; Figure 9.3). Total GSK-3β was increased by RIPC (p<0.01; 
Figure 9.4) but expression of p-GSK-3β was comparable between groups 
(p=0.95; Figure 9.5).  β-catenin was significantly increased by RIPC (p<0.01) 
(Figure 9.6). 
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Figure 9.2: Relative expression of p-Akt between groups (p=0.05). 
 
Figure 9.3: Relative expression of PAN-Akt between groups (p<0.01). 
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Figure 9.4: Relative expression of GSK-3β between groups (p<0.01). 
 
 
Figure 9.5: Relative expression of p-GSK-3β between groups (p=0.95). 
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Figure 9.6: Relative expression of β-catenin between groups (p<0.01). 
 
 
 
4.0 Discussion 
The data presented from this small mechanistic sub-study is the first to 
demonstrate that RIPC increases myocardial expression of the β-catenin 
pathway in humans undergoing CABG.  
The identification of a significant increase in the expression of p-Akt, pan-Akt, 
total GSK-3β and β-catenin represents an important step in understanding the 
cell biology of cardioprotection and the development of clinically viable 
therapeutic strategies for reducing IR injury.  
The Yellon group observed an increase in the activation of the RISK pathway 
in atrium, harvested from patients undergoing cardiac surgery (CABG and/or 
valve replacement), subjected to postconditioning protocols. The results in the 
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present study add support to these findings. It appears that the heart globally 
(atrium and left ventricle) responds to ischaemic stimuli. As pre- and post- 
ischaemic protocols have been successful the timing of stimulus delivery in a 
clinical setting offers flexibility and thus could be selected on practicality. A 
larger scale study to compare the effects of timing of conditioning stimulus on 
magnitude of effect is warranted. 
Haunseloy et al, Solenkova et al and Lecour et al observed increased 
activation of the prosurvival kinases in experimental IP models and correlated 
this with reductions in histological infarct risk-to-volume ratio. Although the 
present study can conclude that a remote ischaemic stimulus has been 
administered unlike other studies it has not correlated this with a functional 
change. In this study cardiac troponin release, a marker of myocardial 
necrosis, was unaltered between groups but with the arrival of advanced 
imaging techniques whether other endpoints such as infarct risk-to-volume 
ratio may show change should be investigated. 
The results are in general concordance with previous work showing up-
regulation and phosphorylation of constituents in the pathway by a 
cytoprotective stimulus.  However, it is rather puzzling that there was no 
change in the phosphorylation status of GSK-3β and the reasons for this are 
unclear.  Indeed this would appear to be a key step in animal models of 
preconditioning with GSK-3β inactivation allowing the preservation of β-
catenin.  Our data would suggest therefore that the human pathway differs 
from that in other mammalian models in this step.   
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Nevertheless this small scale study has shown three 5 min cycles of 
intermittent upper limb ischaemia to activate known cardioprotective pathways 
in humans following coronary bypass surgery. 
 
5.0 Conclusion 
In this small mechanistic study in patients randomised, RIPC increases 
activation of cardioprotective pathways in the myocardium of non-diabetic 
adult humans undergoing first time coronary artery bypass surgery. 
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CHAPTER 10 SUMMARY AND DIRECTIONS FOR FUTURE 
RESEARCH 
     
1.0 Introduction 
Ischaemic preconditioning has been recognised as a major cardioprotective 
phenomenon for many years [102][326]. Cycles of non-lethal ischaemia and 
reperfusion applied to the heart prior to a potentially lethal ischaemic insult 
have the capacity to reduce infarct size by >50%. More recently, it became 
apparent that the protection generated by this classical form of direct 
ischaemic preconditioning could be replicated when the non-lethal ischaemia 
was applied to one segment of the heart and the lethal ischaemia applied to a 
separate segment [108]. Thereafter, it became established that the same 
protection could also occur even if the pre-conditioning ischaemic stimulus 
was applied completely distant to the target organ requiring protection, i.e. 
transient ischaemia of a remote organ or limb could still generate protection 
for the organ being subsequently challenged by lethal ischaemia [327]. There 
is now clinical evidence, suggesting that this remarkable remote ischaemic 
preconditioning (RIPC) phenomenon may represent a simple, inexpensive, 
easily applied method of increasing cardioprotection during an array of 
interventional procedures that require a period of cardiac ischaemia to allow 
repair or intervention. Moreover, as it is now recognised that such protection 
may be achieved by starting the cyclical remote ischaemia and reperfusion 
after the period of injurious cardiac ischaemia has commenced; so called 
remote post- or peri-conditioning, the potential arises of enhancing protection 
in other scenarios, including transplantation [328].  
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Several clinical reports of RIPC in cardiovascular surgery have now been 
published.  In abdominal aortic aneurysm surgery, RIPC, induced by unilateral 
iliac artery clamping has reduced troponin release and renal injury [143]. In 
children undergoing congenital heart defect repairs utilising cardiopulmonary 
bypass, lower limb RIPC has been demonstrated to reduce troponin release 
and inotrope requirements [118]. In adults undergoing coronary artery bypass 
surgery (CABG), intermittent upper limb ischaemia has been followed by 
reductions in post-operative release of lactate dehydrogenase [144] and 
troponin T. In 57 patients, Haunseloy et al observed a >40% reduction in AUC 
serum cTnT where each anastomosis was constructed with either intermittent 
cross clamp fibrillation or cardioplegia [107]. Venugopal et al went on to 
observe 45 patients undergoing CABG (±concomitant aortic valve 
replacement) and antegrade±retrograde cold blood cardioplegia produce a 
similar magnitude of effect [145].  
 
2.0 Summary of effects of RIPC in patients undergoing CABG 
2.1 Cardiac outcomes  
Postoperative cardiac troponin is an independent predictor of in-hospital death 
and high concentrations are associated with a cardiac cause of death and 
major postoperative outcomes. Which troponin measurement; isolated values 
at specific time points or area under the curve (AUC) release provides the 
most prognostically important information is not yet known.  Additionally, 
whether troponin release in the first few hours after surgery reflects true 
infarction or a change in sarcolemmal integrity or permeability has been 
questioned. Previous studies suggested a large treatment effect; a 
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standardised difference of 0.8.  The current study hypothesised that RIPC 
would reduce 48 h AUC cTnT release by a standardised difference of 0.6 at 
90% power and 5% alpha. This required a sample size of 120 subjects which 
was increased by 33% to accommodate withdrawal or missing data points. 
Sufficient patients with full data sets were recruited. 
This double-blind study using an identical RIPC stimulus and cTnT assay has 
not corroborated previous smaller single blind studies that found RIPC to 
reduce troponin release following on-pump CABG. This absence of effect on 
measurable myocardial injury (48h AUC cTnT; peak cTnT; 6h cTnT release) 
is matched by a failure to demonstrate any advantage of RIPC in terms of 
cardiac performance (serial cardiac indices; IABP usage) and inotrope and 
vasoconstrictor requirement. To accommodate for changes in systemic 
vascular resistance left ventricular stroke work indices was analysed and was 
comparable between groups. Thus, there is no evidence to suggest the 
benefit of a ‘first window’ of RIPC protection. 
Post-CABG myocardial injury often manifests as a transient period of 
reversible dysfunction, treatable by hemodynamic optimisation and temporary 
inotropic support. The data has provided no evidence of protection afforded 
by RIPC against this cardiac stunning phenomenon. 
No subtle differences between the groups exist for known preconditioning 
volatile anaesthetic agents (Enflurane or Sevoflurane) usage or AUC cTnT 
when adjusted for calculated CrCl or elective/urgent cases which could bias 
results. 
In conclusion, RIPC in this study has failed to augment myocardial protection 
in patients undergoing CABG.  
181 
 
2.2 Functional impact  
During and following cardiac surgery there is considerable variability in 
preload and afterload. Isovolumic acceleration (IVA) was selected as the 
primary endpoint of LV contractile function due to its load-independent 
qualities. Due to logistical reasons only 72 of the planned 146 patients were 
recruited to this sub-study. With the achieved sample size this study would 
still have the power to detect a difference in IVA ≥0.675SD (α 0.05, 1-β 0.80). 
The observed difference in ∆IVA between the two groups was non-significant 
and the 95% confidence interval of the difference was small (-0.4 to 0.3). 
From this, it is suggested that should a difference between the two groups 
exist as a result of RIPC, this is likely to be small and offer minimal clinical 
benefit. 
This double-blind study is the first to demonstrate that RIPC offers no long 
term functional benefit on LV or RV function assessed by transthoracic 
echocardiography during on-pump CABG.  
Following surgery RIPC afforded no functional improvement in load-
independent (IVA) and load dependent (LVEF with contrast; LV Tei) markers 
of systolic left heart function. Diastolic function (LV Tei; E/A; deceleration time; 
E/e’) and RV contractile function (TAPSE; RV Tei) was not improved either.  
Within groups, markers of LV function were unchanged following surgery. 
Conversely, reduced TAPSE but unchanged RV Tei in both groups would 
suggest a reduction in RV longitudinal function that is compensated for 
circumferentially as global function remains unchanged. This reduced RV 
function was not related to peri-operative myocardial necrosis or inotrope use. 
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Indeed deleterious echocardiographic change post-CABG is not predicted by 
cTnT release or inotrope requirement up to 12 hours postoperatively. 
In conclusion, following surgery a reduction in RV longitudinal function occurs 
although global RV function is preserved. This is the first study to show that 
RIPC fails to preserve late LV or RV contractile function. 
  
2.3 Arrhythmias  
This double-blind study is the first to demonstrate that RIPC has no role in 
reducing arrhythmia rates during on-pump CABG in non-diabetic adults. 
All markers of arrhythmia: perioperative MI by 12 lead ECG (new onset LBBB; 
Q waves); ventricular tachyarrhythmia incidence by continuous Holter 
monitoring; treated AF incidence have found no anti- or pro-arrhythmic 
potential in humans.  
Wu et al observed a benefit of >30% in postoperative ventricular 
tachyarrhythmia’s with IP following CABG. The present study however has 
been unable to replicate these positive findings. A much lower overall 
incidence of reperfusion fibrillation and a lower overall rate in the post-
operative 48 hour period was found. The lower arrhythmia incidence in the 
current study makes it under-powered to exclude a lack of protection by RIPC 
for this end-point. 
 
2.4 Renal outcomes 
This double-blind study is the first to demonstrate that RIPC has no role in 
reducing rates of acute renal injury following on-pump CABG in non-diabetic 
adults. 
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No previous studies have investigated the renal protective effects of RIPC 
following cardiac surgery. However three relatively small experimental and 
human studies have shown a beneficial effect of RIPC on aortic aneursymal 
surgery (including endovascular).  
Intermittent upper limb ischaemia failed to offer any detectable benefit in 
urinary 24h AUC ACR and so at the glomerular level no protection effect from 
the insult of cardiac surgery was found. As urinary 24 h α1-microglobulin level 
was comparable there is no suggestion of protection by RIPC against damage 
to tubular reabsorptive function. 
Other surrogate markers of renal injury: peak serum creatinine concentration, 
change in serum creatinine, incidence of intravenous frusemide requirement; 
incidence of dialysis requirement also failed to support the improvement of 
renal function by RIPC.  
A sub-analysis of the incidence of those patients who suffered a more severe 
acute kidney injury as defined by >44 µmol.L-1 increase in creatinine once 
again demonstrated no benefit afforded in this group by RIPC. 
In spite of early suggestions that RIPC may offer benefit against IR injury of 
the kidneys during on-pump coronary surgery this study has failed to offer 
evidence.  
 
2.5 Lung outcomes 
This double-blind study is the first to demonstrate that RIPC has no role in 
reducing rates of acute lung injury following on-pump CABG in non-diabetic 
adults. 
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No previous studies have investigated the pulmonary protective effects of 
RIPC following CABG in humans. Small human studies have presented 
assuring evidence for the beneficial effect of RIPC in cardiac surgical 
procedures in younger patients. However in this study, RIPC did not improve 
lung preservation as assessed by 6 and 12 hour PaO2:FiO2 ratio and time to 
extubation on the Intensive Care Unit following surgery. 
RIPC does not offer benefit against IR injury of the lungs during on-pump 
coronary surgery in non-diabetic adults. 
 
2.6 Genes and Pathways 
The data presented from this small mechanistic sub-study is the first to 
demonstrate that RIPC increases myocardial expression of the β-catenin 
pathway in humans undergoing CABG.  
The identification of a significant increase in the expression of p-Akt, pan-Akt, 
total GSK-3β and β-catenin represents an important step in understanding the 
cell biology of cardioprotection and the development of clinically viable 
therapeutic strategies for reducing IR injury.  
Although studies have observed an increase in the activation of the RISK 
pathway in atrium, harvested from patients undergoing cardiac surgery, 
subjected to postconditioning protocols this study shows that the heart is 
globally affected (left ventricular biopsy) 10 minutes after reperfusion from a 
prolonged period of ischaemia when a preconditioning stimulus is used also. 
The results are in general concordance with previous work showing up-
regulation and phosphorylation of constituents in the pathway by a 
cytoprotective stimulus.  However, it is rather puzzling that there was no 
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change in the phosphorylation status of GSK-3β and the reasons for this are 
unclear.  Indeed this would appear to be a key step in animal models of 
preconditioning with GSK-3β inactivation allowing the preservation of β-
catenin.  Our data would suggest therefore that the human pathway differs 
from that in other mammalian models in this step.   
This small scale mechanistic study has shown three 5 min cycles of 
intermittent upper limb ischaemia activate known cardioprotective pathways in 
humans following on-pump CABG in non-diabetic adults. 
 
3.0 RIPC from promise to disappointment 
3.1 Cardiac outcomes 
This double-blind study using an identical RIPC stimulus and cTnT assay has 
not corroborated previous smaller single blind studies that found RIPC to 
reduce troponin release following on-pump CABG.  
On initial review the design of Venugopal et al’s investigation into RIPC 
effects on patients undergoing CABG using cold blood cardioplegic arrest is 
identical to the present study. Closer examination however reveals fewer 
similarities which may help explain the difference in results. 
Firstly, blinding of treatment allocation was applied to patients and surgeons 
only; anaesthetists (who administer agents capable of preconditioning or 
affecting myocardial protection) and investigators were not blinded. Similar 
proportions of patients received isoflurane or sevoflurane for anaesthetic 
maintenance but dosages are not reported. As such volatile anaesthetic 
agents may induce a dose dependent conditioning effect [146], a potential for 
inadvertent bias arises.   In the present study a scrupulous technique to blind 
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the surgeon, anaesthetist and investigators from the group allocation was 
developed. The stimulus was administered within an appropriate time-frame 
and delivery verified by observing disappearance of the oximetry pulse signal. 
Isoflurane, a known pre-conditioning agent was specifically avoided. 
Secondly, the Venugopal et al study was small (n=45) compared to the 
current study (n=162) and contained only half of the estimated number of 
patients to detect the initially anticipated difference in AUC cTnT of 15 µg.L-
1
.72hrs (standard deviation 25 µg.L-1.72hrs) quoted in the statistical 
methodology. Statistical significance was actually attained with a smaller 
mean difference and sample size and this is attributable to the lower than 
anticipated variance observed in the RIPC group. Thirdly, the study also 
included patients requiring AVR; whether RIPC was effective in the CABG 
alone patients is not reported. The larger number of combined AVR/CABG 
cases contributed to a longer mean bypass time in the control group and 
bypass time was an independent predictor of greater troponin release. 
Despite this potentially confounding effect, an inter-group statistically 
significant difference was maintained after correction for bypass time using a 
generalised linear model. Fourthly, many of the important variables in the 
study e.g. bypass time, cross-clamp time and AUC cTnT had unequal 
variances yet were analysed parametrically. Lastly, although the drug history 
is reported, whether potentially relevant medications e.g. atorvastatin, 
potassium channel blockers [147][148] administered in the 24 hours pre-
operatively is not clear. Nevertheless, the effect of RIPC on troponin release 
was large and the data encouraging. 
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Differences in other preoperative and intraoperative variables may offer clues 
as to why no cardioprotection was observed in the present study. 
Preoperatively, non-elective patients who had angina or an acute coronary 
syndrome within 30-days of surgery were recruited. However, no patients had 
experienced angina within 48 hours of surgery and no differences between 
those admitted electively and more urgent cases was observed. A higher 
usage of beta-blockers was continued until the morning of surgery. 
Intraoperatively bypass and cross-clamp times were slightly longer due to a 
single clamp technique. The incidence of volatile anaesthetic (Enflurane or 
Sevoflurane) use and AUC cTnT adjusted for calculated creatinine clearance 
(CrCl) was similar between treatment and control groups. 
 
3.2 Functional outcomes 
Early evidence for a benefit from RIPC on LV function had been promising. 
Kharbanda et al in a porcine model undergoing intermittent hindlimb 
ischaemia observed a greater fall in LV function during ischaemia in controls, 
late effects were not studied. This improvement in contractile function was not 
replicated in the present study five to seven days following CABG. Differences 
in the designs of the studies: lower limb vs., upper limb ischaemia; invasive 
vs. non-invasive measurement of LV function; four vs. three 5 min cycles, in 
combination may have increased the likelihood of realisation of 
cardioprotection in the Kharbanda et al study.  
The lack of effect observed in the current study could have been due to a lack 
of statistical power arising from the failure to perform echocardiography in all 
subjects recruited. As mentioned above, with the achieved sample size of 72 
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patients this study would still have the power to detect a difference in IVA 
≥0.675SD (α 0.05, 1-β 0.80). The observed difference in ∆IVA between the 
two groups was non-significant and the 95% confidence interval of the 
difference was small (-0.4 to 0.3). From this, it is suggested that should a 
difference between the two groups exist as a result of RIPC, this is likely to be 
small and offer minimal clinical benefit. 
Another potential reason for the failure to demonstrate an effect could be the 
degree of variability between pre-operative and post-operative measurements 
on echocardiography. Image acquisition is dependent not only on observer 
seniority but also patient morphological variation. Intra-patient variability exists 
particularly in the post-operative setting where “poor acoustic windows” are 
commonplace. Poor pain control, less patient compliance, post-operative fluid 
and ventilation requirements result in a difficulty in obtaining a “good acoustic 
window” postoperatively. This variability may be reflected in the wide standard 
deviations for the LVEF values recorded, albeit similar in both groups. The 
inter-study variability in our population was minimised as far as possible by 
using a single blinded observer to analyse all studies. 
 
3.3 Arrhythmias 
No previous studies have investigated the anti-arrhythmic potential of RIPC in 
humans but reports from experimental models had been encouraging. Again 
whether the use of the lower limb and an extra cycle of stimulus confer extra 
cardioprotective benefit and/or whether RIPC is species-dependent is difficult 
to ascertain but may offer reasoning as to why the purported benefit was not 
observed. 
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The present study did not replicate the >30% reduction in postoperative 
ventricular tachyarrhythmia’s observed by Wu et al, in those receiving IP, 
following CABG. A much lower overall incidence of reperfusion fibrillation and 
a lower overall rate in the post-operative 48 hour period was found suggesting 
important differences in protection efficacy between studies but the lower 
arrhythmia incidence in the current study makes it under-powered to exclude 
a lack of protection by RIPC for this end-point. Other differences between 
studies: central, invasive vs. remote, non-invasive stimulus; 
antegrade+retrograde vs. antegrade only cardioplegia; hot shot vs. no hot 
shot may have advantaged the study by Wu et al to demonstrate a change. 
 
3.4 Renal outcomes 
Although no studies into the renal protective effects of RIPC following cardiac 
surgery have been conducted, three small experimental and human studies 
have presented evidence for a beneficial effect on aortic aneursymal surgery 
(including endovascular). Lazaris et al and Ali et al utilised invasive clamping 
of large blood vessels to deliver remote stimuli and Walsh et al although using 
a non-invasive protocol did so to both lower limbs and for a longer duration 
than the current study. Thus a difference in the ‘strength’ of remote stimulus 
may have been able to produce change in these studies. 
 
3.5 Lung outcomes 
The current study has not replicated the benefit in lung preservation seen in 
three small human studies receiving RIPC in cardiac surgical procedures.  
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Small sample size, age of population, differences in remote stimulus delivery 
and cardioplegia protocols may help explain why RIPC did not produce effect. 
An age-dependent response to RIPC cannot be ruled out as all three human 
studies investigated a considerably younger population group than the 
present study. The three studies used either non-invasive protocols that were 
longer in duration or an invasive protocol for delivering remote stimuli possibly 
providing extra stimulus to cause effect. Although a positive response was 
seen with upper limb ischaemia in Wenwu et al’s study, the stimulus was 
delivered twice at 24h and 1h before surgery again possibly offering a 
synergistic benefit. 
In this study PEEP was set to a standardised level of 5cm H2O. Although 
PEEP improves arterial oxygenation, it can adversely affect systemic 
haemodynamics, reducing venous return and cardiac output. These effects 
are proportional to the PEEP level.[175][329] Any future work should address 
this potential methodological limitation to ensure unbiased results. 
Analysis of bronchoalveolar lavage has been shown to be a sensitive 
technique for the diagnosis of acute lung injury in a wide spectrum of clinical 
scenarios. [310][330][331][332] Although due to resource availability it was not 
employed in this study it may offer useful information in future studies 
investigating the efficacy of RIPC on lung preservation post cardiac surgery. 
 
3.6 Genes and Pathways 
The data presented from this small mechanistic sub-study is the first to 
demonstrate that RIPC increases myocardial expression of the β-catenin 
pathway in humans undergoing CABG. The remote stimulus of three 5 min 
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cycles to the upper limb has replicated findings from the Yellon group which 
showed activation of the RISK pathway in myocardium subjected to 
postconditioning following CABG. IP protocols in three studies have also 
demonstrated activation of prosurvival kinases.  
In conclusion, the remote stimulus delivered in the current study has been 
confirmed to have occurred due to positive changes in the cardioprotective 
pathways within the myocardium. 
 
4.0 Future Direction 
The activation of cardioprotective pathways within the myocardium by three 5 
min cycles of upper limb ischaemia has concurred with previous studies for 
the existence of the RIPC phenomenon. However, it is clear that the stimulus 
was unable to produce functional beneficial change to the heart, kidneys or 
lungs. 
A closer look at the body of literature suggests that use of the lower limb and 
extra cycles of stimulus may be able to increase the ‘strength’ of the stimulus 
itself. Whether this would be able to effect a change in patients undergoing 
CABG where other confounding variables such as CPB, cardioplegia and 
volatile anaesthesia exist is difficult to predict. Invasive remote stimuli have 
also delivered improvement in cardiac, renal and lung preservation but it is 
unlikely this method will ever offer a practical solution.  
In order to corroborate the findings of this study a further study is 
recommended. A more definitive conditioning protocol should be incorporated. 
Biochemical markers of preconditioning should be developed to differentiate 
those that are preconditioned from those that are not. Population investigated 
192 
 
may be those that are higher risk of myocardial injury e.g. left ventricular 
hypertrophy. The role of RIPC in transplantation surgery should also be 
explored further. 
 
5.0 Recommendation I: Trial 
5.1 Aims 
To assess whether four 5 min cycles of lower limb ischaemia at two time 
points (24h and 1 h before surgery) improves myocardial, renal and lung 
outcomes in non-diabetic adult patients undergoing on-pump multi-vessel 
coronary artery surgery. 
 
5.2 Design 
A large scale single centre, prospective randomised, placebo intervention-
controlled trial. Patients, investigators, anaesthetists, surgeons and critical 
care teams will all be blinded to group allocation. Subjects will be randomized 
(1:1) to RIPC (or placebo) stimuli (4x lower limb (or dummy leg) 5 minute 
cycles of cuff inflation/deflation) 24h and 1h prior to surgery. Anaesthesia, 
perfusion, cardioplegia and surgical techniques will be standardized. Patients 
will be stratified to Urgent and Elective CABG. 
 
Primary endpoint:   48h AUC cTnT release 
Cardiac secondary endpoints: MRI assessed infarct risk-to-volume ratio 
     6h and peak cTnT release 
     Perioperative MI (12 lead ECG)  
     Ventricular tachyarrhythmia’s (Holter) 
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     Treated atrial fibrillation incidence 
     Serial cardiac indices 
     Serial left ventricular stroke work indices 
     Low cardiac output episodes 
     IABP usage     
Inotrope and vasoconstrictor usage 
 Echocardiographic parameters 
Renal secondary endpoints: Peak serum creatinine  
>44 µmol.L-1 increase in creatinine  
∆- creatinine (day 0-4)  
Urinary 24h AUC ACR 
Urinary 24 h α1-µglobulin  
Temporary dialysis incidence 
Intravenous frusemide infusion incidence 
Lung secondary endpoints: 6h PaO2:FiO2 ratio 
12h PaO2:FiO2 ratio 
Extubation time 
Other endpoints:   Infection incidence  
     ITU length of stay 
In-hospital length of stay 
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6.0 Recommendation II: Other future work 
There is a need：  
(i) to determine the efficacy of RIPC in promoting protection in other forms 
of cardiac surgery 
(ii)  to ascertain whether changes in troponin release reflects true infarction 
or a change in sarcolemmal integrity or permeability 
(iii)  to establish if changes are reflected in improved clinical outcomes and 
that RIPC independently reduces risk  
(iv) to test if urgent CABG or elective CABG patients are already 
preconditioned 
 
7.0 RIPC in Transplantation 
The national early mortality for heart transplantation is 12.5% and >60% of 
deaths are secondary to dysfunction of the donor heart and so transplantation 
represents a specific challenge to a therapeutic role of RIPC. Theoretically, 
RIPC could be used in the brainstem dead donor to generate 
cardioprotection. However, although the pre-conditioning site would remain 
innervated, central neural connection is lost. Moreover, in this circumstance, 
reperfusion does not occur in the pre-conditioned environment unless the 
stimulus is repeated in the recipient. This is indeed the case, a donor heart, 
denervated at transplantation may still be protected from a post-implantation 
ischaemic insult by a RIPC stimulus in the recipient [333]. However, whether 
such conditioning could protect during the retrieval, transport and implant 
period of transplantation is not clear. 
 
195 
 
8.0 Limitations  
Despite its true double-blind status, the confirmation of stimulus delivery and 
its objective clinical and biochemical end-points our study remains undersized 
to detect smaller differences in a protective effect of RIPC and does not 
explore effect in a  higher risk population. Subtle differences in conditioning 
status may occur in patients presenting with urgent coronary syndromes 
status that preventing further conditioning in this group. 
This study relies heavily on the use of troponin release as a marker of true 
infarction but further research is required to confirm changes postoperatively 
are not due to change in sarcolemmal integrity or permeability.  
 
9.0 Conclusion 
The prospective randomised placebo intervention-controlled trial of RIPC 
described in this thesis has, like its predecessor cardiac same-organ IP, not 
fulfilled the promise of a practically useful form of improved myocardial 
protection. An identical stimulus to smaller positive studies was used with a 
robust technique designed to ensure blinding of all team-members. The 
stimulus of three 5 min cycles of upper limb ischaemia, administered within an 
appropriate time-frame with verified delivery, has been shown to activate 
cardioprotective mechanisms within the myocardium but has not been able to 
mount a beneficial functional response. An absence of effect on measurable 
myocardial injury is matched by a failure to demonstrate any advantage of 
RIPC in terms of cardiac performance, inotrope requirement, 
echocardiographic function, arrhythmia protection or renal and lung outcomes.  
196 
 
As the optimal RIPC stimulus remains elusive further lines of research has 
been generated by this study: the significance of troponin release during on-
pump surgery, the conditioning status of those presenting with urgent 
coronary syndromes, the efficacy of more cycles of lower limb ischaemia, the 
role of RIPC in higher risk and transplantation surgery. The hope is to 
establish a novel practical myocardial protective technique with proven benefit 
in a range of clinical end-points.  
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DATA COLLECTION  
 
SHEET 
 
REMOTE TRIAL  
 
Case …… 
 
If found please contact  
Mr I A Rahman  
 
Mobile :  
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Demographics 
 
REMOTE 
Code 
(IR151106) 
Hospital Reg 
No. 
Study No. D.o.B. D.o.S. 
 
 
 
    
 
Surgeon Gender Height 
pre-op 
Weight 
pre-op 
Weight 
POD 4 
BSA  
pre-op 
 
A  -    RSB 
 
B  -    JM 
 
   
 
  M         F 
    
 
Cardiac History 
 
CCS NYHA MI 
None / Q-wave / Non-Q 
Intervention 
None / PCI / Stent / PPM 
  
 
 
Cardiac Catheterisation 
    
       Date: 
Vessels diseased: 
 
Angio.LVF: Good / Moderate / Poor 
EF (echo): 
 
 
Holter monitoring 
 
Time monitor 
ON (12hrs pre-
op) 
Time Monitor 
OFF (48 hrs 
post-op) 
  
 
 
Pre-op Rhythm 
 
Sinus AF/Flutter PPM 
 
 
Admission from Home     /     In-Patient Transfer 
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Risk Factors 
 
 
Cholesterol / 
TG 
 
Hypertension 
 
Family Hx 
 
TIA (date) 
 
CVA (date) 
 
 
    
 
Peripheral Vascular disease 
 
 
 
 
 
Carotid Endaterectomy                             
Date: 
 
 
Other surgery:                  Date: 
 
 
Smoking 
 
Never        
Current         No. of pack years………. 
                         (20 cig / day / yr= 1 pack yr) 
Ex                                      Date: 
 
Respiratory disease 
 
None                          
Asthma                        
COPD                        
Bronchodilators         
Steroids   PO             
 
 
 
Spirometry 
 
Pre-op SaO2 >95% on 
RA 
  
FEV1   
FVC   
FEV1 / FVC   
Pre-op FEV1 / FVC 
>70% 
  
 
Medications  
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Pre op medication  
 
Premed given yes   no  
 
Aspirin (dose  mg)  days stopped prior to surgery 
 
Clopidrogel (dose mg)  days stopped prior to surgery 
 
Clexane (dose mg)  days stopped prior to surgery 
 
IV Nitrates Yes  No  
 
IV Heparin Yes  No  
 
IABP  Yes  No  
 
 
Echocardiography  PRE_OP       POD  6  
 
 
Operative Details 
 
Date and time fasted from  
Date and time knife to skin   
 
 
 Time on / 
applied 
Time off / 
released 
Reason Re-
instituted 
1st CPB    
2nd CPB    
3rd CPB    
4th CPB    
1st AXC    
2nd AXC    
3rd AXC    
 
  
Trucut Biopsies 
  Time taken 
Atrial   
LV1 Pre 
Ischaemia  
 
LV2 Ischaemia  
AXC removed  
LV3 
Reperfusion 
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 Conduit 
LAD  
Diagonal  
Circumflex  
OM1  
OM2  
RCA  
PDA  
Marginal  
 
Cold Blood Cardioplegia  
 
Induction: 
12mls/kg  
volume 
 
Timing 
 
 
Maintenance: 
300 ml extra 
Timing 
 
 
Enflurane:  pre CPB   intra CPB  
 
Additional protamine  Yes  No  
 
Time heparin given 
 
 
Mannitol 20% volume given 
 
 
 
CARDIAC OUTPUT & OXYGEN EXTRACTION DATA 
 Pre-
Sternotom
y 
Pre- 
Protamin
e 
Post - 
Protami
ne 
Post-
sterna
l 
closur
e 
ITU 
 0 
hrs 
2 hrs 4 hrs 6 hrs 9 hrs 12 hrs 
Time 
 
          
HR 
 
          
Rhyth
m 
 
          
CO 1 
 
          
CO 2 
 
          
CO 3 
 
          
Avera
ge CO 
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Avera
ge CI 
 
          
BP 
 
          
MAP 
 
          
PAP 
 
          
MPAP 
 
          
PAWP 
 
          
CVP 
 
          
Hb 
 
          
PaO2 
 
          
SaO2 
 
          
Temp 
1 
 
          
Temp 
2 
 
          
Mixed 
Venou
s 
SaO2 
 
          
SV 
 
          
SVR 
 
          
SVRI 
 
          
 
 
LCOS 
e.g. Dopamine 5ml/h started at AXC+2, 5,5,6,7,10 
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Inotropes, Insulin and Electrolytes 
 
 KCL Ca Insulin 
Pre-CPB    
CPB    
Post CPB – ITU    
ITU  - 6hrs    
6 – 12hrs    
12 – 24 hrs    
24 – 48 hrs    
48 – 72 hrs    
 
 
 
Inotrope & Drug Requirements 
Time Drug Name Dose Diluent Rate Time Drug Name Dose Diluent Rate
Pre-CPB Dopamine    1 Dopamine    
 Dobutamine     Dobutamine    
 Noradrenaline     Noradrenaline    
 Adrenaline     Adrenaline    
 Phenylephrine     Phenylephrine    
 Vasopressin     Vasopressin    
 GTN     GTN    
 Enoximone     Enoximone    
CPB Dopamine    2 Dopamine    
 Dobutamine     Dobutamine    
 Noradrenaline     Noradrenaline    
 Adrenaline     Adrenaline    
 Phenylephrine     Phenylephrine    
 Vasopressin     Vasopressin    
 GTN     GTN    
 Enoximone     Enoximone    
Post-CPB Dopamine    3 Dopamine    
 Dobutamine     Dobutamine    
 Noradrenaline     Noradrenaline    
 Adrenaline     Adrenaline    
 Phenylephrine     Phenylephrine    
 Vasopressin     Vasopressin    
 GTN     GTN    
 Enoximone     Enoximone    
0 Dopamine    4 Dopamine    
 Dobutamine     Dobutamine    
 Noradrenaline     Noradrenaline    
 Adrenaline     Adrenaline    
 Phenylephrine     Phenylephrine    
 Vasopressin     Vasopressin    
 GTN     GTN    
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 Enoximone     Enoximone    
Time Drug Name Dose Diluent Rate Time Drug Name Dose Diluent Rate 
5 Dopamine    11 Dopamine    
 Dobutamine     Dobutamine    
 Noradrenaline     Noradrenaline    
 Adrenaline     Adrenaline    
 Phenylephrine     Phenylephrine    
 Vasopressin     Vasopressin    
 GTN     GTN    
 Enoximone     Enoximone    
6 Dopamine    12 Dopamine    
 Dobutamine     Dobutamine    
 Noradrenaline     Noradrenaline    
 Adrenaline     Adrenaline    
 Phenylephrine     Phenylephrine    
 Vasopressin     Vasopressin    
 GTN     GTN    
 Enoximone     Enoximone    
7 Dopamine    13 Dopamine    
 Dobutamine     Dobutamine    
 Noradrenaline     Noradrenaline    
 Adrenaline     Adrenaline    
 Phenylephrine     Phenylephrine    
 Vasopressin     Vasopressin    
 GTN     GTN    
 Enoximone     Enoximone    
8 Dopamine    14 Dopamine    
 Dobutamine     Dobutamine    
 Noradrenaline     Noradrenaline    
 Adrenaline     Adrenaline    
 Phenylephrine     Phenylephrine    
 Vasopressin     Vasopressin    
 GTN     GTN    
 Enoximone     Enoximone    
9 Dopamine    15 Dopamine    
 Dobutamine     Dobutamine    
 Noradrenaline     Noradrenaline    
 Adrenaline     Adrenaline    
 Phenylephrine     Phenylephrine    
 Vasopressin     Vasopressin    
 GTN     GTN    
 Enoximone     Enoximone    
10 Dopamine    16 Dopamine    
 Dobutamine     Dobutamine    
 Noradrenaline     Noradrenaline    
 Adrenaline     Adrenaline    
 Phenylephrine     Phenylephrine    
 Vasopressin     Vasopressin    
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 GTN     GTN    
Time Drug Name Dose Diluent Rate Time Drug Name Dose Diluent Rate 
17 Dopamine    22 Dopamine    
 Dobutamine     Dobutamine    
 Noradrenaline     Noradrenaline    
 Adrenaline     Adrenaline    
 Phenylephrine     Phenylephrine    
 Vasopressin     Vasopressin    
 GTN     GTN    
 Enoximone     Enoximone    
18 Dopamine    23 Dopamine    
 Dobutamine     Dobutamine    
 Noradrenaline     Noradrenaline    
 Adrenaline     Adrenaline    
 Phenylephrine     Phenylephrine    
 Vasopressin     Vasopressin    
 GTN     GTN    
 Enoximone     Enoximone    
19 Dopamine    24-48 Dopamine    
 Dobutamine     Dobutamine    
 Noradrenaline     Noradrenaline    
 Adrenaline     Adrenaline    
 Phenylephrine     Phenylephrine    
 Vasopressin     Vasopressin    
 GTN     GTN    
 Enoximone     Enoximone    
20 Dopamine    48 - 72 Dopamine    
 Dobutamine     Dobutamine    
 Noradrenaline     Noradrenaline    
 Adrenaline     Adrenaline    
 Phenylephrine     Phenylephrine    
 Vasopressin     Vasopressin    
 GTN     GTN    
 Enoximone     Enoximone    
21 Dopamine    
 Dobutamine    
 Noradrenaline    
 Adrenaline    
 Phenylephrine    
 Vasopressin    
 GTN    
 Enoximone    
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Time Gelofusine HAS Platelets FFP Cryo Pump PRBC 
Pre-CPB        
        
        
CPB        
        
        
Post-CPB        
        
        
        
        
0        
        
        
        
1        
        
        
        
2        
        
        
        
3        
        
        
        
4        
        
        
        
5        
        
        
        
6        
        
        
        
7        
        
        
        
8        
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9        
        
        
Time Gelofusine HAS Platelets FFP Cryo Pump PRBC 
10        
        
        
        
11        
        
        
        
12        
        
        
        
13        
        
        
        
14        
        
        
        
15        
        
        
        
16        
        
        
        
17        
        
        
        
18        
        
        
        
19        
        
        
        
20        
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21        
        
        
        
22        
        
        
Time Gelofusine HAS Platelets FFP Cryo Pump PRBC 
23        
        
        
        
        
24-48        
        
        
        
48-72        
        
        
 
Blood Results 
 
 
Pre-op                  Day 1 
 
Day 2 
 
Day 4 
Na     
K     
Urea     
Creatinine     
PTTR     
Hb     
Fasting glucose     
 
Assays - Blood 
 Pre-
sternotomy 
6 hours 
post-XC 
12hours 
post-XC 
24 
hours 
post-XC 
48 
hours 
post-XC 
 
cTnT 
 
     
 
 Pre-op 4 hours 
post op 
8 hours 
post op 
12 hrs 
post op 
24 hours 
post op 
Urine ACR 
 
     
Urine 
microglobulin 
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IABP Data 
Pre-op IABP                     Y / N 
 
 
Date: 
Reason: 
IABP post bypass            Y / N 
 
 
Date: 
Reason: 
Post-op IABP                    Y / N 
 
 
Date: 
Reason 
 
Date and time IABP Removed: 
 
 
 
ITU Data 
Date and Time Arrived ITU 
 
 
Date and Time Reached 36 C 
 
 
Bair Hugger 
(all patients should have a bair hugger) 
 
          Y  /  N 
Total Blood drained at 12hrs or reopening 
 
 
Total Blood drained at 24 hours or 
reopening 
 
 
Date and Time Actual Extubation 
 
 
Date and Time Actual Discharge 
 
 
 
Kidneys 
 Start (date and time) End (date and time) 
CVVH   
  
Frusemide infusion   
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ECG 
ECG Preop (date      )    Immediate   POD 1  POD 4  
  
Preop 
 
POD 0 
 
 
POD 1 
 
POD 4 
 
Comment 
 
    
Nil 
 
    
SVT 
 
    
AF/Flutter 
 
    
VT/VF 
 
    
Asystole 
 
    
EMD 
 
    
Amiod 
 
    
Dig 
 
    
Adenosine 
 
    
Lignocaine 
 
    
Shock no. 
 
    
Shock tot 
J 
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New Arrhythmias 
 
 Pre-
CPB 
Post 
AXC 
0-6hrs 6-
12hrs 
12-
24hrs 
24-
48hrs 
48-
72hrs 
Nil 
 
       
SVT 
 
       
AF/Flutter 
 
       
VT/VF 
 
       
Asystole 
 
       
EMD 
 
       
Amiod 
 
       
Dig 
 
       
Adenosine 
 
       
Lignocaine 
 
       
Magnesium 
 
       
Shock no. 
 
       
Shock tot J 
 
       
 
 
 
 
pO2 / FiO2 Ratio 
 
 
 
 
preop 1 hr postop 6 hrs 
postop 
12 hrs 
postop 
pO2 
 
    
FiO2 
 
    
pO2 / FiO2 
ratio 
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COMPLICATIONS 
 
Reoperation   No   Cardiac Arrest  Bleeding/Tamponade  
    LCOS     
 
Bypass used    yes / no  
 
Pulmonary Complication  yes / no 
Chest infection  Re-intubation   Tracheostomy  Other 
 
Renal Complication   yes / no 
Mild/Moderate (Cr>200)  Haemofiltration  Haemodialysis  
 
GI Complication   yes/no   
Pancreatitis   GI bleed  Ischemic bowel   Other: 
 
Leg wound complication  yes / no / N/A 
Infection  Dehiscence  
 
Sternal wound complication  yes / no  
Infection  Dehiscence            VAC/Surgery    
 
Endocarditis      yes / no  
Root abscess   Re-operation   Organism: 
 
 
MRSA statusPre-op   yes / no 
Post-op  yes / no 
 
Neurological complications 
 
Type I neurological complications yes / no 
Fatal injury  Stroke  Coma   TIA 
 
Type II neurological complicationsyes / no 
 
Discharge Rhythm 
SR    AF    PPM  
 
Discharge details 
Home   Transferred   Died  
 
Date:  
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PATIENT INFORMATION SHEETS 
REC Ref. No. 06/Q2702/7 
 
Application of remote ischaemic pre-conditioning to human coronary 
artery bypass surgery (CABG) 
 
AN INVITATION TO PARTICIPATE IN RESEARCH? 
 
The heart surgery team at the Queen Elizabeth Medical Centre is inviting patients to 
participate in research aimed at making coronary artery surgery safer. We include a 
simple and non-technical summary of the reasons for the trial and what it involves for 
patients over and above their routine treatment if they take part. If you are being 
approached in the pre-admission clinic we would like you to take these information 
sheets home with you to read and consider participating in this trial between now and 
your admission date at which time a research doctor will be available to discuss the 
trial further and answer any questions. You can only be included in this clinical trial if 
you give your express permission in the form of signed consent.  If you are already 
an inpatient on the ward then a member of the heart surgical team will be happy to 
discuss the trial with you once you have had at least 24 hours to read through these 
information sheets.  
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PATIENT INFORMATION SHEETS 
REC Ref. No. 06/Q2702/7 
 
Application of remote ischaemic pre-conditioning to human coronary 
artery bypass surgery (CABG) 
 
WHAT IS THE STUDY ABOUT? 
This study is about trying to improve the protection of the heart in patients undergoing 
coronary artery bypass surgery (CABG).  During CABG the blood flow to the heart is 
reduced markedly for 30-90 minutes so that bypass grafts can be constructed and 
during this period the heart has to be protected so that it is not injured by the strain of 
the operation. Despite using standard techniques to protect the heart, some temporary 
injury still occurs from which the heart gradually recovers during the first few hours 
and days following operation. We are seeking ways to improve on standard methods 
to protect the heart by using a technique called remote ischaemic pre-conditioning 
(RIPC).  
Experimentally, we know that short periods (minutes) of reduced blood flow 
(ischaemia) to the heart can substantially reduce the injury caused by a subsequent 
more prolonged episode of reduced blood flow.  This phenomenon is called ischaemic 
pre-conditioning. This protective pre-conditioning effect has been observed in cardiac 
surgery but there are concerns that even the short period of reduced blood flow may 
itself cause injury and therefore, this technique is not in general usage. Recently, it 
has been demonstrated that the same degree of protection against injury occurs when 
a remote organ or limb is pre-conditioned without any reduction in blood flow for the 
heart.  Thus, three 5 minute periods of reduced blood flow of a limb performed 
immediately before a more prolonged period may improve protection of the heart. 
This study assesses whether remote pre-conditioning of the arm improves heart 
protection during coronary artery surgery. Thus, remote ischaemic pre-conditioning 
means that brief episodes of reduced blood supply to a limb can pre-condition or 
prime the heart to better cope with any period during which its own blood flow is 
reduced. 
  
HOW CAN WE DO THIS?  
We seek to investigate whether remote pre-conditioning (RIPC) can improve heart 
protection during coronary artery bypass surgery. To do this, we have designed a 
randomised control trial in which some patients will be allocated by chance to receive 
RIPC or not. Randomized controlled trials are recognized as the very best way of 
answering such a question.  This study will compare whether RIPC improves heart 
protection. The injury that a heart sustains during a heart operation can be detected in 
a number of ways. Blood tests may show biochemical abnormalities, 
electrocardiograms (ECGs) may show changes indicative of injury, echocardiograms 
(ultrasound scans of the heart similar to those used in pregnant women) can show 
changes in muscular function of the heart, and monitoring lines can show changes in 
the pressures and blood flows generated within the heart. Some patients undergoing 
heart surgery require drug therapy to support the heart afterwards. A requirement for 
such drugs and the quantity needed is a further index of heart injury. In addition, 
analysis of tiny samples of heart muscle can show changes in the heart’s energy 
stores. Thus, by performing these investigations in a standard way we can compare 
whether RIPC is beneficial or not. 
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HOW HAS THIS CLINICAL TRIAL BEEN DESIGNED? 
This study is what is called a double-blind randomized placebo-controlled trial. This 
means that if you agree to take part you may be allocated by chance to receive RIPC. 
The RIPC is conducted while you are under anaesthetic in the early stages of your 
heart surgery.  Prior to operation, standard blood pressure cuffs will be applied to your 
left arm and to a dummy cylinder. These will be connected by a switch and depending 
on your chance allocation, either cuff will be inflated for 3 periods of 5 minutes each, 
with 5 minutes of cuff deflation prior to the time when your heart’s blood flow is 
reduced to perform the CABG operation. The cuffs will be obscured from view so 
that the researchers will not know if you received RIPC or not until such time that we 
open the allocation code. Your operation will then proceed in a standard way, you will 
be cared for on our Intensive Care Unit and you will be recovered from surgery in the 
normal manner. This is done to prevent any bias in the results. By comparing the 
results of biochemical, ECG, echocardiographic, muscle analyses and post-operative 
drug requirements between those patients receiving RIPC and those not, we will be 
able to answer whether RIPC is beneficial. 
  
HOW WILL WE MEASURE THE EFFECTS OF RIPC?  
To detect changes in heart function, some measurements need to be taken before, 
during and after surgery. Prior to your operation an ECG and echocardiogram will be 
performed to compare with those taken after the operation. On the evening before 
surgery a portable monitoring ECG will be connected to carefully monitor and record 
your heart rhythm before, during and for 48 hours after operation. All these tests are 
harmless and cause minimal discomfort if any. When you are placed under 
anaesthetic, small monitoring catheters (plastic tubes) are routinely inserted in blood 
vessels and are usually removed on the first or second post operative day. We will 
record measurements from these catheters throughout this period at specific time 
points.  These catheters are all a standard part of your heart operation and are removed 
in the first few days after operation, usually within 48 hours. From these catheters, we 
will draw some additional blood samples for biochemical analysis. During your 
operation, your surgeon will take 3 small samples of heart muscle about the size of 
short length of pencil lead (actual size ====). Analysis of these samples will enable 
us to examine the possible effects of RIPC on the heart’s energy stores or other 
chemicals.  Also during your heart operation, a small catheter is routinely placed in 
your bladder so that your urine output can be measured. The urine is usually discarded 
but we will take some timed samples to measure any possible additional protective 
effect of RIPC on the kidney.   
 
MEASURING THE POSSIBLE BENEFICIAL EFFECTS OF RIPC  
The sampling of additional blood and urine tests: the blood tests performed on 
these samples can tell us how well the heart has tolerated the surgery. These blood 
samples are removed through the same monitoring lines already mentioned. The total 
amount of additional blood taken for this study is about half a cupful (50ml). Samples 
of urine will be collected for analysis from the catheter routinely placed under 
anaesthesia.  
 
Imaging the heart using a trans-thoracic echocardiogram: An echocardiogram is a 
scan that uses ultrasound (sound waves) to produce pictures of the heart.  The test is 
painless and without side effects.  An ultrasound probe and a small amount of gel are 
gently placed on your chest and will be moved to different positions.  The scan will 
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take approximately 20 –40 minutes to complete and will be performed once before 
surgery and once after.  The scan will be performed in a special Echo room. 
Following all our heart surgery, small wires are left on the surface of the heart so that 
we can ensure that your heart rate is satisfactory after the operation. During the 
second scan, we will adjust your heart rate between 70 and 120 beats per minute (a 
normal range of heart rate) using these wires. This will give us extra information 
about heart function. You may be able to feel a change in heart rate. This is harmless, 
but if uncomfortable we would stop and complete the scan without varying the heart 
rate.  
 
ECG and heart monitoring: ECGs are routinely performed before and several times 
after surgery. We will analyse these ECGs carefully as part of the study. Heart injury 
may cause some rhythm changes of the heart that are not detectable by standard 
ECGs. We will, therefore, connect you to a continuous portable (Holter) monitor on 
the evening before your operation which will record your ECG for the pre-operative 
period and for 48 hours afterwards. This will then be removed and analysed by 
computer. This will be able to tell us how many and what duration of any abnormal 
rhythms you had during that period. This test is painless and silent. 
 
Monitoring your heart output 
This will be done at specified time points from the lines inserted during your 
anaesthetic. The lines themselves are a necessary and standard part of the operation. 
We will gather the information from these lines as part of our research. 
  
The removal of tiny samples of the heart muscle, skeletal muscle and fat known 
as biopsies: This will tell us whether RIPC protects the heart by conserving its energy 
stores. We would aim to obtain 3 heart muscle biopsies all whilst you are asleep under 
the anaesthesia, one at the beginning, middle and end of the CABG procedure. A 
stitch is placed in the tiny defect left behind and their removal incurs no increased risk 
during the surgery nor has any effect on the strength of the heartbeat. We have 
performed more than 1500 such biopsies in patients at the time of writing of this 
information leaflet with no complications.  
 
 
The RIPC stimulus 
If you have been allocated to the RIPC group, a blood pressure cuff will be inflated on 
your left arm for three 5 minute periods at the start of your operation while you are 
under anaesthetic. This is exactly the same as having your blood pressure taken but 
for a longer period. Previous studies have shown this to be quite safe and harmless 
and only modestly uncomfortable even in conscious patients. You should not be 
aware of it whatsoever and we would expect that patients will not be able to tell if 
they underwent RIPC or not. To be quite sure that this has not caused any problems 
whatsoever we will ask you to fill in a questionnaire about any symptoms that may 
have arisen in your arm. 
 
WHAT WILL I HAVE TO DO? 
If you decide to participate then there are a number of stages to the study. You will be 
guided through these stages by us (the research doctors looking after you).  
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You will by now have received the written relevant information and asked to read this 
at your leisure at home or on the ward if you are already an inpatient. On the day prior 
to your surgery a member of the research team will visit you so you can ask any 
questions. If you give signed consent to participate then we will take the opportunity 
to perform an echocardiogram (20 minutes) on the day before surgery and also 
connect the ECG monitor. 
 
In the anaesthetic room of the operating theatre the anaesthetist will give you a 
general anaesthetic. The anaesthetists will insert the pressure measuring catheters 
normally inserted at this stage. Once you are asleep, an extra blood pressure cuff will 
be applied to your left arm and inflated for three 5 minute periods as above depending 
upon your allocation code. The operation will be conducted in a normal and standard 
way under the care of the consultant cardiac surgeon, who is in charge of your case. 
The blood samples and biopsies will be performed while you are asleep and you will 
be unaware of them.  
When you awake you will be on the intensive care unit as routine. Blood and urine 
tests will be drawn from the lines and catheters already in place. The last blood test 
will be performed at 72 hours after the operation. Forty-eight hours after your 
operation, the continuous ECG monitor will be removed. On about the fourth day 
after your operation we will perform the second echocardiogram.  Standard tests will 
be performed in the recovery period as for all patients. 
 
In summary we will be taking measurements from pressure measuring catheters that 
are routinely used in heart surgery. The entire sampling of blood for the research will 
total 50 ml and will not affect your recovery and, because we can use intravenous 
pressure measuring lines, there will be no additional need for needles. The biopsies 
that we take are removed painlessly during the operation and have no effect on the 
heartbeat.  
 
WHAT ARE THE BENEFITS? 
We do not know whether RIPC will actually be of benefit. There is sufficient 
evidence to believe that it may be but this study is being performed to prove or 
disprove this. Therefore, we cannot say if you will benefit as an individual. It is hoped 
that this study will provide information that will benefit future populations of patients 
undergoing cardiac surgical procedures.  
 
WHAT ARE THE RISKS? 
Previous studies of RIPC have shown that it is a safe. There is no reason to suspect 
that it would be harmful. Nevertheless the extensive monitoring that is performed as a 
matter of routine in a patient undergoing cardiac surgery would be able to detect any 
side effects at their earliest stages before a problem developed. In addition, the 
questionnaire will help us to establish that it is harmless. All heart operations carry 
some risk and these will have already been discussed with you by your surgical team. 
For this study we insert routinely used monitoring lines to measure heart function. 
These are used in 60% of patients undergoing coronary artery surgery. In the study we 
would use them in all patients to more closely monitor heart function. The risks of 
insertion of these monitoring lines are minimal and the possibility of a severe 
complication is in the region of 1 in 15000. The only additional invasive procedure 
performed on you is the biopsy which as stated above has been performed in over 500 
patients without ill-effect.  
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WHAT ARE THE ALTERNATIVES? 
If you do not wish to take part in the study, your surgery will be undertaken in the 
standard manner without any additional measurements, treatments or tests.  Your 
surgeon and anaesthetist may still use the monitoring lines that we have described if 
they feel that their use is in your best interest. 
 
WHAT HAPPENS TO THE INFORMATION? 
The information from the study will be collected confidentially and coded for 
anonymity. At the end of the study, the information will be analysed. The information 
will be presented at scientific meetings and published in scientific journals to inform 
other doctors and health professionals of our findings. All data is confidential and 
stored by code on secure computers. This ensures that your identity will not be 
revealed at any time. 
 
WHO ELSE IS TAKING PART? 
We hope that 162 patients will participate in this study.  This is the number required 
to establish that we are able to detect a true effect of RIPC. 
 
WHAT IF SOMETHING GOES WRONG? 
Throughout your surgery, your safety is of paramount concern. If for any reason, your 
surgeon and anaesthetist feel that the study should not proceed because of other safety 
concerns, the research will not take place. The standard care of patients undergoing 
heart surgery involves intensive monitoring. This monitoring allows us to detect any 
problems early in their development. We do not expect the study itself to cause any 
problems, however as for all heart surgery we are in an ideal position to deal with any 
untoward events during your operation and these will be treated in the normal manner, 
regardless of the research study. At the time of all the measurements you will be in 
the theatre or I.T.U. where trained staff is at hand at all times.  Should you become ill 
for any reason related to the study, the study would be stopped immediately. Your 
safety during and after surgery is paramount, and takes precedence over any research. 
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WHAT HAPPENS AT THE END OF THE STUDY? 
The main study is undertaken during the surgery and our collection of additional 
information ends on the 4th or 5th day after your operation. At the end of the complete 
study, the codes of allocation will be broken and the overall results analysed.  Your 
direct involvement is complete within your stay in hospital. If you would like to 
receive summary information about the study results, this will be sent to you once the 
study is complete (in approximately 2 ½ years time). 
 
WHAT IF I HAVE MORE QUESTIONS OR DO NOT UNDERSTAND SOMETHING? 
Please feel free to ask one of the investigators about any questions or worries that you 
may have so that any points can be clarified. You should feel free to ask questions at 
any time you like. If you would like more information this can be provided by the 
Research Fellow coordinating the study (see below) or from Professor Bonser’s office 
extension 2543. 
 
WHAT HAPPENS NOW IF I DECIDE TO TAKE PART? 
We will take some details and ask you to sign a consent form that documents your 
willingness to participate. You will be listed for surgery as normal. When your 
surgery is scheduled we will ask your permission to start the study on the evening 
prior to operation and undertake the echocardiogram and ECG monitoring. You are 
free to withdraw from this study after initially consenting without prejudice to your 
continuing care. 
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CONSENT FORM 
Application of remote ischaemic pre-conditioning to human coronary 
artery bypass surgery (CABG) 
 
 
This is a consent form that documents your agreement to participate in this particular 
research.  Before signing this form please tick the boxes below. 
 
I have read the invitation form  
 
I have read the information sheet 
 
I have understood the nature of the research 
 
I have had time to consider my response/reply 
 
I have been able to ask any questions and am satisfied with the answers 
 
I understand that I can withdraw at any time without giving explanation 
 
The participation or lack of it in this research will not affect my clinical care in any way 
 
 
I would like to receive a summary of the research when it is complete. 
 
 
Please remember that there is no obligation to participate in this study and that even 
if you do you can withdraw at any time. If you do not consent to this study your 
operation and care will proceed as planned. There are no rewards or penalties for 
participating in research although we are grateful for your efforts and inconvenience.  
If after reading this consent form and the patient information sheet you agree to 
participate please sign the form below and return to Mr I Rahman. If you have any 
further questions about any aspect of the research feel free to ask Mr I Rahman.  
 
The study has been explained by: 
 
Print Name: 
 
Signature:    Date: 
 
Please sign below if you agree to participate in this study 
  
I have read and understand the above, and I am happy to take part in the above 
study. 
 
 
Signed   Name (Print)    Date 
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APPENDIX B - STANDARDISED PROTOCOLS 
 
Procedures that have been standardised across a number of trials including 
protocols for departmental postoperative management of patients are 
referenced below: 
 
1.0 Preparing the operating schedule 
Operating list for trial patients was annotated thus: 
SMITH John DOB 12/12/45 G236819/A CABG (REMOTE TRIAL) E2B 
This practice was to ensure ward staff, anaesthetists, ODP, theatre staff, 
perfusionists, ITU staff and surgical team were aware of the trial patient and that 
all protocols were adhered to. 
 
2.0 Protamine dose  
Protamine was administered intraoperatively at a dose of 1mg per 100 units of 
heparin once the patient is of CPB.  
Additional protamine to cover the pump blood returned to the patient was given 
to the following regimen: 
• 0-499 ml of pump blood    → no additional protamine 
• 500-999 ml of pump blood returned  → 50 mg protamine 
• ≥ 1l of pump blood returned   → 100 mg protamine 
 
3.0 Placement of epicardial pacing wires 
The placement of atrial and ventricular pacing wires is mandatory. Two 
epicardial atrial pacing wires were sited in the region of the atrial cannulation 
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site and two epicardial ventricular wires were placed in the right ventricular 
outflow tract. 
 
4.0 Postoperative medication 
4.1 Antiplatelet therapy 
Patients received on return to the ITU received a dose of aspirin 300mg rectally 
and thereafter 150mg orally once a day. In the case of aspirin allergy or other 
contra-indications, anti-platelet therapy was at the discretion of the attending 
team. 
 
4.2 Angiotensin converting enzyme (ACE) inhibitors 
All patients received an ACE inhibitor in the postoperative period (unless 
contraindicated). Reinstitution and new prescribing of ACE inhibitor therapy was 
not permitted until the fourth postoperative day. 
 
4.3 Other cardiovascular medication 
All patients received initial diuretic therapy with oral frusemide 40mg daily. 
Long-acting nitrates or nitrate patches were not permitted postoperatively. 
Preoperative antihypertensive medications were recommended as clinically 
indicated.  
β-receptor antagonists, statins and other lipid lowering agents were started as 
soon as possible in the postoperative period. 
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4.4 Non cardiovascular medication 
Treatment was restarted on as soon as possible after surgery at the discretion 
of the caring team. 
 
5.0 Protocols for the management of post-operative complications 
5.1 Protocol for management of pacing and arrhythmias 
5.1.1 Management of ventricular fibrillation post AXC removal 
The management was as follows until the restoration of sinus rhythm: 
• 2 x 10 J shock 
• Administration lignocaine 100mg IV  
All reperfusion VF was recorded, together with shock strengths. Similarly, the 
use of induced VF and subsequent defibrillation to facilitate biopsy or other 
repairs was recorded. 
Treatment beyond this is at the discretion of the patient’s clinical team but was 
recorded as part of the results 
 
5.1.2 Post-operative pacing management 
At the end of cardiopulmonary bypass all patients had ventricular and atrial 
pacing wires in situ. 
During weaning from CPB, the target synchronised heart rate was 90bts/min. 
This was achieved by: 
• native sinus rhythm (± atropine / glycopyrollate) 
• AAI pacing (90 bts.min-1) 
• DDD (or DVI) pacing (90bts.min-1) with a default AV interval of 160ms. 
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Initial haemodynamic studies were performed in the rhythm or pacing mode 
selected by the Consultant Surgeon/Anaesthetist to achieve best overall 
haemodynamic performance. These settings were maintained through transfer 
to ITU and reviewed by the Research Fellow 2 hours following release of the 
aortic cross-clamp. 
At this time, prior to the 2 hour haemodynamic assessment: 
• in patients in SR with a heart rate of ≥90bts.min-1 and normal AV 
conduction no action was required 
• In patients in SR with a heart rate <90 bts/min AAI pacing at 90 bts.min-1 
was instituted 
• In patients DDD or DVI paced (90bts.min-1) the PAUSE button on the 
pacing box was depressed briefly: 
If this demonstrated persistent AV block, DDD or DVD pacing (default AV 
interval 160ms) was continued throughout the study period at 90bts.m-1.  
If the PAUSE query demonstrated a rhythm which had AV conduction, the 
pacing mode was adjusted.   The AV interval setting was increased to a 
maximum of 200ms and the rhythm reviewed.  
If the rhythm was now atrially paced with native AV conduction, this means 
that the native AV interval is <200ms. This rhythm is haemodynamically 
preferable and provided there was not a variable native AV interval and thus 
intermittent pacing, these pacing settings (DDD AV interval 200ms) were 
maintained.  
In circumstances in which the AV interval was ≥200ms or in which the native 
AV interval was variable with intermittent ventricular pacing, the previous 
DDD settings (AV interval 160ms) was resumed. 
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The trial staff would document in the patient notes any pacing changes, 
record the data on the study datasheet and proceed with the haemodynamic 
studies.  
This pacing assessment is the only time when trial staff had a direct clinical 
responsibility regarding a patient’s management.  
 
5.1.3 Protocol for the management of suspected atrial fibrillation and other 
supraventricular tachyarrhythmias 
• Check hypoxia and hypokalaemia (K+ < 4.5 mmol.L-1), record the result 
and correct appropriately 
• Confirm diagnosis with a12 lead ECG (2 copies named, dated and timed) 
• If hypoxia is present a chest radiogram was obtained 
 
5.1.4 Management of AF or atrial flutter: Scenario 1 
If the PR interval <180 millisecs, no new LBBB or no new bifasicular block 
and ventricular rate >80.min-1 the treatment plan was: 
 
5.1.4.1 Patient unable to take oral medication  
If the patient was intubated and ventilated we would strive to ensure oxygen 
saturations were greater than 95%, using supplemental oxygen as required. We 
aimed to maintain serum K+ greater than 4.0 mmol.L-1 
Intravenous Amiodarone 1.2g over 24 hours was administered. The initial bolus 
dose of 300mg was administered intravenously over 1 hour followed by 900mg 
for the remaining part of 24 hours. 
 
270 
 
Intravenous Amiodarone 1.2g was repeated in the second 24 hours, and 
reduced to 600 mg over 24 hours for the next 5 days, and 300mg over 24 hours 
thereafter. 
Oral Amiodarone was commenced when oral or nasogastric medications were 
tolerated. 
Prophylactic anti-coagulation was administered using s/c Enoxaparin 40mg 
daily for the first 48 hours after the commencement of atrial fibrillation, unless 
other anti-coagulation was already ongoing, or unless anti-coagulation was 
contra-indicated. If atrial fibrillation persisted for more than 48 hours, 
Enoxaparin was increased to 1mg/kg s/c BD, unless contraindicated, until 24 
hours after sinus rhythm was restored. 
DC cardioversion was considered if sinus rhythm was not restored after 72 
hours atrial fibrillation. 
If the ventricular capture rate remained high loading with Digoxin 500µg 6 
hourly up to 3 doses according to response was considered. Maintenance dose 
was then continued at half the recommended dose for age, size and renal 
function.  
DC cardioversion was also considered, at any stage, if haemodynamic 
instability ensued. Patients who failed to cardiovert to sinus rhythm were 
warfarinised. Target INR 2.5. 
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5.1.4.2 Patient able to take oral medication 
For awake, extubated patients on the ward or ITU we would strive to ensure 
oxygen saturation’s were greater than 95%, using supplemental oxygen as 
required and aim to maintain serum K+ greater than 4.0 mmol.L-1.  
The regimen of oral Amiodarone 400 mg TDS for 48hrs, followed by 200mg 
TDS for one week, then 200mg BD for one week and finally 200mg OD for one 
week was followed, or until the day of discharge, whichever is the shorter. 
Doses were reviewed if patient weight was less than 50Kg.  
Prophylactic anti-coagulation was administered using s/c Enoxaparin 40mg 
daily for the first 48 hours after the commencement of atrial fibrillation, unless 
other anti-coagulation was already ongoing, or unless anti-coagulation was 
contra-indicated. If atrial fibrillation persisted for more than 48hours Enoxaparin 
was increased to 1mg.kg-1 s/c BD, unless contraindicated, until 24 hours after 
sinus rhythm was restored. 
DC cardioversion was considered if sinus rhythm was not restored after 72 
hours of atrial fibrillation or if at any stage haemodynamic instability ensued. 
If the ventricular capture rate remained high loading with Digoxin 500µg 6 
hourly up to 3 doses according to response was considered. Maintenance dose 
was continued at half the recommended dose for age, size and renal function.  
If atrial fibrillation/atrial flutter was intermittent but persistent despite 
Amiodarone loading anti-coagulation with Warfarin was commenced prior to 
discharge home and continued until review in the outpatient clinic (target INR 
2.5). If sinus rhythm was restored when reviewed in the outpatient clinic 
Warfarin and Amiodarone was discontinued. If atrial fibrillation/atrial flutter 
persisted DC cardioversion was considered. 
272 
 
Amiodarone was discontinued on review in the outpatient clinic at 6 weeks if 
sinus rhythm persisted. 
 
5.1.5 Management of AF or atrial flutter: Scenario 2 
If the PR interval >180 millisecs, or new LBBB or new bifasicular block and 
ventricular rate 80.min-1 the treatment plan was: 
 
5.1.5.1 Patient unable to take oral medication 
If the patient was unable to take oral medication intravenous Amiodarone 600 
mg over 24 hours for 2 days and 300 mg daily thereafter until able to tolerate 
oral/NG medication was commenced. We would strive to ensure oxygen 
saturations were greater than 95%, using supplemental oxygen as required and 
aim to maintain serum K+ greater than 4.0 mmol.L-1. 
Prophylactic anti-coagulation was administered using s/c Enoxaparin 40mg 
daily for the first 48 hours after the commencement of atrial fibrillation, unless 
other anti-coagulation was already ongoing, or unless anti-coagulation was 
contra-indicated. If atrial fibrillation persisted for more than 48 hours, 
Enoxaparin was increased to 1mg.kg-1 s/c BD, unless contraindicated, until 24 
hours after sinus rhythm was restored. 
DC cardioversion was considered if sinus rhythm was not restored after 72 
hours atrial fibrillation.  
If ventricular capture rate remained high loading with Digoxin 500µg 6 hourly up 
to 3 doses according to response was considered. Maintenance dose was 
continued at half the recommended dose for age, size and renal function.  
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DC cardioversion was also considered, at any stage, if haemodynamic 
instability ensued. 
Patients who failed to cardiovert to sinus rhythm were warfarinised. Target INR 
2.5. 
 
5.1.5.2 Patient able to take oral medication 
If the patient was able to take oral medication oral Amiodarone 200 mg TDS for 
8 days or until the time of discharge, whichever is the shorter was commenced. 
We would strive to ensure oxygen saturations were greater than 95%, using 
supplemental oxygen as required and aim to maintain serum K+ greater than 
4.0 mmol.L-1. 
Prophylactic anti-coagulation was administered using s/c Enoxaparin 40mg 
daily for the first 48 hours after the commencement of atrial fibrillation, unless 
other anti-coagulation was already ongoing, or unless anti-coagulation was 
contra-indicated. If atrial fibrillation persisted for more than 48hours, Enoxaparin 
was increased to 1mg.kg-1 s/c BD, unless contraindicated, until 24 hours after 
sinus rhythm was restored. 
DC cardioversion was considered if sinus rhythm was not restored after 72 
hours atrial fibrillation and also at any stage if haemodynamic instability ensued. 
If the ventricular capture rate remained high loading with Digoxin 500µg 6 
hourly up to 3 doses according to response was considered. Maintenance dose 
was continued at half the recommended dose for age, size and renal function.  
If atrial fibrillation/atrial flutter was intermittent but persistent despite 
Amiodarone loading anti-coagulation with Warfarin was commenced prior to 
discharge home and continued until review in the outpatient clinic (target INR 
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2.5). If sinus rhythm was restored when reviewed in the outpatient clinic 
Warfarin and Amiodarone was discontinued. If atrial fibrillation/atrial flutter 
persisted DC cardioversion was considered. Oral Amiodarone 200 mg daily 
thereafter. Amiodarone discontinued on review in the outpatient clinic at 6 
weeks if sinus rhythm persists  
 
5.1.6 D.C. Cardioversion technique for atrial fibrillation/flutter  
Under anaesthesia the cardiovert protocol followed according to the incremental 
energies detailed below: 
Monophasic    Biphasic 
50J x2 attempts   150J x 3 
100J x 2 attempts 
150J x 2 attempts 
360J x 2 attempts 
Abandon if unsuccessful. Consider anticoagulation and further management at 
team discretion. 
 
5.1.7 Diagnosis and management of other supraventricular tachycardias 
In the presence of supraventricular arrhythmias not believed to be AF the aim of 
treatment was to restore normal sinus rhythm. Hypokalaemia and hypoxia were 
corrected. Carotid sinus massage was attempted and if this failed intravenous 
adenosine therapy was instituted as  3 mg in increasing doses of 3 mg (i.e. 3 
mg, 6 mg, 9 mg) unless the patient had contraindications to adenosine (asthma, 
second or third degree heart block, sick sinus syndrome). Further treatment was 
at the discretion of the patient’ consultant/clinical team. 
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5.1.8 Protocol for the management of ventricular dysrythmias 
The following ventricular dysrhythmias require attention: 
• Bigeminy or Trigeminy  
• ‘Salvos” of ventricular tachycardia 
• ‘R on T’ phenomenon 
• 15 ventricular ectopics/minute for > 5 minutes 
• Sustained VT or VF 
In all cases hypoxia,  hypokalaemia and hypomagnaesemia were corrected, the 
diagnosis was confirmed by 12-lead ECG with a lead II rhythm strip unless 
patient was in theatres and a chest x-ray was performed (if no obvious cause 
for hypoxia). 
 
5.1.8.1Treatment of sustained pulseless ventricular tachycardia or ventricular 
fibrillation 
The decision to cardiovert, defibrillate or proceed to resternotomy was at the 
discretion of the caring team. Defibrillation should be the immediate method of 
choice (The Advanced Life Support Guidelines 2000) up to three shocks given 
initially with energies of 200 J, 200 J, 360 J (or their equivalent when using 
defibrillators with alternative waveforms). Amiodarone or lignocaine could next 
be utilised: 
• Amiodarone 300 mg (made up to 20 ml with 5% dextrose or from a 
prefilled syringe) may be administered. A further dose of 150 mg may be 
given for recurrent or refractory VT/VF, followed by an infusion of 1 mg 
min-1 for 6 -12 hours then  at 0.5 mg min-1. 
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• Lignocaine was given at 1 mg min-1, with a further 1-2 doses of 0.5 mg 
min-1 10 minutes apart.  A continuous infusion may be considered as 
1000 mg of lignocaine to a total volume of 50 ml of 0.9%NaCl (20 mg/ml) 
and infused at a rate of 12 ml.hr-1 (4mg.min-1) for 3 hours. 
 
5.1.9 Protocol for the management of bradycardias (<60bpm  for >5 minutes) 
In the instance of bradycardias we would check initially the ECG monitors scale. 
The haemodynamic targets of CVP, MAP and CI would be assessed. A 12lead 
ECG would be performed. 
Sinus bradycardia, nodal bradycardia or first-degree heart block but with MAP 
65-85 mmHg and cardiac index >2.2L.min.-1m-2 required no treatment. 
Sinus bradycardia, nodal bradycardia or first degree heart block but with MAP 
<65-85  mmHg or CI <2.2 L.min-1.m-2 either glycopyrolate boluses of 0.6 mg up 
to a maximum of 1.8 mg or IV atropine boluses of 0.6 mg up to a maximum of 
1.8 mg were used. Pacing or isoprenaline infusion was considered. 
Second or third degree heart block management was at the discretion of the 
managing team. All therapy was recorded.  
 
6.0 The management of post-operative hypertension on ITU 
Hypertension is defined as MAP >85mmHg. If a sustained period of 
hypertension or repeat temporary episode of hypertension develop then the 
patient was managed as below: 
277 
 
• Ensure adequate analgesia 
• GTN (i.v. 50 mg in 50 ml) titrating the dose to achieve MAP ≤85 mmHg 
until the upper limit of infusion of 15 ml.h has been reached. 
• If this failed to reduce the blood pressure then SNP (i.v. 50 mg in 50 ml 
dextrose 5% solution) at 0-15 ml.h-1 was added as directed by the caring 
medical team.  
• Once the patient has been extubated, the need for hypertension control 
should be re-assessed by the caring medical team. Where appropriate, 
intravenous medication should be substituted with either re-
commencement of oral anti-hypertensive therapy or institution of oral 
agent is at the discretion of the managing team. 
  
7.0 Assessment and management of post-operative hypotension (i.e. 
sustained MAP <60mmHg) 
Hypotension is defined as MAP<60mmHg. In the case of hypotension the 
following was assessed: 
• Arterial line calibration and accuracy 
• Cardiac rhythm (if abnormal see treatment of cardiac rhythm 
disturbances) 
• Filling pressures (CVP and PAWP) 
 
278 
 
• If below the range set by the patient’s consultant/clinical team or < 8 cm 
H2O if no range has been set then volume was administered. 
• If above the range set by the patient’s consultant/clinical team or > 12 cm 
H2O then cardiac output studies were performed. 
• If cardiac index was ≤ 2.2 L.min.-1m-2 the protocol for the assessment 
and management of low cardiac output state was followed 
• If cardiac index was > 2.2 L.min.-1m-2 and a normal SVR (800-
1200dyne.cm.sec-5) associated with hypotension management was 
directed by the attending clinical team. 
• If cardiac index > 3 L.min.-1m-2 with a low SVR (<800dyne.cm.sec-5) was 
the cause of hypotension phenylephrine was prescribed as an infusion of 
10mg made to 50 ml with 5% dextrose.  The infusion was to start at 2 
ml.h-1 
 
8.0 Assessment and management of suspected low cardiac output 
state  
For the purpose of this study a low cardiac output state is defined as a C.I. of ≤
2.2 L.min.-1m-2 refractory to appropriate intra-vascular volume expansion 
following correction or attempted correction of any dysrhythmias including sinus 
bradycardia, nodal rhythms, atrial and ventricular tachycardia or dysrhythmias.  
 
8.1 Low cardiac output state in theatres and anticipatory treatment 
Whenever possible the surgeon/anaesthetist was to await the results of cardiac 
output studies performed and recorded after CPB had been discontinued. In 
some cases the surgeon/anaesthetist will anticipate a low cardiac output state 
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and the need for inotropes on subjective and objective features of cardiac 
performance before and during surgery. If possible confirmatory cardiac output 
studies should be awaited but if not inotropic therapy is started at the discretion 
of the managing team. The exact time of commencement and dosage was 
recorded. 
Low cardiac output state in the presence of adequate ‘filling pressures’ is an 
endpoint for this study.  
The charts of patients who have had anticipatory inotropic treatment underwent 
a review by the low cardiac output committee.  The aim of the review was to 
confirm that in the absence of C.O.S. data we had a bonafide case of low 
cardiac output.  
 
8.2 Post-operative low cardiac output state diagnosed in the ITU/HDU 
Any patient having a measured cardiac index of  ≤ 2.2 L.min.-1m-2 was assessed 
as follows: 
• Assess heart rate and rhythm and correct as appropriate 
• Measure filling pressures (CVP and PAWP) and correct as appropriate 
within targets set by the caring team. Consider overt or covert 
haemorrhage 
• Consider the possibility of cardiac tamponade  
Appropriate management of the above factors is at the discretion of the caring 
team. Once these factors were assessed and treated and if the patient still had 
a cardiac index of ≤ 2.2 L.min.-1m-2 then the patient was considered to be 
suffering from a low cardiac output state and initial management was as follows: 
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• Dopamine (first line inotrope) 200mg in 50ml 5% dextrose commenced at 
a dose of 1-10 µg.kg-1.min-1 at the discretion of the caring team. 
• All management considered necessary above and beyond dopamine 10µ
g/kg/min is at the discretion of the caring team. 
 
8.3 Management of a ‘Reopening’ Procedure 
The decision to reopen a patient is purely a clinical one at the discretion of the 
patient’s consultant/team. The intra-operative reopening ‘findings’ were 
recorded. 
 
9.0 Protocol for the administration of colloids and blood products 
Colloid is prescribed to replace drain losses and maintain adequate filling 
pressures to achieve the desired mean arterial pressure (MAP 65-85mmHg) 
and cardiac index. The colloid of first choice for this study was Gelofusin©.  
The maximum volume of gelofusin© permissible over 12 hours is  
• 2 L if the patient is ≥ 70 kg  
• 1.5 L if < 70 kg.  
If additional filling was required beyond these volumes:  
• H.A.S. 4.5% if HB ≥ 8.5 
• Packed red cells if HB < 8.5 or active bleeding through drains above 
specified rate 
Clotting factors, platelets and cryoprecipitate administered to restore clot 
formation also served as volume expanders in addition to the Gelofusin@. 
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10.0 Protocol for the management of a low urine output  
Low urine output was defined as <0.5ml.kg-1.hr-1. If the urine output fell below 
this in any 1 hour the following was checked: 
• adequate mean arterial pressure 
• adequate CVP and PAWP  
• a working urinary catheter. Consider a 50 ml flush 
If this checklist is normal then intravenous frusemide 10mg was administered 
and response awaited. 
If any of the above checklist were not in the target parameters appropriate 
colloid was given and cardiac indices repeated considering the use of inotropes 
as protocol. 
Failure to maintain a satisfactory diuresis would prompt an enquiry regarding a 
possible low cardiac output state. If a satisfactory cardiac output is the case but 
urine output remains inadequate dopamine (200 mg in a 50ml of 5% dextrose) 
run at 3 µg/kg/hr was used supplemented by a low dose frusemide infusion as 
necessary. Treatment beyond this was at the discretion of the patient’s clinical 
team. 
 
11.0 Protocol for the management of suspected wound infection 
11.1  Suspected sternal or leg wound Infection 
Bacteriological swabs were taken from sternal or leg wounds in cases of 
suspected infection. Treatment was at the discretion of the clinical team. 
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11.2 Other infections 
Bacteriological specimens were taken as appropriate in all suspected infection 
episodes and treatment was at the discretion of the clinical team. 
 
12.0 Protocol for management of blood glucose 
The normal range for random blood glucose was defined as 4 .4-10 mmol.L-1 
Post-operative hyperglycaemia and insulin resistance was managed with 
standard Trust sliding scale insulin protocols.  
3 examples of sliding scale protocols (A, B and C) are given according to 
insulin-resistance of the patients below. 
Management would start from protocol A and escalate if necessary. The aim 
was to maintain blood sugars ≤10mmol/L. 
A B C 
BM  
(mmol.L-1) 
Units.h-1 BM  
(mmol.L-1) 
Units.h-1 BM 
(mmol.L-1) 
Units.h-1 
0 - 7 0 0 - 7 0 0 - 7 0 
7.1 – 11 1 7.1 – 11 2 7.1 – 11 4 
11.1 – 15 2 11.1 – 15 4 11.1 – 15 8 
15.1 – 20 4 15.1 – 20 6 15.1 – 20 10 
>20 6 >20 8 >20 14 
 
In more severe cases of insulin-resistance intermittent boluses of insulin of 5-10 
units could be administered if serum potassium concentration was ≥4 mmol.L-1 
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13.0 Post-operative prescription for all ITU trial patients 
13.1 Fluids 
5% Dextrose at 1ml.kg-1h-1 was prescribed 
 
13.2 Potassium 
Potassium chloride (KCl) 10-20mmol in 30ml 5% dextrose over 30 minutes was 
prescribed as required to maintain K+ 4.5-5.5mmol.L-1.  
 
13.3 Insulin 
As per ITU sliding scales 
 
13.4 Sedation and continuous intravenous analgesia   
Propofol 10mg/ml at 0-15 ml.h-1 
Alfentanil 25mg in 50ml 5% Dextrose at 0-2ml.hr-1  
Followed by: 
Paracetamol 1q p.o. QDS 
Tramadol (PRN) i.v. 50-100 mg 4 hrly or Tramadol p.o. 50-100 mg qds 4hrly  
And or Codeine Phosphate 30-60mg 4hrly (max 240mg.24h-1) or 
Dihydrocodeine 30-60mg qds (max 240mg.24h-1). 
 
13.5 Antihypertensive medication  
Glyceryl trinitrate solution (GTN) 50 mg in 50 ml at 1-15 ml.hr-1 ± 
Sodium nitroprusside (SNP) 50mg in 50ml. D5%W at 0-20ml.h-1 or 
Nifedipine 10mg sub-lingual PRN for sustained hypertension (>160/90)  
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13.6 Anti-emetic medications 
Maxalon 10 mg 8 hrly i.v./i.m./p.o.  ± 
Cyclizine 50 mg i.v. 8 hrly ±  
Ondansetron 4-8 mg IV/IV/PO PRN 6-8 hourly  
 
13.7 Antibiotics  
As per the standard unit policy. 
 
13.8 Heparin DVT prophylaxis 
Enoxaparin 40mg s/c o.d.  
 
13.9 Intravenous diuretic therapy 
Frusemide 10mg i.v. PRN  
 
13.10  Inotropes and Vasoconstrictors 
The trial staff would always aim to perform a full series of cardiac output studies 
prior to the commencement or escalation of inotropes. 
Inotropes would always be prescribed and used in the 50ml 5% dextrose as per 
unit policy. The dose of drug required to constitute a single strength solution for 
each inotrope is detailed below: 
Dopamine 200mg 
Dobutamine 250mg 
Adrenaline 2mg 
Noradrenaline 2mg 
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Phenylephrine should be made up as 10mg / 50mls 5% dextrose. 
Enoximone should be made up as 100mg / 40mls N/Saline 
The loading dose should be run at 1mg.kg-1 for 1 hour 
Enoximone in the pump was not allowed.  
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APPENDIX C - PRESENTATIONS AND PUBLICATIONS ARISING FROM   
THIS THESIS AND THE RESEARCH FELLOWSHIP 
 
1.0 PRESENTATIONS 
 
[1] Does remote ischaemic preconditioning during on-pump coronary 
artery bypass grafting enhance lung preservation? Rahman IA, Mascaro 
JG, Green D, Townsend P, Bonser R. ESCVS International Congress, 2010 
(oral presentation). 
 
[2] Does remote ischaemic preconditioning protect the heart and 
kidneys in human coronary artery bypass surgery – a randomised 
controlled trial. Rahman IA,  Mascaro JG, Steeds RP, Frenneaux MP, 
Nightingale P, Gosling P, Townsend P, Townend J, Green D, Bonser RS. 
SCTS 2010 (oral presentation). 
 
[3] Remote ischaemic pre-conditioning in human coronary artery 
bypass surgery, from promise to disappointment. Rahman IA, Mascaro 
CJ, Steeds RP, Frenneaux M, Nightingale P, Gosling P, Townsend P, 
Townend J, Green D, Bonser RS. American Heart Association Scientific 
Session, November 2009 (oral presentation) 
 
[4] Increased beta-catenin pathway expression by a remote 
ischaemic preconditioning stimulus: first evidence in humans. 
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Contractor H, Ashrafian H, Rahman IA, Redington A, Frenneaux M, Bonser 
RS, Kharbanda R. American College of Cardiology, 2009 (oral presentation) 
 
[5] The functional impact of remote ischaemic preconditioning on 
patients undergoing first time coronary artery bypass surgery. Rahman 
IA, Nightingale P, Marsh AM, Williams L, Mascaro CJ, Bonser RS, Steeds R. 
British Cardiovascular Society, 2009 (poster presentation) 
 
[6] Does remote ischaemic preconditioning during on-pump coronary 
artery bypass grafting enhance renal and pulmonary protection? 
Rahman IA, Mascaro CJ, Nightingale P, Gosling P, Green D, Townsend P, 
Bonser RS. Royal Society Medicine [Cardiothoracic Section].2009 (poster 
presentation) 
 
[7] The variability of ejection fraction in patients following on-pump 
coronary artery bypass grafting. Rahman IA, Alvior A, Nightingale P, Marsh 
AM, Mascaro CJ, Bonser RS, Steeds R. 13th Asia Pacific Congress of Doppler 
Echocardiography, 2009 (poster presentation) 
 
[8] Investigating the reduction in right ventricular function following 
on-pump coronary artery bypass surgery. Rahman IA, Marsh AM, Williams 
L, Mascaro CJ, Bonser RS, Steeds R. 13th Asia Pacific Congress of Doppler 
Echocardiography, 2009 (poster presentation) 
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[9] Right ventricular functional change following on-pump coronary 
artery bypass grafting and its relationship with perioperative myocardial 
necrosis and inotropic support. Rahman IA, Mascaro CJ, Nightingale P, 
Green D, Townsend P, Bonser RS. Royal Society Medicine [Cardiothoracic 
Section].2008 (poster presentation) 
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